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ABSTRACT 
 Heme proteins have recently been demonstrated to catalyze cyclopropanation reactions 
via a putative carbene transfer mechanism. Carbene transfer reactions are not known to occur 
in natural biological systems, but are highly useful synthetic reactions. There is growing 
interest in developing new “carbene transferases” that bring new chemical reactions into the 
realm of biology, and growing interest in engineering these enzymes for use in organic 
synthesis. Additionally, the mechanistic details of iron porphyrin-catalyzed carbene transfer 
reactions are largely unknown, especially with regards to how the enzyme environment 
influences the outcome of a carbene transfer reaction. This thesis details both the engineering 
of carbene transferases with novel catalytic capabilities and investigations into how these 
enzymes catalyze carbene transfer reactions. Chapter 1 introduces heme protein-catalyzed 
carbene transfer reactions and describes the directed evolution of new enzymes that allow 
access to a range of useful cyclopropane products. Chapter 2 describes the evolution of an 
enzyme that performs carbene transfer to silicon–hydrogen bonds, resulting in a highly 
efficient and selective carbon–silicon bond-forming enzyme, the first of its kind. Chapter 3 
focuses on the characterization of a key reactive intermediate, the iron-porphyrin carbene, in 
the active site of the evolved carbon–silicon bond-forming enzyme. This study provides an 
explanation of the remarkable enantioselectivity of the enzyme and provides a foundation 
from which to investigate the enzyme reaction mechanism. The mechanism of carbon–
silicon bond formation is elucidated in Chapter 4, and the is then used to explain how the 
enzyme achieves chemoselectivity, which in turn guides the evolution of enzyme variants 
with altered chemoselectivity. Finally, two off-cycle catalytic pathways that cause 
inactivation of the carbene transferase are characterized, and methods to prevent and/or 
circumvent inactivation are investigated (Chapter 5). Overall, the work presented here 
expands the repertoire of enzyme-catalyzed reactions and facilitates the continuing 
development of new carbene transferases by developing our mechanistic understanding of 
this novel class of enzymes.  
  
 v 
PUBLISHED CONTENT AND CONTRIBUTIONS 
(† indicates equal contributions by authors) 
1. Renata, H.†, Lewis, R.D.†, Sweredoski, M.J., Moradian, A., Hess, S., Wang, Z.J. 
Arnold, F.H. Identification of Mechanism-Based Inactivation in P450-Catalyzed 
Cyclopropanation Facilitates Engineering of Improved Enzymes. J. Am. Chem. Soc. 
138, 12527-12533 (2016). doi:10.1021/jacs.6b06823 
 
 R.D.L participated in the design and execution of research, including the mass 
spectrometry, circular dichroism, and protein engineering.  R.D.L. participated in the 
writing of the manuscript. 
 
2. Hernandez, K.E., Renata, H., Lewis, R.D., Kan, S.B.J., Zhang, C., Forte, J., Rozzell, 
D., McIntosh, J.A., Arnold, F.H. Highly stereoselective biocatalytic synthesis of key 
cyclopropane intermediate to ticagrelor. ACS Catal. 7810–7813 (2016). 
doi:10.1021/acscatal.6b02550 
 
 R.D.L participated in the design and execution of the protein engineering associated 
with this project. R.D.L. participated in the writing of the manuscript. 
 
3. Kan, S.B.J., Lewis, R.D., Chen, K., Arnold, F.H. Directed evolution of cytochrome c 
for carbon–silicon bond formation: Bringing silicon to life. Science 354, 1048–1051 
(2016). doi: 10.1126/science.aah6219 
 
 R.D.L participated in the conception, design, and execution of the research, focusing 
mainly on protein engineering and cytochrome c biochemistry. R.D.L. participated in 
the writing of the manuscript. 
 
4. Knight, A.M., Kan, S.B.J., Lewis, R.D., Brandenberg, O.F., Chen, K., Arnold, F.H. 
Diverse Engineered Heme Proteins Enable Stereodivergent Cyclopropanation of 
Unactivated Alkenes. ACS Cent. Sci. 4, 372–377 (2018). doi: 
10.1021/acscentsci.7b00548 
 
 R.D.L helped concieve the project, and participated in the design and execution of 
experiments including protein engineering and chemical synthesis. R.D.L. 
participated in the writing of the manuscript. 
 
5. Lewis, R.D.†, Garcia-Borràs, M.†, Chalkley, M.J., Buller, A.R., Houk, K.N., Kan, 
S.B.J., Arnold, F.H. Catalytic iron-carbene intermediate revealed in a cytochrome c 
carbene transferase. Proc. Natl. Acad. Sci. U.S.A. 115, 7308–7313 (2018). doi: 
10.1073/pnas.1807027115 
 
 R.D.L participated in the conception, design, and execution of the research. R.D.L 
solved and analyzed the crystal structures, and participated in the analysis of 
 vi 
spectroscopic and computational data. R.D.L. prepared the manuscript. 
 
PUBLISHED CONTENT NOT INCLUDED IN THESIS 
6. Wu, Z., Kan, S.B.J., Lewis, R.D., Wittmann, B.J., Arnold, F.H. Machine learning-
assisted directed protein evolution with combinatorial libraries. Proc. Natl. Acad. Sci. 
U.S.A. (2019). doi:10.1073/pnas.1901979116 
  
 R.D.L participated in the conception of the project, and helped design the molecular 
cloning strategy. 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
vii 
TABLE OF CONTENTS 
Acknowledgments .............................................................................................. iv 
Abstract ................................................................................................................ v 
Published Content and Contributions ................................................................ vi 
Table of Contents ............................................................................................ viii 
List of Tables and Schemes ............................................................................... xii 
List of Figures .................................................................................................. xiii 
Abbreviations .................................................................................................... xvi 
 
Chapter I: Beyond cytochrome P450: introduction to heme protein  
 catalyzed carbene transfer reactions ................................................. 1 
1.1   Abstract ................................................................................................. 1 
1.2   Enzymes and directed evolution ........................................................... 2 
1.3   New reactions and catalytic promiscuity .............................................. 2 
1.4   Cyclopropanation via carbene transfer ................................................. 3 
1.5   Results and discussion ........................................................................... 5 
 1.5.1   Cyclopropanation to produce a key intermediate to  
  ticagrelor ................................................................................... 5 
 1.5.2   Cyclopropanation of unactivated alkenes ................................. 7 
1.6   Conclusions ......................................................................................... 10 
1.7   References ........................................................................................... 11 
 
 
Appendix A: Supporting Information for Chapter 1 ....................................... 14 
A.1    Materials and methods ...................................................................... 14 
A.2    Cloning and library generation ......................................................... 15 
A.3    Hemochrome assay ........................................................................... 16 
A.4    Growth and induction in 96-well plates ............................................ 16 
A.5    Growth and induction in flasks ......................................................... 17 
A.6    Reactions screening in 96-well plates ............................................... 17 
 A.6.1    Ticagrelor .............................................................................. 17 
 A.6.2    Unactivated alkenes .............................................................. 18 
A.7    Small scale biocatalytic reactions ..................................................... 18 
 A.7.1    Ticagrelor .............................................................................. 18 
 A.7.2    Unactivated alkenes .............................................................. 19 
A.8    Proteins investigated and homology modeling ................................. 20 
A.9    Synthesis and characterization of authentic products ....................... 20 
 A.9.1    Ticagrelor .............................................................................. 20 
 A.9.2    Unactivated alkenes .............................................................. 21 
A.10  Calibration curves ............................................................................. 24 
A.11  Nucleotide and amino acid sequences .............................................. 26 
  
viii 
A.12  References ......................................................................................... 26 
 
 
Chapter II: Directed evolution of cytochrome c for carbon–silicon bond 
 formation ...................................................................................... 28 
2.1    Abstract .............................................................................................. 28 
2.2    Introduction ........................................................................................ 29 
2.3    Results and discussion ........................................................................ 29 
 2.3.1    Heme catalyzed carbon–silicon bond formation ................... 29 
 2.3.2    Evolution of Rhodothermus marinus cytochrome c ............. 30 
 2.3.3    Substrate scope ....................................................................... 33 
 2.3.4    Chemoselectivity changes over the course of evolution ....... 33 
 2.3.5    Hypothesized substrate binding modes ................................. 35 
2.4    Conclusions ........................................................................................ 36 
2.5    References .......................................................................................... 37 
 
Appendix B: Supporting Information for Chapter 2 ........................................ 40 
B.1    Materials and methods ....................................................................... 40 
B.2    Plasmid construction ......................................................................... 41 
B.3    Cytochrome c expression and purification ........................................ 41 
B.4    P450 and globin expression and purification .................................... 42 
B.5    Hemochrome assay ............................................................................ 43 
B.6    Ferrous assay ..................................................................................... 44 
B.7    Library construction .......................................................................... 45 
B.8    Enzyme library screening .................................................................. 45 
B.9    Protein lysate preparation .................................................................. 46 
B.10  Small-scale biocatalytic reactions ..................................................... 47 
B.11  Supporting tables ............................................................................... 48 
B.12  Supporting figures ............................................................................. 52 
B.13  References ......................................................................................... 54 
 
Chapter III: Catalytic iron-carbene intermediate revealed in a cytochrome c 
 carbene transferase ..................................................................... 57 
3.1    Abstract .............................................................................................. 57 
3.2    Introduction ........................................................................................ 58 
3.3    Results and discussion ........................................................................ 59 
 3.3.1    Structural characterization of engineered carbene 
 transferase, Rma TDE ............................................................ 59 
 3.3.2    Crystallographic observation of an iron porphyrin carbene 
 in Rma TDE ........................................................................... 61 
 3.3.3    Iron porphyrin carbene electronic structure and 
 spectroscopy .......................................................................... 64 
 3.3.4    Computational models of the iron porphyrin carbene .......... 65 
3.4    Summary and conclusions ................................................................. 66 
3.5    References .......................................................................................... 66 
  
ix 
 
Appendix C: Supporting Information for Chapter 3 ....................................... 70 
C.1    Materials and methods ....................................................................... 70 
C.2    Plasmid construction ......................................................................... 71 
C.3    Cytochrome c expression and purification ........................................ 72 
C.4    57Fe-labelled cytochrome c expression and purification ................... 73 
C.5    Hemochrome assay ............................................................................ 75 
C.6    Synthesis and characterization of authentic organosilicon product .. 75 
C.7    Biocatalytic reactions ........................................................................ 76 
C.8    UV-Visible spectroscopy .................................................................. 77 
C.9    X-ray crystallography ........................................................................ 77 
C.10  Mössbauer spectroscopy ................................................................... 79 
 C.10.1    General description of Mössbauer spectroscopy ................ 79 
 C.10.2    Sample preparation for Mössbauer spectroscopy ............... 79 
C.11  Electron paramagnetic resonance (EPR) spectroscopy .................... 80 
 C.11.1    General description of EPR spectroscopy .......................... 80 
 C.11.2    Sample preparation for EPR spectroscopy ......................... 80 
C.12  Supporting tables and figures ............................................................ 81 
C.13  References ......................................................................................... 95 
 
Chapter IV: Origins of chemoselectivity in cytochrome c-catalyzed carbene 
 insertions into silicon–hydrogen bonds ..................................... 98 
4.1    Abstract .............................................................................................. 98 
4.2    Introduction ........................................................................................ 99 
4.3    Results and discussion ...................................................................... 100 
 4.3.1    Quantum mechanical characterization of the reaction 
 mechanism ........................................................................... 100 
 4.3.2    Rate-determining step of the enzymatic reaction ................ 103 
 4.3.3    Silane binding to Rma cyt c ................................................. 105 
 4.3.4    Rationalization of chemoselectivity .................................... 107 
 4.3.5    Engineering inverted chemoselectivity in Rma TDE .......... 109 
4.4    Conclusions ...................................................................................... 112 
4.5    References ........................................................................................ 113 
 
Appendix D: Supporting Information for Chapter 4 ..................................... 116 
D.1    Materials and methods .................................................................... 116 
D.2    Plasmid construction ....................................................................... 117 
D.3    Cytochrome c expression and purification ..................................... 118 
D.4    Hemochrome assay ......................................................................... 119 
D.5    Library construction ........................................................................ 120 
D.6    Enzyme library screening ................................................................ 120 
D.7    Protein lysate preparation ................................................................ 121 
D.8    Biocatalytic reactions ...................................................................... 121 
 D.8.1    Kinetic time course reactions .............................................. 122 
D.9    Synthesis and characterization of organosilicon compounds ......... 123 
  
x 
D.10  Supporting figures and tables .......................................................... 125 
D.11  References ....................................................................................... 132 
 
Chapter V: Mechanism based inactivation in heme-dependent carbene 
 transferases ................................................................................. 133 
5.1    Abstract ............................................................................................ 133 
5.2    Introduction ...................................................................................... 134 
5.3    Results .............................................................................................. 135 
 5.3.1    EDA-induced inactivation of P450 BM3-Hstar .................. 135 
 5.3.2    Heme cofactor modification ................................................ 136 
 5.3.3    Modification of protein side chains and structural changes 139 
 5.3.4    Identification of modified residues ...................................... 140 
 5.3.5    Site-directed mutagenesis of modified residues improves 
 catalyst performance ............................................................ 143 
 5.3.6    Characterization of BM3-HStar H92N H100N .................. 144 
 5.3.7    Replacement of the modified heme cofactor ....................... 145 
5.4    Discussion ........................................................................................ 148 
5.4    Conclusion ........................................................................................ 151 
5.5    References ........................................................................................ 152 
 
Appendix E: Supporting Information for Chapter 5 ...................................... 157 
E.1    Materials and methods ..................................................................... 157 
E.2    Generation of enzyme variants ........................................................ 158 
E.3    Hemochrome binding assay ............................................................ 158 
E.4    Determination of εmax for ferrous histidine-ligated P450 enzymes 158 
E.5    Ferrous concentration assay ............................................................. 159 
E.6    P450 expression and purification .................................................... 160 
E.7    Small-scale whole-cell bioconversions ........................................... 160 
E.8    Small-scale cyclopropanation reaction with purified enzymes ...... 161 
E.9    Analysis of diazo-induced inactivation  .......................................... 162 
E.10  Liquid chromatography-mass spectrometry (LCMS) analysis of  
 cofactor modification ....................................................................... 163 
E.11  Isolation of modified porphyrin cofactor ........................................ 163 
E.12  Analysis of enzyme modification by top-down proteomics ........... 164 
E.13  Alkylation analysis by bottom-up proteomics ................................ 164 
E.14  Circular dichroism analysis ............................................................. 165 
E.15  Whole-cell reaction of styrene with EDA catalyzed by BM3-HStar 
variants ............................................................................................ 166 
E.16  Whole-cell reaction of aniline with EDA catalyzed by BM3-HStar 
variants ............................................................................................ 166 
E.17  Immobilization of Bsu TrHb LAA .................................................. 167 
E.18  Protein-bead reactions ..................................................................... 167 
E.19  Protein-bead heme removal and replacement ................................. 168 
E.20  Supporting tables and figures .......................................................... 169 
E.21  References ........................................................................................ 175 
  
xi 
LIST OF TABLES AND SCHEMES 
 
Table Number Page 
A-1     Heme binding proteins for unactivated alkene cyclopropanation ......... 20 
B-1     Catalytic systems for enantioselective carbene insertion into 
            silicon–hydrogen bonds ......................................................................... 48 
B-2     Preliminary experiments with heme and heme proteins ........................ 50 
B-3     Carbon–silicon bond formation catalyzed by Rma cyt c variants ......... 51 
C-1     Data collection and refinement statistics for Rma TDE ........................ 81 
C-2     Bond lengths of interest .......................................................................... 82 
C-3     Out-of-plane distortions for various IPC structures ............................... 93 
E-1     Amino acids substitutions relative to WT P450-BM3 ......................... 169 
E-2     TTN and selectivity for whole-cell BM3-HStar variants .................... 169 
E-3     TTN and selectivity for purified BM3-Hstar variants ......................... 169 
E-4     Representative deconvolution for purified, intact protein ................... 172 
E-5     Representative deconvolution of EDA-treated intact protein .............. 172 
 
Scheme Number Page 
4-1     General reaction catalyzed by Rma TDE ............................................. 100 
4-2     Schematic representation of the IPC insertion into the Si–H bond ...... 104 
D-1    How silane binding might affect the enzyme rate-determining step .... 131 
5-1     Cyclopropanation catalyzed by BM3-Hstar ......................................... 136 
5-2     Proposed method for replacing modified heme cofactor  .................... 146 
  
xii 
LIST OF FIGURES 
Number Page 
1-1     Cytochrome P450-catalyzed cyclopropanation and epoxidation ............. 4 
1-2     Ticagrelor and key synthetic intermediates .............................................. 5 
1-3     Site selection in Bacillus subtilis TrHb .................................................... 7 
1-4      Test reactions for unactivated alkene cyclopropanation ......................... 9 
1-5      Substrate scope of ApePgb AGW and RmaNOD Q52V ....................... 10 
A-1     Achiral GC calibration curve of 6 .......................................................... 25 
A-2     Achiral GC calibration curve of 12 ........................................................ 25 
A-3     Achiral GC calibration curve of 13 ........................................................ 25 
2-1      Heme protein-catalyzed carbon–silicon bond formation ...................... 32 
2-2      Scope of Rma TDE-catalyzed carbon–silicon bond formation ............. 34 
2-3      Chemoselectivity of evolved Rma cyt c ................................................ 35 
2-4      Proposed model for carbene orientation ................................................ 36 
B-1      SDS-PAGE of purified Rma cyt c ........................................................ 52 
B-2      Circular dichroism spectra of purified Rma TDE ................................. 52 
B-3      Hammett analysis of Rma TDE-catalyzed carbon–silicon  
            bond formation ...................................................................................... 53 
3-1      The scope of laboratory-evolved biocatalytic carbene transfer  
            reactions ................................................................................................. 59 
3-2      Carbene transfer silylation reaction and structures of resting and 
           carbene-bound Rma TDE ....................................................................... 63 
C-1     Active-site front loop deviation ............................................................. 82 
C-2     UV-vis spectra ........................................................................................ 84 
C-3     EPR spectroscopic analysis .................................................................... 86 
C-4     Mössbauer spectroscopy studies ............................................................ 87 
C-5     GC standard curve for ethyl 2-(dimethylphenylsilyl)propanoate .......... 94 
C-6    1H NMR for ethyl 2-(dimethylphenylsilyl)propanoate .......................... 94 
  
xiii 
C-7    Separation of ethyl 2-(dimethylphenylsilyl)propanoate ......................... 95 
4-1     Computed reaction pathway for carbene Si–H insertion reaction 
           between PhMe2SiH and Me-EDA ....................................................... 102 
4-2      Intrinsic reaction coordinate for the lowest energy Si–H carbene 
            insertion transition state ....................................................................... 102 
4-3      Silane binding and MD simulations with Rma TDE and  
           WT Rma cyt c ....................................................................................... 106 
4-4      Comparison of amination and silylation transition states ................... 108 
4-5      Evolution of an amination-selective variant of Rma cyt c .................. 111 
D-1      Kinetic time course data for Rma cyt c variants ................................. 125 
D-2      1H NMR for phenyl(dimethyl)silane-d ............................................... 129 
D-3      GC standard curve for ethyl 2-(dimethylphenylsilyl)propanoate ...... 130 
5-1       On-cycle and off-cycle catalytic pathways for carbene transfer ........ 135 
5-2       LC-MS monitoring of heme content over time .................................. 138 
5-3       Analysis of modified porphyrin isolated after the cyclopropanation . 138 
5-4       CD spectra of BM3-Hstar before and after EDA treatment ............... 140 
5-5       Representative LC-MS/MS analysis of alkylated peptides ................ 141 
5-6       Location of alkylated residues relative to the heme cofactor ............. 142 
5-7       Site-directed mutagenesis of BM3 Hstar to improve cyclopropanation 
             yield and selectivity ............................................................................ 145 
5-8       Use and re-use of agarose bead immobilized Bsu TrHb LAA ........... 148 
E-1       Pre-incubation experiments with EDA and BM3-Hstar .................... 170 
E-2       Comparison of isolated porphyrin with PPIX standard ..................... 171 
E-3       Whole protein MS of BM3-Hstar before and after EDA treatment .. 171 
E-4       Polar contact between K69 and heme cofactor .................................. 172 
E-5       TTN comparison for styrene cyclopropanation and N–H insertion 
             between BM3-HStar and BM3-HStar H92N H100N ........................ 173 
E-6       Whole cell time course using HStar variants ..................................... 173 
E-7       Circular dichroism of HStar H92N H100N before and  
             after reaction ....................................................................................... 174 
  
xiv 
E-8       GC calibration curve for aniline/EDA product .................................. 174 
E-9       Control reactions with immobilized Bsu TrHb LAA ......................... 175 
  
xv 
ABBREVIATIONS 
Å  angstrom(s) 
AcOH  acetic acid 
ALA 5-aminolevulinic acid 
amp ampicillin 
ApePgb protoglobin from Aeropyrum pernix 
Bsu Bacillus subtilis 
BM3-Hstar a histidine-ligated P450 variant engineered for cyclopropanation 
cyt c cytochrome c 
CD  circular dichroism 
chlor chloramphenicol 
CSS closed-shell singlet 
DCM dichloromethane 
DFT density functional theory 
d.r.  diastereomeric ratio 
ee  enantiomeric excess 
EDA ethyl diazoacetate 
EtOH ethanol 
FID flame ionization detection 
FPLC fast protein liquid chromatography 
GC  gas chromatography 
HB  hyperbroth medium 
HPLC  high performance liquid chromatography 
HRMS  high resolution mass spectrometry 
IPC iron porphyrin carbene 
LB  Luria-Bertani medium 
LC-MS  liquid chromatography with mass spectrometry 
M9-N  M9 minimal media with no nitrogen source added 
MD molecular dynamics 
Me-EDA  ethyl 2-diazopropanoate (methyl-EDA) 
MeCN acetonitrile 
MeOH methanol 
MOPS 3-(N-morpholino)propanesulfonic acid 
NaPi sodium phosphate 
OD600 optical density at 600 nm 
OSS open-shell singlet 
P450 BM3 Cytochrome P450 from Bacillus megaterium (CYP102A1) 
PDB  Protein Data Bank 
QM/MM quantum mechanics / molecular mechanics 
Rma Rhodothermus marinus 
RmaNOD nitric oxide dioxygenase from Rhodothermus marinus 
  
xvi 
Rma TDE Rma cytochrome c V75T M100D M103E 
Rma TDFPI Rma cytochrome c V75T M100D (N80F M99P E103I) 
RT  room temperature 
SFC supercritical fluid chromatography 
tR  retention time 
TrHb truncated hemoglobin 
TS transition state 
TTN total turnover number 
WT wild type 
 
 
 
 
 
  
1 
C h a p t e r  1  
BEYOND CYTOCHROME P450: INTRODUCTION TO HEME 
PROTEIN CATALYZED CARBENE TRANSFER REACTIONS 
Material from this chapter appears in “Hernandez KE, Renata 
H, Lewis RD, Kan SBJ, Zhang C, Forte J, Rozzell D, McIntosh 
JA, Arnold FH (2016) Highly stereoselective biocatalytic 
synthesis of key cyclopropane intermediate to ticagrelor. 
ACS Catalysis, 6:7810-7813. doi: 10.1021/acscatal.6b02550” 
and “Knight AM, Kan SBJ, Lewis RD, Brandenberg OF, Chen 
K, Arnold FH (2018) Diverse engineered heme proteins 
enable stereodivergent cyclopropanation of unactivated 
alkenes. ACS Cent Sci, 4:372-377. doi: 
10.1021/acscentsci.7b00548” Reprinted with permission from 
the American Chemical Society. 
 
 
1.1 Abstract 
 
Heme proteins have been discovered to catalyze cyclopropanation reactions via a 
putative carbene transfer mechanism, which is not known to occur in nature. Although 
initially discovered through studies of cytochrome P450 enzymes, trace cyclopropanation 
activity is found in many heme proteins, including those not known to have any natural 
catalytic function. Through directed evolution, these heme proteins can be engineered into 
highly efficient and selective cyclopropanation enzymes, and the natural diversity of heme 
proteins provides a functionally diverse panel of starting points from which we can rapidly 
engineer biocatalysts to produce new and useful cyclopropane products. This work highlights 
how directed evolution, reaction mechanism, and the natural diversity of proteins can be 
leveraged to develop biocatalysts for synthetically important reactions, which provides new 
opportunities to replace traditional chemical syntheses of cyclopropanes with efficient, clean, 
and highly selective enzyme-catalyzed processes. 
  
  
2 
1.2 Enzymes and directed evolution 
 
Over the billions of years that life has been evolving on earth, nature has engineered 
enzymes to catalyze a multitude of biochemical reactions. Through the natural process of 
evolution, enzymes have become finely tuned for their specific functions and are highly 
efficient for their native reactions. Because of their remarkable efficiency and selectivity, 
enzymes are attractive candidates for use in industrial chemical synthesis1,2. However, the 
enzymes found in nature are not optimized for use by human chemists—natural enzymes 
may be poor catalysts under industrial conditions or may have low activity with non-native 
substrates2. 
In order to create enzymes optimized for industrial purposes, researchers turn to directed 
evolution, a laboratory process designed to mimic evolution in the natural world3,4. In a 
directed evolution experiment, researchers start with an enzyme that has some measureable 
desired property (or properties) that they wish to optimize. Next, a library of genes is created, 
each encoding an enzyme containing a few mutations (≥1) relative to the “parent” enzyme. 
The variants are then evaluated for the desired property (“fitness”). When researchers 
identify a mutation that improves enzyme fitness, this variant can serve as a new parent 
enzyme, and the directed evolution cycle can be repeated. Iteration of the directed evolution 
cycle leads to an accumulation of beneficial mutations in the enzyme, ultimately optimizing 
the enzyme for the desired property. 
 
1.3 New reactions and catalytic promiscuity 
 
Directed evolution is the method of choice for creating enzymes of high value to 
chemists: enzymes with improved stability, activity with non-native substrates, and/or altered 
selectivity1. More recently, directed evolution has been applied to solve a new problem—
creating enzymes that catalyze reactions not known to occur in biology5,6. Many useful 
reactions known in synthetic chemistry have no biological counterpart, and developing 
enzymes to catalyze these reactions would provide new green routes for chemical 
synthesis5,6.  
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A good strategy for identifying and evolving an enzyme to catalyze a synthetic reaction 
is to take a mechanism-guided approach5. Enzymes often display “catalytic promiscuity”, 
meaning that in addition to catalyzing their native reaction they also display low-level 
activity for mechanistically similar reactions7–9. Thus, by looking for similarity between the 
mechanism of a desired synthetic reaction and enzyme mechanisms, we can identify 
candidate enzymes to screen for the new, desired catalytic activity5. Once an enzyme with 
the desired catalytic activity is identified, directed evolution can be used to re-optimize the 
enzyme for its new function. 
 
1.4 Cyclopropanation via carbene transfer 
 
In a seminal example, Coelho et al. investigated the ability of cytochrome P450 proteins 
to catalyze a non-natural cyclopropanation reaction between ethyl diazoacetate (EDA, 1) and 
styrene10 (2, Figure 1-1a). Mechanistic studies of small molecule iron porphyrin 
cyclopropanation catalysts had shown that the reaction proceeds by formation of a reactive 
iron porphyrin carbene (IPC) intermediate, and subsequent transfer of the carbene to an 
alkene, yielding a three-membered ring (cyclopropane) product11 (Figure 1-1c). Mechanistic 
studies have also demonstrated that cytochrome P450 catalyze epoxidation reactions by a 
similar mechanism12. Cytochrome P450 proteins use an iron porphyrin (heme) cofactor, and 
catalyze epoxidation by first forming a reactive iron-oxo (oxene equivalent) intermediate 
(Figure 1-1b). The oxene equivalent is then transferred to an alkene, yielding a three-
membered ring (epoxide) product.  
By providing proteins with a carbene precursor (1) and an alkene (2), Coelho et. al found 
that cytochrome P450 proteins displayed some promiscuous activity for the 
cyclopropanation reaction. After discovering the initial reactivity, the researchers were able 
to evolve cytochrome P450 variants with improved cyclopropanation activity and evolved 
variants that allowed access to different stereoisomers of the cyclopropane product. 
Interestingly, Coelho et. al also found measureable activity for styrene cyclopropanation in 
other heme binding proteins that were not typically considered “enzymes”, including heme-
dependent electron- and oxygen-transport proteins (cytochrome c and globin proteins). These  
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proteins are small, well-studied proteins that have been shown to be robust to mutation 
and can be easily expressed to high titers in E. coli—making them promising scaffolds for 
biocatalysts13,14. 
Following the initial report of heme protein catalyzed cyclopropanation, researchers from 
the lab of Rudi Fasan (University of Rochester) began to engineer sperm whale myoglobin 
for cyclopropanation activity. Fasan and coworkers targeted mutations to the distal oxygen 
binding pocket of the protein, and after introducing only two mutations, they produced a 
variant which catalyzed cyclopropanation reactions with efficiency and selectivity rivalling 
the best P450-derived cyclopropanation catalysts13. Their work showed that myoglobin was 
an easily engineered scaffold for cyclopropanation reactions, and suggested that other 
members of the globin superfamily might also be easily engineered into cyclopropanation 
enzymes.  
 
Figure 1-1. Cytochrome P450 catalyzed cyclopropanation and epoxidation. A. The reaction 
between ethyl diazoacetate and styrene produces a cyclopropane with two chiral centers. B. 
Epoxidation is a natural reaction catalyzed by cytochrome P450 proteins, which proceeds 
through the key catalytic intermediate Compound I, an iron-oxo species. C. Proposed 
mechanism for P450-catalyzed cyclopropanation. A diazo compound serves as a carbene 
precursor, and reacts with the heme cofactor to form an iron-porphyrin carbene intermediate. 
Figure adapted from Coelho et al. This is reference 11. 
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1.5 Results and discussion 
1.5.1 Cyclopropanation to produce a key intermediate to ticagrelor 
 
Cyclopropyl motifs are present in many bioactive and synthetic compounds and serve as 
versatile intermediates in organic synthesis15,16. Thus, after the initial reports of heme protein 
catalyzed cyclopropanation reactions, we sought to apply enzymatic cyclopropanation to a 
pharmaceutically relevant synthetic problem. Ticagrelor (3) is an FDA-approved, 
multibillion-dollar small-molecule therapeutic for which most of the patented syntheses use 
a key chiral cyclopropane intermediate, (1R,2S)- 2-(3,4-difluorophenyl)cyclopropan-1-
amine17 (4). This key chiral intermediate can be accessed by a single-step derivatization of 
ethyl-(1R, 2R)-2-(3,4-difluorophenyl)-cyclopropane-1-carboxylate (6), which closely 
resembles products made already made by P450- and globin-derived cyclopropanation 
enzymes.  
 
 
Figure 1-2. Ticagrelor and key synthetic intermediates. A. Structure of ticagrelor (3) B. The 
cyclopropyl ester precursor 6 can be converted to the cyclopropylamine precursor (4) by a 
Curtius rearrangement or Hofmann rearrangement of the corresponding amide C. 
Cyclopropanation reaction between ethyl diazoacetate (1) and 3,4-difluorostyrene (5) makes 
the cyclopropyl ester (6). 
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In order to evolve a cyclopropanation enzyme that could be used in the synthesis of 
ticagrelor, we began screening heme proteins for their ability to selectively produce the 
desired R,R isomer. We screened proteins previously engineered to catalyze 
cyclopropanation reactions, as well as wild-type globin and cytochrome c proteins. We 
identified a wild-type globin protein that produced the desired trans isomer with >99:1 
diastereomeric ratio (d.r.) and 34% enantiomeric excess (ee) for the desired (R,R) 
enantiomer. The protein, a type II truncated hemoglobin (TrHb) from Bacillus subtilis, is a 
small (132 residues, 15 kDa) monomeric protein with high oxygen affinity and a published 
crystal structure18 (PDB ID: 1UX8). By aligning19 the crystal structure of TrHb with the 
structure of sperm whale myoglobin20, we chose residues to mutate in TrHb that were 
analogous to those targeted by the Fasan lab in sperm whale myoglobin (T45 and Q49 in 
TrHb, Figure 1-3). The two residues were mutated simultaneously to one of three residues 
(leucine, phenylalanine, and alanine) and the mutant proteins were screened for improved 
cyclopropane yield and enantioselectivity. The TrHb T45A Q49A double mutant stood out 
as highly selective, yielding the desired product in 95% ee with an analytical yield of 57%. 
To further improve enantioselectivity, site-saturation mutagenesis was performed at position 
A45, and the putative distal heme ligand Y25. While mutations at A45 failed to improve 
enantioselectivity, screening of the Y25 library led to the discovery of variant TrHb Y25L 
T45A Q49A, which maintained the yield of the parent protein while affording >99% d.r. and 
97% ee at 40 mM 1 and 20 mM 5.  
Like Fasan’s earlier work with sperm whale myoglobin, our work provided an example 
of a wild-type, non-enzyme heme protein that could be easily evolved into a highly efficient 
and selective cyclopropanation catalyst. Together, our work and Fasan’s work demonstrated 
that cyclopropanation enzymes with divergent stereospecificity can be easily evolved from 
parent proteins found in nature’s repertoire of non-enzyme heme proteins. More generally, 
the results suggest that the natural diversity of heme proteins can be leveraged to discover 
functionally diverse cyclopropanation catalysts. 
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Figure 1-3. Site selection in Bacillus subtilis TrHb. A. Structure-guided sequence alignment 
between sperm whale myoglobin (Physter macrocephalus Mb) and Bacillus subtilis TrHb. 
Resides highlighted in red were targeted for mutagenesis by the Fasan lab13, and the 
analogous residues in Bacillus subtilis TrHb, T45 and Q49, were targeted for mutagenesis in 
this work. B. Positions of the Y25, T45, and Q49 residues near the heme iron in the B. subtilis 
wild-type protein (PDB ID: 1UX8).  
 
1.5.2 Cyclopropanation of unactivated alkenes 
 
Although capable of high turnover and selectivity, the first cyclopropanation enzymes 
were limited to activity on aryl alkenes10,13,21–23. Unactivated, aliphatic alkenes are attractive 
feedstocks for chemical synthesis, but their transformation to higher-value chiral products is 
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challenging due to their inert nature, high degree of conformational flexibility, and limited 
steric and electronic bias to guide stereocontrol24. We therefore set out to discover heme 
proteins that could cyclopropanate unactivated alkenes, and test our hypothesis that we could 
leverage the natural diversity of heme proteins to find functionally diverse cyclopropanation 
catalysts.  
We collected a panel of eleven heme proteins from thermophilic and hyperthermophilic 
bacteria and archaea to test for unactivated alkene cyclopropanation (Appendix A.6, Table 
A-1). Proteins from thermophiles were selected because thermostable proteins are better able 
to withstand the destabilizing effects of mutations, and are therefore more “evolvable”25. 
They are also often easier to work with and better tolerate polar organic solvents used to 
solubilize substrates. We screened this panel of proteins for cyclopropanation activity on 1-
octene (7) with ethyl diazoacetate (1), and found that Aeropyrum pernix protoglobin (ApePgb 
WT, UniProt ID: Q9YFF4) and Rhodothermus marinus nitric oxide dioxygenase (RmaNOD 
WT, UniProt ID: D0MGT2) had low but measurable activity for this reaction, catalyzing the 
reaction with 18 and 27 total turnovers (Figure 1-4a). Notably, ApePgb WT and RmaNOD 
WT displayed complementary diastereoselectivity, preferentially producing cis (R,S)-8 and 
trans (S,S)-8, respectively.  
Site-saturation mutagenesis libraries were generated and screened to increase the 
activities and selectivities of the different enzymes. Because crystal structures of ApePgb and 
RmaNOD have not been reported, homology models were built to help us identify residues 
within the putative distal heme pocket, where carbene formation and substrate binding are 
predicted to take place (Appendix A.6, Table A-1). Individual site-saturation libraries were 
screened for increased activity and diastereoselectivity using 4-phenyl-1-butene (9) and EDA 
(1) as substrates (9 was chosen as a substrate for library screening because the UV-visible 
phenyl group enables screening by HPLC-UV). Variants with enhanced diastereoselectivity 
in the production of 10 were regrown in larger scale, and their activities were tested for 
cyclopropanation of 1-octene (7) and 4-phenyl-1-butene (9) and with EDA. Enzyme variants 
with the greatest overall selectivity enhancements were used as parents in the next rounds of 
site-saturation mutagenesis and screening. A single mutation (Q52V) gave RmaNOD near-
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perfect stereoselectivity for producing trans (S,S)-7. Three mutations (W59A Y60G 
F145W, or “AGW”) gave ApePgb the ability to make cis (R,S)-7 with 89:11 d.r. and 99% ee. 
In addition to activity on the two unactivated alkene substrates 7 and 9, RmaNOD Q52V 
and ApePgb AGW were found to have even higher activity for cyclopropanation of an 
acrylate compound, an electron-deficient alkene (Figure 1-5a). ApePgb AGW was also 
found to have activity on a variety of other alkene substrates including sterically hindered 
alkenes and small electron-deficient alkenes (Figure 1-5b). Though activity and 
stereoselectivity differed on different substrates, the broad range of alkenes accepted by 
ApePgb AGW suggests that this variant could serve as a good parent protein from which to 
evolve cyclopropanation catalysts that accept specific alkene substrates to make a specific 
desired product, as has been shown in many other directed evolution studies3,4. 
 
 
Figure 1-4. Test reactions for unactivated alkene cyclopropanation. A. Cyclopropanation of 
1-octene (7) with ethyl diazoacetate (1). B. Cyclopropanation of 4-phenyl-1-butene (9) with 
ethyl diazoacetate (1). 
 
 
  
10 
 
Figure 1-5. Substrate scope of ApePgb AGW and RmaNOD Q52V. Reactions were 
performed under anaerobic conditions using whole E. coli cells at OD600 = 5.0 in M9-N 
buffer with 25 mM glucose, 5% ethanol as a cosolvent, 10 mM alkene, and 20 mM 1. A. 
ApePgb AGW and RmaNOD Q52V are able to produce cyclopropane products using the 
unactivated alkene screening substrates, as well as using an electron deficient alkene to 
produce product 10. B. Activity and selectivity for a range cyclopropane products produced 
by ApePgb AGW. Reaction conditions for product 13 used cells at OD600 = 10 and for product 
15 OD600 = 20. 
 
1.6 Conclusions 
 
While biocatalysts often possess very high selectivity, this selectivity can be synthetically 
limiting. A single enzyme may make only a single isomer, and/or may only accept a certain 
range of substrates, but a synthetic chemist may want a to access a wide range of substrates 
and a variety of product isomers. Therefore, for broad synthetic utility, an array of 
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biocatalysts may be needed to access a broad range of chemical transformations. For 
natural reactions, the natural diversity of enzymes has been leveraged to meet this challenge: 
genome mining has been used to discover lipases, ketoreductases, and transaminases with 
different stereoselectivities and substrate preferences26–28. However, when engineering 
enzymes for a new-to-nature reaction, this genome mining approach may be impractical. In 
the case of cyclopropanation reactions, there is no established family of “carbene 
transferases” to use as a template for genome mining. Here, we have addressed this problem 
by demonstrating that heme-binding globin proteins are a rich source of functionally diverse 
cyclopropanation catalysts. With just a few mutations, they can catalyze cyclopropanation 
reactions with high efficiency and selectivity, despite the fact that they may not have any 
known natural catalytic activity. Thus, by surveying the natural diversity of heme binding 
proteins, we can find good starting points for evolution and rapidly engineer novel 
cyclopropanation biocatalysts. This approach has allowed us to develop catalysts for 
pharmaceutical precursors as well as cyclopropanes derived from electronically challenging 
substrates. As these cyclopropanation enzymes function via a carbene transfer mechanism, 
they may also display promiscuous activity for new carbene transfer reactions and serve as 
starting points from which to evolve novel reactivity in biological systems.  
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A p p e n d i x  A  
SUPPLEMENTARY INFORMATION FOR CHAPTER 1 
Material from this chapter appears in “Hernandez KE, Renata 
H, Lewis RD, Kan SBJ, Zhang C, Forte J, Rozzell D, McIntosh 
JA, Arnold FH (2016) Highly stereoselective biocatalytic 
synthesis of key cyclopropane intermediate to ticagrelor. 
ACS Catalysis, 6:7810-7813. doi: 10.1021/acscatal.6b02550” 
and “Knight AM, Kan SBJ, Lewis RD, Brandenberg OF, Chen 
K, Arnold FH (2018) Diverse engineered heme proteins 
enable stereodivergent cyclopropanation of unactivated 
alkenes. ACS Cent Sci, 4:372-377. doi: 
10.1021/acscentsci.7b00548” Reprinted with permission from 
the American Chemical Society. 
 
 
A.1 Materials and methods 
All chemicals and reagents were purchased from chemical suppliers (Sigma-Aldrich, 
Fischer Scientific, Combi-Blocks, Alfa Aesar, TCI) and used without purification. Silica gel 
chromatography purifications were carried out using AMD Silica Gel 60, 230-400 mesh. 1H 
and 13C NMR spectra were recorded on a Bruker Prodigy 400 MHz instrument and are 
internally referenced to the residual solvent peak (chloroform). Data for 1H NMR are 
reported in the conventional form: chemical shift (δ ppm), integration, multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet), coupling constant (Hz). Data for 
13C are reported in terms of chemical shift (δ ppm). High-resolution mass spectra were 
obtained with a JEOL JMS-600H High Resolution Mass Spectrometer at the California 
Institute of Technology Mass Spectral Facility. Sonication was performed using a Qsonica 
Q500 sonicator. Chemical reactions were monitored using thin layer chromatography 
(Merck 60 silica gel plates) and a UV-lamp for visualization. GC-FID data were collected on 
a Shimadzu GC-17A, Agilent 6850 GC system, and Agilent 7820A GC system. GC-MS data 
were collected on a Shimadzu GCMS-QP2010 SE. Screening HLPC-UV data were taken on 
an Agilent 1200 series HPLC. Normal-phase chiral HPLC data were taken on an Agilent 
1100 series HPLC. Optical rotation data were collected on a JASCO P-2000 Polarimeter.  
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A.2 Cloning and library generation 
Plasmid pET22b was used as a cloning vector, cloning was performed using Gibson 
assembly1. Cells were grown using Luria-Bertani medium or HyperBroth (AthenaES) with 
100 µg/mL ampicillin (LBamp or HBamp). Electrocompetent Escherichia coli cells were 
prepared using E. cloni® Express BL-21 (DE3) cells following the protocol of Sambrook 
et al.2 T5 exonuclease, Phusion polymerase, and Taq ligase were purchased from New 
England Biolabs (NEB, Ipswich, MA). Electroporation was carried out in 2 mm 
electroporation cuvettes using the Gene Pulser XCell Electroporation System (Bio-Rad). 
Codon-optimized gBlocks of the various heme binding proteins were ordered from from 
Integrated DNA Technologies (IDT). As the putative distal ligand could interfere with the 
initially low substrate binding affinities, some proteins were ordered with the distal axial 
ligands mutated to smaller, nonpolar residues, found to be beneficial for vinylarene 
cyclopropanation in myoglobin3. Some gBlocks (Table A-1) were also ordered with a 
mutation in a putative entrance tunnel residue previously found to enhance styrene 
cyclopropanation activity in myoglobin3. 
Site-saturation mutagenesis was performed using the 22-codon method4. Briefly, 
oligonucleotides were ordered with NDT, VHG, and TGG codons in the coding strand at 
the amino acid position to be saturated. A reverse primer complementary to all three 
forward primers was also ordered. Two PCRs were performed for each library, the first 
containing a mixture of forward primers (12:9:1 NDT:VHG:TGG) and a pET22b(+) 
internal reverse primer and the second containing the complementary reverse primer and a 
pET22b(+) internal forward primer. The two PCR products were gel-purified with 
Zymoclean Gel DNA Recovery Kit (Zymo Research Corp, Irvine, CA) and ligated together 
via Gibson assembly. The Gibson assembly product was transformed into 
electrocompetent E. cloni EXPRESS BL21(DE3) cells (Lucigen, Middleton, WI). Aliquots 
of SOC medium (750 µL) were added and the cells were incubated at 37°C for 45 minutes 
before being plated on LB-ampicillin (100 µg mL-1) agar plates. 
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A.3 Hemochrome assay 
 
An aliquot of cells for protein concentration determination was sonicated for 2 minutes, 
1 second on, 1 second off at 25% amplitude. Cells expressing ApePgb or RmaNOD variants 
had 0.1 eq. Bugbuster 10X protein extraction reagent (EMD Millipore) added prior to 
sonication. The sonicated lysate was clarified via centrifugation at 4500×g and 4°C for 10 
minutes. 
At room temperature, 1.75 mL pyridine was combined with 0.75 mL of 1M NaOH. The 
solution was vortexed for 30 seconds to ensure complete mixing then centrifuged for 1 
minute at 5000 rpm to remove excess base from the pyridine solution. 0.75 mL of protein 
lysate in M9-N minimal medium was combined with 0.25 mL of the pyridine solution along 
with about 2.0 mg of sodium dithionite, the cuvette’s contents were mixed with a pipet and 
sealed with parafilm. The content’s absorbance was immediately read. The concentration of 
B. subtilis TrHb was determined using an extinction coefficient of 196 mM-1 cm-1 at 420 nm. 
Baseline absorbance was determined through extrapolation of two points on either side of 
the hemochrome peak at 390 and 450 nm.  
For ApePgb and Rma NOD, 500 µL clarified lysate was sterile filtered and added to a 
cuvette. 500 µL of solution I (0.2 M NaOH, 40% (v/v) pyridine, 500 µM potassium 
ferricyanide) was added and the spectrum of this oxidized sample was taken from 350-600 
nm. Sodium dithionite (10 µL of 0.5 M solution in 0.5 M NaOH) was added and the reduced 
spectrum was taken from 350-600 nm. The pyridine hemochromagen concentration was 
determined using its Q bands, with extinction coefficient 23.98 mM-1 cm-1 for (557 nmreduced 
– 540 nmoxidized)5. 
 
A.4 Growth and induction in 96 well plates 
 
Single colonies from the LB-ampicillin agar plates were picked using sterile toothpicks 
and grown in 300 µL LB-ampicillin in 2 mL 96 deep-well plates at 37°C, 250 rpm, 80% 
humidity overnight (12-18 hours). Multi-channel pipettes were used to transfer 30 µL of 
starter culture into deep-well plates containing 1 mL HB-amp per well. Glycerol stocks of 
these plates were prepared in parallel by adding starter culture (100 µL) and 50% (v/v) sterile 
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glycerol (100 µL) to a 96-well microplate, which was then stored at -80°C. The deep-well 
expression culture plate was incubated at 37°C, 250 rpm, 80% humidity for 2.5 hours. The 
plate was then chilled on ice for 30 minutes. The cultures were induced with 0.5 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) and supplemented with 1 mM 5-
aminolevulinic acid (ALA) to increase cellular heme production. The plate was incubated at 
22°C and 250 rpm overnight. The plate was centrifuged at 4000×g for 10 minutes at 4°C.  
 
A.5 Growth and induction in flasks 
Overnight cultures were prepared in LBamp medium (100 µg/mL ampicillin) from 
glycerol stocks of protein variants. The overnight cultures were incubated at 37 °C for 12 
hours. Flasks containing HBamp medium (100 µg/mL ampicillin) were inoculated with 1% 
volume of the overnight culture. Flasks were incubated at 37 °C until they reached 
OD600=0.6-0.8. Flasks were cooled on ice for 20 minutes, then induced with 0.5 mM final 
concentration IPTG and 1 mM final concentration ALA. Flasks were incubated at 25 °C for 
18-24 hours. Cells were harvested via centrifugation at 4000 rpm, 10 minutes, at 4 °C.  
A.6 Reaction screening in 96 well-plates 
A.6.1 Ticagrelor 
 
After harvesting cells, pellets were resuspended in 350 µL M9-N minimal media. In the 
anaerobic chamber 50 µL of 3,4 difluorostyrene (0.16 M in ethanol) and EDA (0.32 M in 
ethanol) were added to the whole cells in each well. The plate was sealed with a gas-
impermeable membrane and allowed to shake in the anaerobic chamber at room temperature 
at 400 rpm for 1 hour. The plate was then removed from the anaerobic chamber, and 1 mL 
of cyclohexane was added to each well using a multichannel pipette and mixed up and down 
three times. The plates were spun for 5 minutes at 4000 rpm and 20 ºC to separate the organic 
and aqueous layers. 600 µL of the organic layer was transferred into a shallow 96-well plate 
and screened for enantioselectivity on the SFC. Analytical chiral supercritical fluid 
chromatography was performed with a JACSO 2000 series instrument using 2% i-PrOH and 
98% supercritical CO2 as the mobile phase (2.5 mL/min), with visualization at 210 and 254 
nm. The column used was Chiralpak AD-H (4.6 mm x 250 mm).  
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A.6.2 Unactivated Alkenes 
 
After harvesting cells, pellets were resuspended in 400 µL M9-N minimal media. In an 
anaerobic chamber, 50 µL reactant mixture in ethanol (final concentrations in a 450 µL 
reaction: 20 mM EDA 1, 20 mM 4-phenyl-1-butene 9) were added to the reaction plate. The 
reaction plate was covered with a gas-impermeable membrane and allowed to shake in the 
anaerobic chamber at room temperature at 500 rpm for 3 hours. To quench the reaction and 
extract the substrates, 400 µL of a mixture of acetonitrile (49 mL) and 3 M HCl (1 mL) was 
added to each well. The reaction plate was shaken for an additional 30 minutes, followed by 
centrifugation (4000×g, 10 minutes, 4°C). The supernatant was filtered through a 0.2 µm 
PTFE 96-well filter plate into a 96-well microplate (4000×g, 1 minute, RT). The microplate 
was sealed with a pierceable foil cover. The wells were screened for activity and 
diastereoselectivity of 10 formation via HPLC using a Kromasil 100-5-C18 column, 4.6x50 
mm with a 71% acetonitrile isocratic method (3 minutes). In later screening with higher 
enzymatic activity, the separation of cis- and trans-isomers of 10 was improved with the use 
of an Eclipse XDB-C18 column, 5 µm particle size, 4.6x150 mm and a 6-minute 71% 
acetonitrile isocratic method. Wells with improved activity relative to the parent protein were 
streaked out from the glycerol stock onto LB-amp plates. A single colony was picked and 
grown in 5 mL LB-amp overnight (230 rpm, 37°C). These overnight cultures were used in 
flask protein expression and small-scale biocatalytic reactions to verify enhanced activity 
and/or selectivity relative to the parent sequence.  
 
 
A.7 Small scale biocatalytic reactions 
A.7.1 Ticagrelor 
 
Small-scale (400 µL) reactions took place in 2 mL glass crimp vials. Whole cells 
expressing the enzyme were resuspended in M9-N minimal medium to the OD600 specified 
in the reaction conditions. The headspace of the vials was purged during gas cycling of an 
anaerobic chamber. The open vials were allowed to shake in the anaerobic chamber for one 
minute before reagents were added. 10 µL of 3,4-difluorostyrene (800 mM in ethanol) was 
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added to the reactions followed by 10 µL of ethyl diazoacetate (1.6 M in ethanol). Vials were 
crimp-sealed with silicone septa and removed from the anaerobic chamber and allowed to 
shake at 400 rpm at room temperature for 1 hour. After reaction completion, reactions to be 
screened with gas chromatography (GC) had 0.9 mL cyclohexane and 20 µL acetophenone 
(40 mM in cyclohexane) added to them. The vials were vortexed for 30 seconds two times 
and then centrifuged at 13000 rpm for 5 minutes at 20 °C. The supernatant was transferred 
to a clean 2 mL glass vial for analysis by GC. Reactions to be screened via supercritical fluid 
chromatography (SFC) had 0.9 ml of cyclohexane added to them then were vortexed twice 
for 30 seconds and centrifuged at 13000 rpm for 5 minutes at 20 °C. The supernatant was 
moved to a clean 2 mL glass vial for analysis on the SFC. Enantioselectivity was screened 
using SFC, while yield and diastereoselectivity were determined by GC. All reactions were 
performed in triplicate (unless otherwise noted).  
 
A.7.2 Unactivated alkenes 
 
Small-scale reactions were set up in 2 mL GC crimp vials. E. coli expressing the 
appropriate heme protein catalyst (380 µL, adjusted to the appropriate optical density or 
protein concentration) was added to the vials and they were brought into a Coy anaerobic 
chamber (~ 0-10 ppm O2). To each vial was added alkene (final concentration 10 mM) 
followed by EDA 1 (final concentration 20 mM) with 5% ethanol as a cosolvent. Directly 
following addition of EDA, the reaction vial was crimped and shaken at 500 rpm at RT. 
Reactions were worked up by the addition of HCl (16 µL, 3 M stock) and internal standard 
(16 µL of 40 mM acetophenone in cyclohexane). Cyclohexane (700 µL) was added and the 
reaction was transferred into 1.7 mL Eppendorf tubes for extraction. The extraction was 
carried out with a Retsch MM 301 mixing mill (1 minute, 30 Hz / 1800 rpm). Samples were 
centrifuged at 20000×g for 5 minutes at RT and the organic layer was used for 
chromatographic analysis. 
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A.8 Proteins investigated and homology modeling 
 
ApePgb was modeled with the Methanosarcina acetivorans protoglobin (PDB ID: 3ZJL) 
and RmaNOD was modeled with Alcaligenes eutrophus flavohemoglobin (PDB ID: 1CQX) 
using SWISS-MODEL6  
 
Table A-1. Heme-binding proteins tested for unactivated alkene cyclopropanation activity 
using 1,7-octadiene and EDA as substrates. 
UniProt ID Organism Annotation Mutation(s) from WT 
Cyclopropane 
product 
formation 
detected 
Q3IDI7 Pseudoalteromonas haloplanktis 
Putative hemoglobin-
like oxygen-binding 
protein 
Y42V 
F69A No 
Q7CX73 Agrobacterium fabrum Uncharacterized protein Y26V F53A No 
Q5L1S0 Geobacillus kaustophilus Hypothetical conserved protein 
Y29V 
Q50A No 
Q9NPG2 Homo sapiens Neuroglobin F28V F61I H64A No 
Q0PB48 Campylobacter jejuni Truncated hemoglobin none No 
B3DVC3 Methylacidiphilum infernorum Hemoglobin IV 
H71V 
L93A Yes 
D0MGT2 Rhodothermus marinus Nitric oxide dioxygenase 
Y32V 
Q52A Yes 
G7VHJ7 Pyrobaculum ferrireducens Protoglobin Y58V Yes 
Q9YFF4 Aeropyrum pernix Protoglobin Y60V Yes 
O66586 Aquifex aeolicus Thermoglobin Y29V Q50A Yes 
 
 
A.9 Synthesis and characterization of authentic products 
A.9.1 Ticagrelor 
 
Racemic ticagrelor cyclopropane rac-(6) was prepared according to the following 
procedure: To hemin (1.63 g, 2.5 mmol) in water (20 mL) under Ar was added 3,4-
difluorostyrene (1.72 g, 10 mmol). Ethyl diazoacetate (2.42 mL, 20 mmol) in DCM (3 mL) 
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was added dropwise to the vigorously stirred mixture, and the reaction was left to stir for 12 
h. The reaction was extracted with hexane (20 mL x 3), and the organic extracts were washed 
with brine (50 mL), dried (MgSO4) and concentrated in vacuo. Purification by silica flash 
chromatography (2 to 20% EtOAc in hexane) separated the desired trans-cyclopropane from 
its cis-isomer and gave rac-(5) as a colorless oil (1.43 g, 6.3 mmol, 63%). Absolute 
configuration was determined by comparing HPLC retention times to those reported in 
literature7. 
 
1H NMR (400 MHz, CDCl3) δ 7.05 (1H, td, J = 10.3, 8.5 Hz, H11), 6.94–6.74 (2H, m, H8 and 
H12), 4.17 (2H, q, J = 7.2 Hz, H2), 2.47 (1H, ddd, J = 9.4, 6.4, 4.2 Hz, H6), 1.84 (1H, ddd, J 
= 8.5, 5.3, 4.2 Hz, H4), 1.59 (1H, ddd, J = 9.2, 5.3, 4.8 Hz, H5a), 1.28 (3H, t, J = 7.1 Hz, H1), 
1.24 (1H, ddd, J = 8.4, 6.4, 4.8 Hz, H5b). 
 
13C NMR (100 MHz, CDCl3) δ 173.1, 151.0 (dd, 1JC−F = 118.7 Hz, 2J C−F = 12.8 Hz), 148.6 
(dd, 1JC−F = 117.5 Hz, 2J C−F = 12.7 Hz), 137.3 (dd, 3JC−F = 5.9 Hz, 4J C−F = 3.7 Hz), 122.5 
(dd, 3JC−F = 6.2 Hz, 4J C−F = 3.4 Hz), 117.3 (dd, 2JC−F = 17.2 Hz, 3J C−F = 0.2 Hz), 115.3 (d, 
2JC−F = 17.6 Hz), 61.0, 25.3 (d, 4JC−F = 1.7 Hz), 24.3, 17.1, 14.4. 
 
A.9.2 Unactivated alkenes 
 
General Procedure A: Rhodium acetate dimer (10 µmol, 4.4 mg) and a stir bar were 
added to a 5 mL dram vial and it was sealed with a septum. The sealed vial was purged with 
three cycles of vacuum and argon. Neat olefin (8 mmol) was added to the vial. EDA (2 mmol) 
was added in a 2-hour slow addition on ice and reacted overnight at room temperature. The 
crude reaction mixture was concentrated in vacuo and loaded on a SNAP Ultra silica flash 
cartridge. The reaction mix was separated on an Isolera flash purification system (Biotage, 
Charlotte, NC) with a hexane/ethyl acetate gradient. Fractions containing the desired product 
were pooled and concentrated in vacuo. Yields were approximately 5-30%, due in part to 
both significant EDA dimer formation and low conversion of the unactivated alkenes. 
General procedure B: Rhodium acetate dimer (40 µmol, 17 mg) and a stir bar was added 
to a scintillation vial and sealed with a septum. The sealed vial was purged with three cycles 
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of vacuum and argon. The vial was charged with alkene (5 mmol) and dichloromethane (5 
mL). EDA 1 (2.0 eq. diluted in 4 mL dichloromethane) was added at room temperature by 
slow addition over 2 hours and reacted overnight at room temperature. The crude reaction 
mixture was concentrated in vacuo and loaded on a SNAP Ultra silica flash cartridge. Using 
pentane/diethyl ether as eluents, the reaction mix was separated on an Isolera flash 
purification system (Biotage, Charlotte, NC). Fractions containing the desired product were 
pooled and concentrated in vacuo. Yields of pure fractions were approximately 5-30%, due 
in part to both significant EDA dimer formation and low conversion of the unactivated 
alkenes. This method is preferable for more volatile alkenes, and the pentane/diethyl ether 
gradients appeared to give better separation from the EDA dimer byproducts compared to 
the hexanes/ethyl acetate gradient. 
Absolute configurations of 8 were confirmed by comparison to literature chiral GC8. 
Cyclosil-B column, 90°C isothermal, absolute configuration of products elute in order: cis 
(1S, 2R)–8, (1R, 2S)–8, trans: (1R, 2R)–8, (1S, 2S)–8. The absolute configurations of other 
compounds in this study were not determined, but one could infer them by analogy, assuming 
the facial selectivity of the diazo reagents and olefins from which these products were made 
remains the same for each protein variant. The inferred absolute configurations provided here 
should be used with caution, understanding that substrate effects could have inverted the 
absolute stereochemistry. The chiral separation conditions for all cyclopropane products are 
detailed in the section below (A.8). 
 
Ethyl 2-(4-bromobutyl)cyclopropane-1-carboxylate (12) 
 
12 was synthesized with procedure A, d.r. not determined.  
 
Cis-12 1H NMR (400 MHz, Chloroform-d) δ 4.14 (q, J = 7.1 Hz, 2H), 3.40 (t, J = 6.8 Hz, 
2H), 1.93 – 1.80 (m, 2H), 1.74 – 1.38 (m, 4H), 1.56 (s, 1H), 1.33 – 1.15 (m, 4H), 1.02 (td, J 
= 8.0, 4.5 Hz, 1H), 0.92 (ddd, J = 7.2, 5.4, 4.5 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) 
δ 173.1, 60.5, 34.0, 32.6, 28.4, 26.3, 21.7, 18.3, 14.5, 13.5. HR-MS (FAB+): Fragment ion, 
  
23 
loss of ethoxy group [M - CH3CH2O]+ C8H1279BrO,calculated 203.0072, found 203.0026. 
 
12 fraction containing 71:29 trans/cis diastereomeric mixture, reporting shifts characterized 
as trans-12. 1H NMR (400 MHz, Chloroform-d) δ 4.21 – 4.04 (m, 2H), 3.40 (td, J = 6.8, 3.6 
Hz, 2H), 1.94 – 1.79 (m, 2H), 1.72 – 1.46 (m, 3H), 1.39 – 1.31 (m, 2H), 1.31 – 1.19 (m, 4H), 
1.22 – 1.12 (m, 1H), 0.74 – 0.64 (m, 1H). 13C NMR (101 MHz, Chloroform-d) δ 174.5, 60.5, 
33.8, 32.5, 32.3, 27.8, 22.6, 20.3, 15.6, 14.4.  
 
Ethyl 2-cyclohexylcyclopropane-1-carboxylate (13) 
 
13 was synthesized with general procedure A; d.r. not determined. 
 
Cis-13: 1H NMR (300 MHz, Chloroform-d) δ 4.18 – 4.04 (m, 1H), 1.85 – 1.51 (m, 6H), 1.29 
– 0.92 (m, 2H). 13C NMR (75 MHz, Chloroform-d) δ 173.2, 60.2, 35.8, 33.3, 33.2, 28.6, 
26.4, 26.1, 25.9, 17.9, 14.4, 12.5. HR-MS (FAB+): [M]+ C12H20O2, calculated 196.1463, 
found 196.1464. 
 
Ethyl spiro[2.5]octane-1-carboxylate (14) 
 
14 was synthesized with general procedure A.  
 
1H NMR (400 MHz, Chloroform-d) δ 4.11 (qd, J = 7.1, 1.0 Hz, 2H), 1.62 – 1.27 (m, 11H), 
1.24 (t, J = 7.1 Hz, 3H), 1.06 (dd, J = 5.4, 4.3 Hz, 1H), 0.79 (dd, J = 7.8, 4.3 Hz, 1H). 13C 
NMR (101 MHz, Chloroform-d) δ 173.1, 60.2, 37.4, 30.7, 28.8, 26.2 (2 overlapping 
carbons), 25.7, 25.7, 20.6, 14.4. HR-MS (FAB+): [M]+ C11H18O2, calculated 182.1307, 
found 182.1282 
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A.10 Calibration curves 
 
The calibration curve for 6 was generated by performing extraction on mock 
reactions (spiked with authentic standard) with final concentrations of product ranging from 
0 – 25 mM. Mock reactions were then extracted in 0.9 mL of cyclohexane, and 20 µL of 
acetophenone (40 mM in cyclohexane). Samples were vortexed for 30 seconds two times 
then spun at 14,000 rpm and 20 °C for 5 minutes. The cyclohexane supernatant was 
transferred to 2 mL glass vials and quantified using the GC. The average of duplicate 
extractions was used for the GC standard curve. 
Calibration curves for the unactivated alkene-derived proteins were prepared with 
analogous conditions to the analytical scale reactions. Cyclopropane product standards were 
diluted in ethanol and added (20 µL) to M9-N buffer (380 µL), with final concentrations of 
product ranging from 0 – 20 mM (with two to three technical replicates). The samples were 
worked up the same as analytical-scale reactions, by the addition of HCl (16 µL, 3 M stock) 
and internal standard (16 µL of 40 mM acetophenone in cyclohexane). Cyclohexane (700 
µL) was added and the samples were transferred into 1.7 mL Eppendorf tubes for extraction. 
The extraction was carried out with a Retsch MM 301 mixing mill (1 minute, 30 Hz / 1800 
rpm). Samples were centrifuged at 20000×g for 5 minutes at RT and the organic layer was 
used for chromatographic analysis.  
The ratio of the product area and internal standard (P/S ratio) was determined for 
each sample, and a linear regression was performed for the P/S ratio versus the known 
concentration in each reaction, with the y–intercept set to 0. The resulting slopes were used 
to determine the concentration of product in the analytical-scale reactions, which is in turn 
used to calculate the total turnover number (TTN) per enzyme. 
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Figure A-1. Achiral GC calibration curve of 6. 
 
 
Figure A-2. Achiral GC calibration curve of 12.  
 
 
 
 
Figure A-3. Achiral GC calibration curve of 13. 
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A.11 Nucleotide and amino acid sequences 
 
B. subtilis truncated globin Y25L T45A Q49A amino acid sequence  
MGQSFNAPYEAIGEELLSQLVDTFLERVASHPLLKPIFPSDLTEAARKAKQFLTQYLGGPPLYTEEHGHPMLR
ARHLPFPITNERADAWLSCMKDAMDHVGLEGEIREFLFGRLELTARHMVNQTEAEDRSSLEHHHHHH* 
 
B. subtilis truncated globin Y25L T45A Q49A nucleotide sequence  
ATGGGTCAAAGTTTCAATGCACCATACGAAGCCATCGGGGAAGAGCTGCTCAGTCAGCTCGTTGATACGTT
CCTGGAGCGTGTGGCGTCTCATCCGCTGCTCAAACCGATTTTTCCGTCTGATCTGACGGAAGCCGCACGTA
AAGCGAAGCAGTTTCTGACGCAATATCTCGGTGGTCCGCCGTTATACACTGAAGAACATGGTCACCCAATG
CTTCGCGCGCGGCACCTCCCATTCCCGATCACCAATGAGCGTGCGGACGCTTGGCTCTCCTGTATGAAAGA
CGCAATGGATCACGTGGGACTGGAAGGTGAAATTCGTGAATTCCTGTTTGGTCGTTTAGAACTGACGGCGC
GCCACATGGTCAATCAGACCGAAGCAGAAGACCGGAGCAGCCTCGAGCACCACCACCACCACCACTGA 
 
ApePgb AGW amino acid sequence 
MTPSDIPGYDYGRVEKSPITDLEFDLLKKTVMLGEKDVMYLKKACDVLKDQVDEILDLAGGWVASNEHLIYYF
SNPDTGEPIKEYLERVRARFGAWILDTTCRDYNREWLDYQYEVGLRHHRSKKGVTDGVRTVPHIPLRYLIAWI
YPITATIKPFLAKKGGSPEDIEGMYNAWFKSVVLQVAIWSHPYTKENDWLEHHHHHH* 
 
ApePgb AGW nucleotide sequence 
ATGACTCCCTCGGACATCCCGGGATATGATTATGGGCGTGTCGAGAAGTCACCCATCACGGACCTTGAGTTTG
ACCTTCTGAAGAAGACTGTCATGTTAGGTGAAAAGGACGTAATGTACTTGAAAAAGGCGTGTGACGTTCTGAA
AGATCAAGTTGATGAGATCCTTGACTTGGCGGGTGGTTGGGTAGCATCAAATGAGCATTTGATTTATTACTTC
TCCAATCCGGATACAGGAGAGCCTATTAAGGAATACCTGGAACGTGTACGCGCTCGCTTTGGAGCCTGGATTC
TGGACACTACCTGCCGCGACTATAACCGTGAATGGTTAGACTACCAGTACGAAGTTGGGCTTCGTCATCACCG
TTCAAAGAAAGGGGTCACAGACGGAGTACGCACCGTGCCCCATATCCCACTTCGTTATCTTATCGCATGGATC
TATCCTATCACCGCCACTATCAAGCCATTTTTGGCTAAGAAAGGTGGCTCTCCGGAAGACATCGAAGGGATGT
ACAACGCTTGGTTCAAGTCTGTAGTTTTACAAGTTGCCATCTGGTCACACCCTTATACTAAGGAGAATGACTG
GCTCGAGCACCACCACCACCACCACTGA 
 
RmaNOD Q52V amino acid sequence 
MAPTLSEQTRQLVRASVPALQKHSVAISATMYRLLFERYPETRSLFELPERVIHKLASALLAYARSIDNPSAL
QAAIRRMVLSHARAGVQAVHYPLVWECLRDAIKEVLGPDATETLLQAWKEAYDFLAHLLSTKEAQVYAVLAEL
EHHHHHH* 
 
RmaNOD Q52V nucleotide sequence 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTGTGCCTGCACTGCAGAAACACTCAG
TCGCTATTAGCGCCACGATGTATCGGCTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTTGTTTGAACTTCC
TGAGAGAGTTATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAGTATCGACAACCCATCGGCGTTA
CAGGCGGCCATCCGCCGCATGGTGCTTTCCCACGCACGCGCAGGAGTGCAGGCCGTCCATTATCCGCTGGTTT
GGGAATGTTTGAGAGACGCTATAAAAGAAGTCCTGGGCCCGGATGCCACCGAGACCCTTCTGCAGGCGTGGAA
GGAAGCCTATGATTTTTTAGCTCATTTACTGTCTACCAAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTC
GAGCACCACCACCACCACCACTGA 
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C h a p t e r  2  
DIRECTED EVOLUTION OF CYTOCHROME C FOR CARBON–
SILICON BOND FORMATION 
Material from this chapter appears in “Kan SBJ, Lewis RD, 
Chen K, Arnold FH. (2016) Directed evolution of 
cytochrome c for silicon–carbon bond formation: 
Bringing silicon to life. Science, 354:1048-1051. doi: 
10.1126/science.aah6219” Reprinted with permission from 
the American Association for the Advancement of Science. 
 
 
2.1 Abstract 
 
Enzymes that catalyze carbon–silicon bond formation are unknown in nature, despite the 
natural abundance of both elements. Such enzymes would expand the catalytic repertoire of 
biology, enabling living systems to access chemical space previously only open to synthetic 
chemistry. We have discovered that heme proteins catalyze the formation of organosilicon 
compounds under physiological conditions via carbene insertion into silicon–hydrogen 
bonds. In particular, we found that the cytochrome c from Rhodothermus marinus is capable 
of catalyzing the reaction with high enantioselectivity. Using directed evolution, we 
enhanced the catalytic function of cytochrome c from Rhodothermus marinus to achieve 
more than 15-fold higher turnover than state-of-the-art synthetic catalysts, and find that the 
evolved protein can produce a broad range of enantiopure organosilicon products, and 
displays high chemoselectivity for functionalization of the silicon–hydrogen bond. This 
carbon–silicon bond-forming biocatalyst offers an environmentally friendly, efficient and 
selective route to producing organosilicon molecules.  
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2.2 Introduction 
 
Silicon is ubiquitous in the earth’s biosphere, but biochemistry is almost completely 
devoid of reactions that involve silicon1,2. Some organisms use silicate as an integral 
structural component in their biology, but even in these organisms, enzymes that can form 
bonds between carbon and silicon atoms are unknown1,2. Despite the absence of 
organosilicon compounds in the biological world, synthetic chemists have found that 
organosilicon compounds have distinctive and desirable properties that have led to their 
broad utility in synthetic chemistry and material science3,4. Organosilicon compounds also 
have potential uses in medicinal chemistry; as a biocompatible carbon isostere, silicon can 
also be used to optimize and repurpose the pharmaceutical properties of bioactive 
molecules5,6.  
Despite utility of organosilicon compounds and the natural abundance of silicon, there is 
a dearth of sustainable methods for synthesizing organosilicon compounds7–9. In particular, 
methods that can enantioselectively introduce silicon motifs to organic molecules via 
carbon–silicon bond formation rely on multistep synthetic campaigns to prepare and 
optimize chiral reagents or catalysts, and precious metals are also sometimes needed to 
achieve the desired activity10–16. Carbene transfer to silicon–hydrogen bonds is one such 
carbon–silicon bond-forming reaction that can be rendered enantioselective using chiral 
transition metal complexes based on rhodium12,13, iridium14, and copper15,16. These catalysts 
can provide optically pure products, but not without limitations: they have limited turnovers 
(<100), require halogenated solvents, and sometimes require low temperatures for optimum 
selectivity (Appendix B, Table B-1).  
 
2.3 Results and discussion 
2.3.1 Heme catalyzed carbon–silicon bond formation 
 
Based on previous work demonstrating that heme proteins can function as carbene 
transfer biocatalysts for cyclopropanation reactions17–21, we hypothesized that heme proteins 
might also catalyze carbene insertion into silicon–hydrogen bonds. Because iron is not 
known to catalyze this transformation (using iron, only stoichiometric carbene transfer to Si–
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H bonds has been reported22), we first examined whether free heme could function as a 
catalyst in aqueous media. Initial experiments showed that the reaction between 
phenyldimethylsilane and ethyl 2-diazopropanoate (Me-EDA) in neutral buffer (M9-N 
minimal medium, pH 7.4) at room temperature gave racemic organosilicon product 3 at very 
low levels, a total turnover number (TTN) of 4 (Figure 2-1A). No product formation was 
observed in the absence of heme, and the organosilicon product was stable under the reaction 
conditions. 
We next investigated whether heme proteins could catalyze the same carbon–silicon 
bond- forming reaction. We screened a panel of heme proteins, including both wild-type 
proteins and those previously evolved to catalyze carbene transfer reactions. We observed 
that many heme proteins could catalyze our test reaction with more turnovers than the control 
catalysts, (hemin and hemin with bovine serum albumin (BSA)) but almost all proteins tested 
had negligible enantioinduction (Table S4). However, we observed that the wild-type 
cytochrome c from Rhodothermus marinus (Rma cyt c) catalyzed the reaction with 97% 
enantiomeric excess (ee), indicating that the reaction took place in an environment where the 
protein exerted excellent stereocontrol. Rma cyt c is highly thermostable protein, and in its 
native environment it serves as an electron-transfer protein in the respiratory electron 
transport chain23. Like other bacterial cytochrome c proteins, it is not known to have any 
catalytic function in living systems24, but when we tested other cytochrome c proteins (both 
bacterial and eukaryotic) for the carbon–silicon bond forming reaction, all had substantially 
lower enantioselectivity. We thus chose Rma cyt c as the platform for evolving a carbon–
silicon bond-forming enzyme.  
 
2.3.2 Evolution of Rhodothermus marinus cytochrome c 
 
The crystal structure of wild-type Rma cyt c [Protein Data Bank (PDB) ID: 3CP5]23 
reveals that the heme prosthetic group resides in a hydrophobic pocket, with the iron axially 
coordinated to a proximal His (H49) and a distal Met (M100), the latter of which is located 
on a loop (Figure 2-1B, 2-1C). The distal Met, common in cytochrome c proteins, is 
coordinately labile25,26. We hypothesized that M100 must be displaced in order to allow for 
iron-carbene formation, and that mutation of this amino acid could facilitate formation of 
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this adventitious “active site” and yield an improved carbon–silicon bond-forming 
biocatalyst. Therefore, a variant library made by site-saturation mutagenesis of M100 was 
cloned and recombinantly expressed in E. coli. After protein expression, the bacterial cells 
were heat treated (75°C for 10 min) before screening in the presence of phenyldimethylsilane 
(10 mM), Me-EDA (10 mM), and sodium dithionite (Na2S2O4, 10 mM) as a reducing agent, 
at room temperature under anaerobic conditions. The M100D mutation stood out as highly 
activating: this first-generation mutant provided chiral organosilicon 3 as a single enantiomer 
in 550 TTN, a 12-fold improvement over the wild-type protein (Figure 2-1D).  
Further analysis of the wild-type Rma cyt c crystal structure revealed that amino acid 
residues V75 and M103 reside close (within 7Å) to the heme iron center in wild-type Rma 
cyt c. Sequential site-saturation mutagenesis at these positions in the M100D mutant led to 
the discovery of triple-mutant V75T M100D M103E, which catalyzed carbon–silicon bond 
formation in >1500 turnovers and >99% ee. This level of activity is more than 15 times the 
total turnovers reported for the best synthetic catalysts for this class of reaction (Appendix 
B, Table B-1). As standalone mutations, both V75T and M103E are activating for wild-type 
Rma cyt c, and the beneficial effects increase with each combination (Appendix B, Table B-
3). Comparison of the initial reaction rates established that each round of evolution enhanced 
the rate: relative to the wild-type protein, the evolved triple mutant catalyzes the reaction 
more than seven times faster, with turnover frequency (TOF) of 46 min-1 (Figure 2-1E). 
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Figure 2-1. Heme protein-catalyzed carbon–silicon bond formation. A. Carbon–silicon bond 
formation catalyzed by heme and purified heme proteins. B. Surface representation of the 
heme-binding pocket of wild-type Rma cyt c (PDB ID: 3CP5). C. “Active site” structure of 
wild-type Rma cyt c showing a covalently bound heme cofactor ligated by axial ligands H49 
and M100. Amino acid residues M100, V75, and M103 residing close to the heme iron were 
subjected to site- saturation mutagenesis. D. Directed evolution of Rma cyt c for carbon–
silicon bond formation [reaction shown in (A)]. Experiments were performed using lysates 
of E. coli expressing Rma cyt c variant (OD600 = 15; heat-treated at 75°C for 10 min), 10 mM 
silane, 10 mM diazo ester, 10 mM Na2S2O4, 5 vol % MeCN, M9-N buffer (pH 7.4) at room 
temperature under anaerobic conditions for 1.5 hours. Reactions were done in triplicate. E. 
Carbon–silicon bond forming rates over four generations of Rma cyt c.  
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2.3.3 Substrate scope 
 
Assaying the new enzyme against a panel of silicon and diazo reagents, we found that 
the mutations were broadly activating for enantioselective carbon–silicon bond formation. 
The reaction substrate scope was surveyed with the use of heat-treated lysates of E. coli 
expressing Rma cyt c V75T M100D M103E (Rma TDE), with 10 mM of both silane and 
diazo ester to determine TTN. Whereas many natural enzymes excel at catalyzing reactions 
on only their native substrates and little else (especially primary metabolic enzymes), Rma 
TDE catalyzed the formation of 20 silicon-containing products, most of which were obtained 
cleanly as single enantiomers, demonstrating the broad substrate scope of this reaction with 
just a single variant of the enzyme (Figure 2-2).  
 
2.3.4 Chemoselectivity changes over the course of evolution 
 
The evolved Rma cyt c also exhibits high specificity for carbon–silicon bond formation. 
Even in the presence of carbene-reactive functional groups (e.g. alkenes, alkynes, O–H 
bonds, N–H bonds), the enzyme selectively reacts with the Si–H functionality. In contrast, 
when the same reactants were subjected to rhodium catalysis [1 mol % Rh2(OAc)4], O–H 
and N–H insertions were the predominant reaction pathways, and copper catalysis [10 mol% 
Cu(OTf)2] gave complex mixtures of products.  
We next asked whether all Rma cyt c variants would catalyze carbon–silicon bond 
formation selectively over insertion of the carbene into an N–H bond in the same substrate. 
We reexamined the evolutionary lineage and tested all four generations of Rma cyt c (wild-
type, M100D, V75T M100D, and V75T M100D M103E) with Me-EDA and 4-
(dimethylsilyl)aniline (23), a reagent that could serve as both nitrogen and silicon donor, to 
probe the proteins’ bond-forming preferences. The wild-type cytochrome c exhibited a slight 
preference for forming amination product 24 over organosilicon product 22. Even though 
silane 23 was not used for screening, and the Rma cyt c, therefore, did not undergo direct 
selection for chemoselectivity, each round of evolution effected a distinct shift from 
amination to carbon–silicon bond-forming activity (Figure 2-3). This evolutionary path that 
focused solely on increasing desired product formation culminated in a catalyst that 
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channeled most of the reactants (97%) through carbon–silicon bond formation (>30-fold 
improved with respect to the wild type), presumably by improving the orientation and 
binding of the silicon donor.  
 
 
Figure 2-2. Scope of Rma cyt c V75T M100D M103E-catalyzed carbon–silicon bond 
formation. Standard reaction conditions: lysate of E. coli expressing Rma cyt c V75T M100D 
M103E (OD600 = 1.5; heat-treated at 75°C for 10 min), 20 mM silane, 10 mM diazo ester, 10 
mM Na2S2O4, 5% v/v MeCN, M9-N buffer (pH 7.4) at room temperature under anaerobic 
conditions. Reactions performed in triplicate. [a] OD600 = 5 lysate. [b] OD600 = 0.5 lysate. [c] 
OD600 = 15 lysate. [d] 10 mM silane. [e] OD600 = 0.15 lysate.  
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Figure 2-3. Chemoselectivity of evolved Rma cyt c. Chemoselectivity for carbene Si–H 
insertion over N–H insertion increased markedly during directed evolution of Rma cyt c. 
Standard reaction conditions as described in Figure 2-2. Reactions were performed in 
duplicate using heat-treated lysates of E. coli expressing Rma cyt c with protein concentration 
normalized across variants. Product distribution was quantified after 2 hours of reaction time 
(before complete conversion, no double insertion product was observed under these 
conditions).  
 
2.3.5 Hypothesized substrate binding modes 
 
From our work on the substrate scope of Rma cyt c V75T M100D M103E (Rma TDE), 
we concluded that Rma TDE has an overall high tolerance for different silane and carbene 
precursor substrates, except for substitution of the α-methyl group on Me-EDA (Figure 2-
4A). This suggested that the methyl group may be buried in the protein, and larger groups 
cause steric clashes with the protein that impede catalysis. Based on this information and the 
published crystal structure of the wild-type protein, we hypothesized that the iron porphyrin 
carbene forms in the enzyme such that the methyl group on the carbene occupies the same 
space as the methyl group of residue M100 in the wild-type structure (Figure 2-4B, 2-4C). 
Then, if the silane substrate approaches from the more solvent-exposed face of the carbene 
(the M103 face) the transition state would be expected to be pro-R, which matches the 
observed absolute configuration of the organosilicon products produced by Rma TDE. 
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Figure 2-4. Proposed model for carbene orientation. A. Groups on the silane and a group 
on the ester are found to be highly tolerant to substitution, which may suggest that these 
groups are not in the active site and solvent-exposed during catalysis. B. Structure of wild-
type Rma cyt c showing residues V75, M100, and M103 (PDB ID: 3CP5). C. Proposed 
binding mode for the iron-carbene, where the carbene forms in the place of the distal 
methionine. The silane is proposed to approach from the more solvent-exposed side in the 
wild-type protein, which would result in the observed R stereochemistry of the 
organosilicon products. The V75T, M100D, and M103E mutations may promote reactivity 
by improving solvent and substrate access to the iron center. 
 
2.4 Conclusions 
 
This work developing a highly efficient and selective iron-dependent enzyme that 
catalyzes carbon–silicon bond formation affirms the notion that nature’s protein repertoire is 
highly evolvable and poised for adaptation, including proteins that have no known catalytic 
activity. With only a few mutations, existing heme proteins can be repurposed to efficiently 
perform carbene transfer reactions. The substrate scope of the evolved protein and available 
crystal structure of the wild-type protein provide clues as to how the active site of the protein 
may be structured, and how the reaction occurs in the active site. As Rma cytochrome c does 
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not naturally bind substrates or have biologically relevant enzymatic function, further 
investigations into the effects of the mutations introduced to the protein may provide insight 
into how new families of enzymes evolve in nature, and how evolution can access to areas 
chemical space that have not yet been explored by biological systems. 
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A p p e n d i x  B  
SUPPORTING INFORMATION FOR CHAPTER 2 
Material from this chapter appears in “Kan SBJ, Lewis RD, 
Chen K, Arnold FH. (2016) Directed evolution of 
cytochrome c for silicon–carbon bond formation: 
Bringing silicon to life. Science, 354:1048-1051. doi: 
10.1126/science.aah6219” Reprinted with permission from 
the American Association for the Advancement of Science. 
 
 
B.1 Materials and methods 
 
Unless otherwise noted, all chemicals and reagents for chemical reactions were obtained 
from commercial suppliers (Acros, Arch Bioscience, Fisher Scientific, Sigma-Aldrich, TCI 
America) and used without further purification. The following proteins were all purchased 
from Sigma-Aldrich: bovine serum albumin (BSA), cytochrome c (from bovine, equine heart 
and S. cerevisiae), peroxidase II (from horseradish), and catalase (from C. glutamicum). 
Silica gel chromatography purifications were carried out using AMD Silica Gel 60, 230-400 
mesh. 1H and 13C NMR spectra were recorded on a Bruker Prodigy 400 MHz instrument and 
are internally referenced to the residual solvent peak (chloroform). 29Si NMR spectra were 
recorded on the same instrument and referenced to tetramethoxysilane (δ −78.9 ppm). Data 
for 1H NMR are reported in the conventional form: chemical shift (δ ppm), multiplicity (s = 
singlet, d = doublet, t = triplet, q = quartet, hept = heptet, m = multiplet, br = broad, app = 
appears as), coupling constant (Hz), integration. Data for 13C and 29Si are reported in terms 
of chemical shift (δ ppm). High-resolution mass spectra were obtained with a JEOL JMS-
600H High Resolution Mass Spectrometer at the California Institute of Technology Mass 
Spectral Facility. Sonication was performed using a Qsonica Q500 sonicator. Chemical 
reactions were monitored using thin layer chromatography (Merck 60 silica gel plates) and 
a UV-lamp for visualization. Gas chromatography (GC) analyses were carried out using a 
Shimadzu GC-17A gas chromatograph, a FID detector, and J&W HP-5 (30 m x 0.32 mm, 
0.25 µm film; 90 °C hold 1 min, 90 to 110 °C at 15 °C/min, 110 to 280 °C at 60 °C/min, 
280 °C hold 1 min, 6.2 min total). Analytical chiral supercritical fluid chromatography (SFC) 
  
41 
was performed with a JACSO 2000 series instrument using i-PrOH and supercritical CO2 as 
the mobile phase, with visualization at 210 nm. The following chiral columns were used: 
Daicel Chiralpak IC, Chiralpak AD-H, or Chiralcel OD-H (4.6 mm x 25 cm). 
Plasmid pET22 was used as a cloning vector, and cloning was performed using Gibson 
assembly1. The cytochrome c maturation plasmid pEC862 was used as part of a two-plasmid 
system to express prokaryotic cytochrome c proteins. Cells were grown using Luria-Bertani 
medium or HyperBroth (AthenaES) with 100 µg/mL ampicillin and 20 µg/mL 
chloramphenicol (LBamp/chlor or HBamp/chlor). Cells without the pEC86 plasmid were grown 
with 100 µg/mL ampicillin (LBamp or HBamp). Primer sequences are available upon request. 
Electrocompetent Escherichia coli cells were prepared following the protocol of Sambrook 
et al.3. T5 exonuclease, Phusion polymerase, and Taq ligase were purchased from New 
England Biolabs (NEB, Ipswich, MA). M9-N minimal medium (abbreviated as M9-N 
buffer; pH 7.4) was used as a buffering system for whole cells, lysates, and purified proteins, 
unless otherwise specified. M9-N buffer was used without a carbon source; it contains 47.7 
mM Na2HPO4, 22.0 mM KH2PO4, 8.6 mM NaCl, 2.0 mM MgSO4, and 0.1 mM CaCl2. 
 
B.2 Plasmid construction 
 
All variants described in this paper were cloned and expressed using the pET22(b)+ 
vector (Novagen). The gene encoding Rma cyt c (UNIPROT ID B3FQS5)4 was obtained as 
a single gBlock (IDT), codon-optimized for E. coli, and cloned using Gibson assembly into 
pET22(b)+ (Novagen) between restriction sites NdeI and XhoI in frame with an N-terminal 
pelB leader sequence (to ensure periplasmic localization and proper maturation; 
MKYLLPTAAAGLLLLAAQPAMA) and a C-terminal 6xHis-tag. This plasmid was co-
transformed with the cytochrome c maturation plasmid pEC862 into E. cloni® EXPRESS 
BL21(DE3) cells (Lucigen). 
 
B.3 Cytochrome c expression and purification 
  
Purified cytochrome c proteins were prepared as follows. One liter HBamp/chlor in a 4 L 
flask was inoculated with an overnight culture (20 mL, LBamp/chlor) of recombinant E. cloni® 
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EXPRESS BL21(DE3) cells containing a pET22(b)+ plasmid encoding the cytochrome c 
variant, and the pEC86 plasmid. The culture was shaken at 37 °C and 200 rpm (no humidity 
control) until the OD600 was 0.7 (approximately 3 hours). The culture was placed on ice for 
30 minutes, and isopropyl β-D-1-thiogalactopyranoside (IPTG) and 5-aminolevulinic acid 
(ALA) were added to final concentrations of 20 µM and 200 µM respectively. 
The incubator temperature was reduced to 20 °C, and the culture was allowed to shake 
for 20 hours at 200 rpm. Cells were harvested by centrifugation (4 °C, 15 min, 4,000xg), 
and the cell pellet was stored at −20 °C until further use (at least 24 hours). The cell pellet 
was resuspended in buffer containing 100 mM NaCl, 20 mM imidazole, and 20 mM Tris-
HCl buffer (pH 7.5 at 25 °C) and cells were lysed by sonication (2 minutes, 2 seconds on, 
2 seconds off, 40% duty cycle; Qsonica Q500 sonicator). Cell lysate was placed in a 75 °C 
heat bath for 10 minutes, and cell debris was removed by centrifugation for 20 min 
(5000xg, 4 °C). Supernatant was sterile filtered through a 0.45 µm cellulose acetate filter 
and purified using a 1 mL Ni-NTA column (HisTrap HP, GE Healthcare, Piscataway, NJ) 
using an AKTA purifier FPLC system (GE healthcare). The cytochrome c protein was 
eluted from the column by running a gradient from 20 to 500 mM imidazole over 10 
column volumes. 
The purity of the collected cytochrome c fractions was analyzed using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Pure fractions were pooled and 
concentrated using a 3 kDa molecular weight cut-off centrifugal filter and dialyzed 
overnight into 0.05 M phosphate buffer (pH = 7.5) using 3 kDa molecular weight cut-off 
dialysis tubing. The dialyzed protein was concentrated again, flash-frozen on dry ice, and 
stored at −20 °C.  
The concentration of cytochrome c was determined in triplicate using the ferrous assay 
described in section B.5. 
 
B.4 P450 and globin expression and purification 
 
Purified P450s and globins were prepared differently from the cytochrome c proteins, 
and described as follows. One liter HBamp in a 4 L flask was inoculated with an overnight 
culture (20 mL, LBamp) of recombinant E. cloni® EXPRESS BL21(DE3) cells containing a 
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pET22(b)+ plasmid encoding the P450 or globin variant. The culture was shaken at 37 °C 
and 200 rpm (no humidity control) until the OD600 was 0.7 (approximately 3 hours). The 
culture was placed on ice for 30 minutes, and IPTG and 5-ALA were added to final 
concentrations of 0.5 mM and 1 mM, respectively. The incubator temperature was reduced 
to 20 °C, and the culture was allowed to shake for 20 hours at 200 rpm. Cells were harvested 
by centrifugation (4 °C, 15 min, 4,000xg), and the cell pellet was stored at −20 °C until 
further use (at least 24 hours). The cell pellet was resuspended in buffer containing 100 mM 
NaCl, 20 mM imidazole, and 20 mM Tris-HCl buffer (pH 7.5 at 25 °C). Hemin (30 mg/mL, 
0.1 M NaOH; Frontier Scientific) was added to the resuspended cells such that 1 mg of hemin 
was added for every 1 gram of cell pellet. Cells were lysed by sonication (2 minutes, 1 
seconds on, 2 seconds off, 40% duty cycle; Qsonica Q500 sonicator). Cell debris was 
removed by centrifugation for 20 min (27,000xg, 4 °C). Supernatant was sterile filtered 
through a 0.45 µm cellulose acetate filter, and purified using a 1 mL Ni-NTA column 
(HisTrap HP, GE Healthcare, Piscataway, NJ) using an AKTA purifier FPLC system (GE 
healthcare). The P450 and globin proteins were eluted from the column by running a gradient 
from 20 to 500 mM imidazole over 10 column volumes.  
The purity of the collected protein fractions was analyzed using SDS-PAGE. Pure 
fractions were pooled and concentrated using a 10 kDa molecular weight cut-off 
centrifugal filter and buffer-exchanged with 0.1 M phosphate buffer (pH = 8.0). The 
purified protein was flash-frozen on dry ice and stored at −20 °C. P450 and globin 
concentrations were determined in triplicate using the hemochrome assay described in 
section B.5 
 
B.5 Hemochrome assay 
 
A solution of sodium dithionite (10 mg/mL) was prepared in M9-N buffer. Separately, a 
solution of 1 M NaOH (0.4 mL) was mixed with pyridine (1 mL), followed by centrifugation 
(10,000xg, 30 seconds) to separate the excess aqueous layer gave a pyridine-NaOH solution. 
To a cuvette containing 700 µL protein solution (purified protein or heat-treated lysate) in 
M9-N buffer, 50 µL of dithionite solution and 250 µL pyridine-NaOH solution were added. 
The cuvette was sealed with Parafilm, and the UV-Vis spectrum was recorded immediately. 
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Cytochrome c concentration was determined using ε550-535 = 22.1 mM-1cm-1 5. Protein 
concentrations determined by the hemochrome assay were in agreement with that determined 
by the bicinchoninic acid (BCA) assay (Thermo Fisher) using bovine serum albumin (BSA) 
for standard curve preparation.  
 
B.6  Ferrous assay 
 
To a cuvette containing 700 µL protein solution in M9-N buffer was added 50 µL of 
dithionite solution (10 mg/mL in M9-N buffer). The cuvette was sealed with Parafilm, and 
the UV-Vis spectrum was recorded immediately. The absorbance value for the peak at 550 
nm was recorded, and background absorbance at 600 nm was subtracted. Using the protein 
concentration as determined by the hemochrome assay, ferrous ε550-600 was determined to be 
27 mM-1cm-1 for wild-type Rma cyt c, and 21 mM-1cm-1 for Rma V75T M100D M103E (see 
calibration curves shown on the following page). Concentrations of Rma M100D and V75T 
M100D were determined using the extinction coefficient calculated for V75T M100D 
M103E.  
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B.7 Library construction 
 
Cytochrome c site-saturation mutagenesis libraries were generated using a modified 
version of the 22-codon site-saturation method6. For each site-saturation library, 
oligonucleotides were ordered such that the coding strand contained the degenerate codon 
NDT, VHG or TGG. The reverse complements of these primers were also ordered. The three 
forward primers were mixed together in a 12:9:1 ratio, (NDT:VHG:TGG) and the three 
reverse primers were mixed similarly. Two PCRs were performed, pairing the mixture of 
forward primers with a pET22(b)+ internal reverse primer, and the mixture of reverse primers 
with a pET22b internal forward primer. The two PCR products were gel purified, ligated 
together using Gibson assembly, and transformed into E. cloni® EXPRESS BL21(DE3) 
cells.  
 
B.8 Enzyme library screening 
 
Single colonies were picked with toothpicks off of LBamp/chlor agar plates, and grown in 
deep-well (2 mL) 96-well plates containing LBamp/chlor (400 µL) at 37 °C, 250 rpm shaking, 
and 80% relative humidity overnight. After 16 hours, 30 µL aliquots of these overnight 
cultures were transferred to deep-well 96-well plates containing HBamp/chlor (1 mL) using a 
12-channel EDP3-Plus 5-50 µL pipette (Rainin). Glycerol stocks of the libraries were 
prepared by mixing cells in LBamp/chlor (100 µL) with 50% v/v glycerol (100 µL). Glycerol 
stocks were stored at −78 °C in 96-well microplates. Growth plates were allowed to shake 
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for 3 hours at 37 °C, 250 rpm shaking, and 80% relative humidity. The plates were then 
placed on ice for 30 min. Cultures were induced by adding 10 µL of a solution, prepared in 
sterile deionized water, containing 2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
20 mM ALA. The incubator temperature was reduced to 20 °C, and the induced cultures 
were allowed to shake for 20 hours (250 rpm, no humidity control). Cells were pelleted 
(4,000xg, 5 min, 4 °C) and resuspended in 500 µL M9-N buffer. For cell lysis, plates were 
placed in a 75 °C water bath for 10 min, followed by centrifugation (4,000xg, 5 min, 4 °C) 
to remove cell debris. The resulting heat-treated lysates (340 µL) were then transferred to 
deep-well plates for biocatalytic reactions. In an anaerobic chamber, to deep-well plates of 
heat-treated lysates were added Na2S2O4 (40 µL per well, 100 mM in dH2O), PhMe2SiH (10 
µL per well, 400 mM in MeCN) and Me-EDA (10 µL per well, 400 mM in MeCN). The 
plates were sealed with aluminum sealing tape, removed from the anaerobic chamber, and 
shaken at 400 rpm for 1.5 h. After quenching with cyclohexane (1 mL), internal standard 
was added (20 µL of 20 mM methyl 2-phenylacetate in cyclohexane) and the reaction 
mixtures were pipetted up and down to thoroughly mix the organic and aqueous layers. The 
plates were centrifuged (4,000xg, 5 min) and the organic layer (400 µL) was transferred to 
shallow-well 96-well plates for SFC analysis. Hits from library screening were confirmed by 
small-scale biocatalytic reactions, which were analyzed by GC and SFC for accurate 
determination of turnovers and enantioselectivities. 
 
B.9 Protein lysate preparation 
 
Protein lysates for biocatalytic reactions were prepared as follow: E. coli cells expressing 
Rma cyt c variant were pelleted (4,000xg, 5 min, 4 °C), resuspended in M9-N buffer and 
adjusted to the appropriate OD600. The whole-cell solution was heat-treated (75 °C for 10 
min) then centrifuged (14,000xg, 10 min, 4 °C) to remove cell debris. The supernatant was 
sterile filtered through a 0.45 µm cellulose acetate filter into a 6 mL crimp vial, crimp sealed, 
and the head space of the crimp vial was degassed by bubbling argon through for at least 10 
min. The concentration of cytochrome c protein lysate was determined using the ferrous 
assay described in section (E). Using this protocol, the protein concentrations we typically 
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observed for OD600 = 15 lysates are in the 8-15 µM range for wild-type Rma cyt c and 2-10 
µM for other Rma cyt c variants.  
 
B.10 Small-scale biocatalytic reactions 
 
In an anaerobic chamber, protein lysate (340 µL) in a 2 mL crimp vial was added 40 µL 
Na2S2O4 (100 mM in dH2O), 10 µL PhMe2SiH (400 or 800 mM in MeCN) and 10 µL Me-
EDA (400 mM in MeCN). The vial was crimp sealed, removed from the anaerobic chamber, 
and shaken at 400 rpm at room temperature for the stated reaction time. At the end of the 
reaction, the crimp vial was opened and the reaction was quenched with cyclohexane (1 mL). 
Internal standard was added (20 µL of 20 mM 2-phenylethanol in cyclohexane) and the 
reaction mixture was transferred to a microcentrifuge tube, vortexed (10 seconds, 3 times), 
then centrifuged (14,000xg, 5 min) to completely separate the organic and aqueous layers 
(the vortex-centrifugation step was repeated if complete phase separation was not achieved). 
The organic layer (750 µL) was removed for GC and SFC analysis. All biocatalytic reactions 
were performed in triplicate unless otherwise stated. The total turnover numbers (TTNs) 
reported are calculated with respect to the protein catalyst and represent the total number of 
turnovers that is possible to obtain from the catalyst under the stated reaction conditions. 
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B11.  Supporting tables 
Table B-1. Summary of known catalytic systems for enantioselective carbene insertion 
into silicon−hydrogen bonds 
Chiral catalytic 
system 
Ref Reaction condition Substrate scope TTN % ee 
Copper      
              A  7 CH2Cl2, rt, 18 h 4 17 to 25 17 to 98 
B  8 C6H6, 0 °C, 13.5 h 1 8 to 10 29 to 78 
C  9 CH2Cl2, −60 to 0 °C, 2-12 h 24 3 to 19 12 to 99 
B  10 CH2Cl2, −40 to 0 °C, 48-72 h 8 5 to 9 49 to 88 
B  11 CH2Cl2, −40 to −10 °C 9 5 to 8 40 to 84 
Iridium      
D  12 CH2Cl2, −78 or −30 °C, 24 h 15 24 to 50 94 to 99 
E  13 CH2Cl2, −78 °C, 24 h 7 75 to 94 72 to 91 
Rhodium      
F  14 CH2Cl2, rt to 40 °C, 6-12 h 34 9 to 30 77 to 99 
G  15 CH2Cl2, −78 °C or rt, 3-12 h 5 8 to 45 20 to 63 
H  8  C5H12, −78 to −75 °C, 24 h 1 24 to 70 48 to 97 
I  16 CF3CH2OH, −35 °C 10 51 to 97 20 to 99 
H  17 CH2Cl2, −78 °C then rt, 23 h 6 22 to 54 77 to 94 
various Rh(II)-
carboxylate 
18 
CH2Cl2, rt or −78 °C, 0.5 to 24 h 
to overnight 
6 <1 to 23 6 to 76 
J 19 CH2Cl2, −78 °C to rt, 23 h 2 35 to 40 38 to 58 
H  20 CH2Cl2, −78 °C, 1 to 1.5 h 4 34 to 43 35 to 72 
H  21 C5H12, −78 °C, 24 h 5 13 to 19 75 to 95 
various Rh(II)-
carboxylate 
22 CH2Cl2, rt or reflux 1 8 to 17 6 to 47 
Catalytic systems that could yield enantiopure products are highlighted in blue. rt = room 
temperature. In cases where the reaction times were not documented in the original literature, 
this information is not shown in the table above. 
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Table B-2. Preliminary experiments with heme and purified heme proteins 
 
 
 
Catalyst TTN % ee 
Controls   
None 0 - 
Hemin 4 ± 1 0 
Hemin + BSA 1 ± 1 0 
P450s   
BM3 P450 T268A23 44 ± 15 0 
BM3 P450 T268A C400H24 45 ± 3 <5 
BM3 P450 CIS I263F C400S T438S25 24 ± 9 <5 
BM3 P450 F87A T268A C400S26 40 ± 15 <5 
BM3 P450 Hstar H92N H100N27 46 ± 7 0 
Myoglobins   
Sperm whale Mb 12 ± 1 0 
Sperm whale Mb H64V V68A28 17 ± 1 0 
Cytochromes c   
Horse heart cyt c 31 ± 10 <5 
Bovine heart cyt c 54 ± 2 6 
S. cerevisiae cyt c 11 ± 1 <5 
R. marinus cyt c 34 ± 10 97 
H. thermophilus cyt c 8 ± 2 16 
R. globiformis cyt c 4 ± 1 <5 
Others   
Horse radish peroxidase 0 - 
C. glutamicum catalase 0 - 
 
Heme proteins that are available commercially or in our laboratory inventory were 
screened to identify the most enantioselective protein variant as starting point for directed 
evolution. Experiments with heme proteins were performed using 10 µM purified heme 
protein, 10 mM silane, 10 mM diazo ester, 10 mM Na2S2O4, 5 vol% MeCN, M9-N buffer 
Si
HPh
+ OEt
O
N2
Catalyst
M9-N buffer (pH 7.4), Na2S2O4
room temperature, 1.5 hours
OEt
O
H
Si
Ph
  
51 
at room temperature under anaerobic conditions for 1.5 h. Experiments with hemin were 
performed using 100 µM hemin. Experiments with hemin and BSA were performed using 
100 µM hemin in the presence of BSA (0.75 mg/mL). Reactions were performed in 
triplicate. TTNs reported are the average of three experiments. Within instrument detection 
limit, variability in % ee was not observed. Unreacted starting materials were observed at 
the end of all reactions and no attempt was made to optimize these reactions. 
 
Table B-3. Carbon−silicon bond formation catalyzed by Rma cyt c variants  
 
 
Rma cyt c TTN 
WT 44 ± 27 
M100D 549 ± 24 
V75T 150 ± 48 
M103E 70 ± 21  
V75T M100D 892 ± 20 
V75T M100E 154 ± 37 
M100D M103E 520 ± 88 
V75T M100D M103E 1518 ± 51 
Experiments were performed using lysates of E. coli expressing Rma cyt c variant (OD600 
= 15; heat-treated at 75 °C for 10 min), 10 mM silane, 10 mM diazo ester, 10 mM Na2S2O4, 
5 vol% MeCN, M9-N buffer at room temperature under anaerobic conditions for 1.5 h. 
Reactions were performed in triplicate. TTNs reported are the average of three 
experiments. 
  
Si
HPh
+ OEt
O
N2
Rma cyt c variant
M9-N buffer (pH 7.4), Na2S2O4
room temperature, 1.5 hours
OEt
O
H
Si
Ph
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B.12 Supporting Figures 
 
 
Figure B-1. Representative SDS-PAGE gel of purified wild-type Rma cyt c and its V75T 
M100D M103E variant (TDE) in comparison to a standard protein ladder. The second and 
third lanes from the left are the same samples loaded at lower protein concentration. 
 
 
Figure B-2. Circular dichroism (CD) spectra of purified Rma cyt c V75T M100D M103E 
(Rma TDE). Rma cyt c V75T M100D M103E was purified without performing the heat 
treatment step. Two identical samples were prepared in M9-N buffer, and one was heat 
treated at 75 °C for 10 minutes. After cooling to room temperature, the samples were 
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analyzed by CD. The CD spectra of heat-treated and untreated Rma cyt c V75T M100D 
M103E are identical, suggesting that heat treatment at 75 °C for 10 minutes does not cause 
irreversible denaturation of the protein. The ΔεMRW values shown here are similar to 
previously published values for wild-type Rma cyt c4, which suggests mutations V75T, 
M100D, and M103E are not highly disruptive to the protein secondary structure. 
 
R kR / kH log(kR / kH) σ 
H 1 0 0 
MeO 1.3 0.13 −0.27 
NH2 3.2 0.50 −0.66 
Cl 0.78 −0.11 0.23 
CO2Me 0.47 −0.32 0.45 
 
Figure B-3. Hammett analysis of Rma cyt c V75T M100D M103E catalyzed 
carbon−silicon bond formation. The Hammett plot suggests a small build-up of positive 
charge on the silane in the reaction transition state. This observation is similar to that 
reported for carbene insertion into Si−H bond catalyzed by copper (ρ = −0.54)10 and 
rhodium (ρ = −0.31)30  
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C h a p t e r  3  
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3.1 Abstract 
 
Reactive iron porphyrin carbenes (IPCs) are presumed to be the key catalytic 
intermediate common to an array of abiological, but synthetically useful carbene transfer 
reactions catalyzed by wild-type and engineered heme proteins. Despite growing interest in 
developing new and highly-active carbene transfer enzymes, the IPC intermediate has never 
been observed in a protein. Using crystallographic, spectroscopic, and computational 
methods, we have captured and studied a catalytic IPC intermediate in the active site of an 
enzyme derived from thermostable Rhodothermus marinus (Rma) cytochrome c. High-
resolution crystal structures and computational methods reveal how directed evolution 
created an active site for carbene transfer in an electron transfer protein, and how the 
laboratory-evolved enzyme achieves perfect carbene transfer stereoselectivity by holding the 
catalytic IPC in a single orientation. We also discovered that the IPC in Rma cytochrome c 
has a singlet ground electronic state, and that the protein environment uses geometrical 
constraints and non-covalent interactions to influence different IPC electronic states. 
Knowledge gained by studying this versatile intermediate provides a foundation for studying 
the mechanisms of carbene transfer reactions and will facilitate the engineering of new 
carbene transfer enzymes. 
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3.2 Introduction 
 
Carbenes are formally neutral, divalent carbon species with two non-bonded electrons. 
They are typically reactive due to their incomplete octet electron configuration1. Highly 
stabilized (“persistent”) carbenes exist in biological systems, most notably as the 
deprotonated thiazolium group of thiamine in pyruvate oxidases2. In contrast, reactive metal-
carbenes have not been found in nature, despite their versatility and utility in chemical 
synthesis3–5. Recent protein engineering efforts have revealed that heme proteins can catalyze 
a myriad of formal carbene transfer reactions including alkene cyclopropanation6–9, alkyne 
cyclopropenation and bicyclobutanation10, carbonyl olefination11, as well as carbon-boron12, 
–nitrogen13, –silicon14, and –sulfur15 bond formation (Figure 3-1). The proteins enable the 
heme center to make products that iron porphyrin alone does not10,12, and their genetically-
encoded structures direct selectivities that can be switched by evolution6,8–10,12,14, making it 
possible to create whole new biocatalytic pathways to important molecules.  
By analogy to known transition-metal catalyzed reactions that use diazo reagents as 
carbene precursors3–5, the emerging enzymatic carbene transfer activities of heme proteins 
are all thought to involve a reactive iron porphyrin carbene (IPC) intermediate; transfer of 
the carbene to a second substrate and product release regenerate the protein catalyst6–15. Our 
current understanding of enzyme-catalyzed carbene transfer reactions comes primarily from 
experimental characterizations of model IPC compounds16–21 and their computational 
studies22–27. Determining the structures and properties of reactive intermediates is central to 
deciphering how enzymes enhance reaction rates and dictate selectivities28, and recent 
mechanistic studies of cyclopropanation enzymes24,26,27 have also underscored the 
importance of the IPC intermediate and the need to characterize it within a protein scaffold.  
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 Figure 3-1. The scope of laboratory-evolved biocatalytic carbene transfer reactions. 
Engineered heme proteins catalyze a broad range of abiological reactions with diazo 
reagents. These reactions are assumed to proceed through a catalytic IPC intermediate. X 
indicates porphyrin proximal ligand, usually serine or histidine. All published examples of 
heme-dependent car- bene transfer enzymes accept diazo reagents having one or more 
electron- withdrawing groups (e.g., COOR, CF3) as carbene precursors. The active resting 
state of the catalyst is Fe(II)-porphyrin.  
 
3.3 Results and discussion 
3.3.1  Structural characterization of engineered carbene transferase, Rma TDE 
 
Rma cyt c is an electron transfer protein (Protein Data Bank (PDB) accession number 
3CP529) previously engineered to catalyze the formation of carbon-silicon14 and 
carbon-boron12 bonds by inserting a reactive iron-carbene into the corresponding Si–H and 
B–H bonds of a silane or borane substrate. We set out to capture and characterize the IPC 
intermediate in Rma cyt c by turning to “Rma TDE”, a variant previously engineered to 
catalyze silylation reactions with high efficiency14 This protein is capable of catalyzing 
thousands of rounds of carbene transfer using ethyl 2-diazopropanoate (Me-EDA, Figure 3-
2a) as a carbene precursor, presumably through the intermediacy of IPC 1 (Figure 3-2a). To 
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visualize the active site for carbene transfer, we obtained an X-ray crystal structure of Rma 
TDE at 1.47 Å (PDB 6CUK, Appendix C, Table C-1).  
The original construct of Rma TDE had a C-terminal His-Tag to facilitate easy 
purification, but efforts to crystallize this variant were not successful. In contrast, the crystals 
of the wild-type Rma cyt c had been obtained using an untagged protein29, which suggested 
that the C-terminal His-Tag might be interfering with our ability to grow crystals of Rma 
TDE. Close examination of the crystal packing in the structure of wild-type Rma cyt c 
revealed that the C-terminus resides in close proximity to residues 23-27 of an adjacent 
symmetry mate, suggesting that additional residues on the C-terminus might disrupt this 
crystal contact. In contrast, the first seven N-terminal residues of the mature Rma cyt c were 
unresolved in the crystal structure, suggesting that these residues were not involved in crystal 
contacts, and thus not necessary to obtain crystals of the protein. Therefore, we generated 
two new constructs for Rma TDE: a tag-less construct and an N-terminally tagged construct, 
where the first seven residues of the mature protein were replaced by six histidine residues. 
By performing fine screening around the various conditions reported to generate crystalline 
material for the wild-type protein30, we found that small crystals of the tag-less Rma TDE 
could be grown using a well solution containing 1.8-1.9 M (NH4)2SO4 and 2% v/v 
isopropanol. Through additive screening, we found that addition of NaSCN greatly improved 
the size of crystals, but single crystals were difficult to obtain. Ultimately, changing the 
protein from the tag-less Rma TDE to the N-terminal tagged Rma TDE and using 1.43-1.48 
M (NH4)2SO4, 300-400 mM NaSCN, and 1.5% isopropanol yielded large, well-diffracting 
single crystals. 
The structure obtained of Rma TDE reveals a pocket on the distal face of the heme created 
by the three mutations (Figure 3-2b). In Rma TDE, the native distal methionine has been 
mutated to an aspartate (M100D), the α-carbon of which is displaced by 4.8 Å relative to its 
position in the wild-type structure (Figure C-1). This displacement produces a cavity in the 
space previously occupied by the M100 sidechain and allows a water molecule (or hydroxide 
ion) to coordinate to the heme iron in the enzyme resting state. Overall, directed evolution 
created an entirely new active site in Rma TDE where substrates bind, the carbene forms, 
and catalysis takes place.  
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3.3.2 Crystallographic observation of an iron porphyrin carbene in Rma TDE  
 
To observe an IPC in the protein scaffold, crystals of Rma TDE were soaked with Me-
EDA at room temperature for 30 minutes under air, reduced with sodium dithionite, and 
flash-frozen in liquid nitrogen prior to diffraction. Under these conditions, we determined an 
X-ray crystal structure at 1.29 Å that shows a new species bound to the iron porphyrin (PDB 
6CUN, Appendix C, Table C-1). We observed contiguous electron density from the iron 
porphyrin to an active-site ligand, consistent with an enzymatic IPC intermediate, rather than 
iron-bound Me-EDA (Figure 3-2c). The observed electron density is in agreement with a 
single carbene species in a single conformation (Appendix C, section C.9), suggesting this 
structure represents the dominant form of the IPC intermediate in solution during catalysis. 
The high occupancy of the carbene indicates the rate of carbene formation greatly exceeds 
the rate of carbene decay in the absence of a second substrate, making the direct 
characterization of an enzymatic IPC intermediate possible for the first time. 
The crystal structure of carbene-bound Rma TDE displays some similarities to previously 
studied small-molecule IPC complexes. The Fe–C bond length of 1.9 Å is consistent with 
the previously determined structure of the IPC 1-methylimidazole-ligated meso-
tetrakis(pentafluorophenyl)porphyrin (TPFPP) diphenylcarbene, where the reported Fe–C 
bond length is 1.83 Å20. The Fe–N (imidazole) bond length of 2.1 Å in the protein is also 
consistent with that in the small molecule structure (2.17 Å)20. Out-of-plane distortions, 
particularly ruffling distortions, are observed in both the imidazole-ligated TPFPP 
diphenylcarbene structure and the carbene-bound Rma TDE structure. Whereas the mean 
out-of-plane deviation for TPFPP diphenylcarbene was 1.03 Å (Appendix C, Table C-2), it 
is smaller for carbene-bound Rma TDE (0.6 Å; the deviation for Rma TDE alone is 0.7 Å). 
The difference in distortion between both Rma TDE structures is small, and both values are 
within the range reported for c-type cytochrome proteins (0.3-1.2 Å)31. Ruffling is known to 
be the main distortion in these proteins and is thought to be induced by covalent attachment 
of the heme to the protein32. 
In contrast to what we observed in Rma TDE in the absence of Me-EDA, amino acid 
residues D100, T101, and D102 are unresolved in the carbene-bound Rma TDE structure, 
indicating that this loop region is flexible and the carbene is solvent-accessible (Figure 3-
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2c). The crystal structure also reveals close, non-polar contacts between the iron-carbene and 
five amino acid side chains (T75, M76, P79, I83 and M89 lie 3.5-4.3 Å from the carbene, 
Figure 3-2c), suggesting that the new active site is strongly hydrophobic, despite its solvent 
accessibility.  
We had previously predicted an orientation of the carbene in the context of the Rma cyt 
c protein (Figure 2-4). When the observed orientation of the carbene is compared with the 
orientation proposed in Chapter 2, (Figure 2-4, Figure 3-2D) it is clear that the positioning 
of the α-methyl substituent on the carbene is close to correct, differing by only a 20º rotation 
around the Fe–C bond. The predicted carbene orientation was based on the hypothesis that 
the α-methyl substituent of the carbene occupied the space left when the native distal heme 
ligand, M100 is displaced or mutated. When the carbene-bound Rma TDE structure is 
compared to the wild-type crystal structure, it is clear that the two methyl groups do indeed 
occupy the same space. 
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Figure 3-2. Carbene transfer silylation reaction and structures of resting and carbene-bound 
Rma TDE. A. The C–Si bond-forming reaction catalyzed by Rma cytochrome c proceeds via 
intermediate IPC 1. B. Mutations V75T, M100D, and M103E (Rma TDE) in Rma 
cytochrome c increased its carbene transfer activity (14). The crystal structure of Rma TDE 
with no Me-EDA bound (1.47 Å; PDB ID code 6CUK) reveals a cavity distal to the heme 
(orange surfaces) that is not present in wild-type Rma cyt c. C. The crystal structure of 
carbene-bound Rma TDE (1.29 Å; PDB ID code 6CUN), with the carbene species in cyan. 
Residues D100, T101, and D102 are unresolved. (Inset) Omit map in green (FO–FC) of the 
carbene electron density contoured at 3σ. Interactions between the carbene and amino acid 
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residues are shown with yellow lines. (i) T75, 3.7 Å. (ii) M76, 4.3 Å. (iii) P79, 3.5 Å. (iv) 
I83, 3.6 Å. (v) M89, 3.5 Å. D. Comparison of the predicted carbene orientation (purple, 
proposed in Chapter 2) and the crystallographically observed carbene (cyan). E. Comparison 
of the positioning of residue M100 in wild-type Rma cyt c (purple, PDB ID: 3CP5) and the 
observed carbene (cyan). The methyl groups of the carbene and residue M100 occupy the 
same space, as previously hypothesized.  
   
 
3.3.3 Iron porphyrin carbene electronic structure and spectroscopy 
 
When first proposed as a reactive enzyme intermediate, the IPC in cytochrome P450 was 
presented as analogous to oxo-ferryl intermediates found in the natural P450 catalytic cycle6. 
This assignment was supported by the Fe(IV)-like Mössbauer parameters obtained for small 
molecule IPC complexes20,21,33. However, Zhang and co-workers have argued that IPCs are 
better described as Fe(II) closed-shell singlets, lower in energy than the triplet states24,26,27. 
Most recently, Shaik and co-workers studied a model IPC complex, and concluded that the 
lowest energy state for their IPC was an open-shell singlet, best described as an S = 1/2 Fe(III) 
that is antiferromagnetically coupled to a carbene radical23. Although the IPC open-shell 
singlet is similar to the Fe(III)-superoxide electronic structure in heme oxygen binding34, no 
experimental evidence has been published to support the relevance of an open-shell singlet 
configuration in IPCs. Computational studies from both the Zhang and Shaik groups suggest 
that the energy differences between electronic states are small22–24,27, and thus the open-shell 
singlet, closed-shell singlet, and triplet states should all be considered plausible ground states 
for the IPC intermediate in the environment of an enzyme active site.  
Encouraged by our success in capturing the IPC in the enzyme crystals, we sought to use 
spectroscopy to characterize the electronic structure of the IPC in Rma TDE. Under 
conditions similar to those where Rma TDE is catalytically active, we prepared solution 
samples of both Rma TDE and Me-EDA-treated Rma TDE and analyzed them with UV-Vis 
(Appendix C, Figure C-2), electron paramagnetic resonance (EPR), and Mössbauer 
spectroscopy. Neither sample gave EPR signals in either parallel (10 mW) or perpendicular 
(2 mW) mode at 4 K (Appendix C, Figure C-3). While the absence of EPR signals under 
these conditions does not prove that the samples are diamagnetic, these results are consistent 
with our assignment of the resting enzyme and carbene-bound enzyme as low-spin species 
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(vide infra). Mössbauer spectra of Rma TDE at 80 K were best fit as a single species with an 
isomer shift (∂Fe) of 0.45 mm·s-1 and a quadrupole splitting (|∆EQ|) of 1.18 mm·s-1 (Appendix 
C, Figure C-4), consistent with an S = 0 low spin Fe(II) resting-state species. This 
observation is in contrast to other Fe(II) hemes in proteins lacking an endogenous distal 
ligand to iron, which have been shown to favor high spin (S = 2) states35,36. Mössbauer spectra 
of Me-EDA-treated Rma TDE at 80 K indicated the presence of a major (88% abundance) 
and a minor species (12% abundance), the latter of which was assigned as ferrous Rma TDE. 
The major species was assigned as carbene-bound Rma TDE based on the Mössbauer 
parameters obtained (∂Fe = 0.18 mm·s-1, |∆EQ| = 1.83 mm·s-1) and the lack of observed EPR 
signal (Supplementary Fig. 3, 4). The symmetric Mössbauer lineshape of Me-EDA-treated 
Rma TDE and its lack of EPR signal suggested this is an S = 0 species, or an S = 1 species 
with a large zero-field splitting. Thus, this reactive intermediate can be made in high yields 
and studied in both freeze-quenched solutions and crystals to determine its electronic and 
geometric structure.  
 
3.3.4 Computational models of the iron porphyrin carbene 
 
Density functional theory (DFT) calculations were used to model the three potential 
electronic structures of IPC 1.  The DFT calculations shows that the triplet state is disfavored, 
and the triplet structure is not consistent with the observed IPC structure. DFT calculations 
were unable to distinguish between the two singlet states; both singlet states are close in 
energy, and both have structures consistent with the observed IPC structure.  
Molecular dynamics (MD) simulations were also used to characterize the structure of 
IPC 1 in Rma TDE.  MD simulations showed that the IPC favors a structure like that found 
in the crystal structure, but also revealed a persistent hydrogen bonding interaction between 
a water molecule and the IPC in a region where the electron density of the X-ray crystal 
structure is poor (and the water molecule is not observed).  Integrating the newly identified 
water molecule into quantum mechanical calculations on the IPC reveals that the hydrogen 
bonding interactions causes stabilization of the singlet states relative to the triplet. 
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3.4 Summary and conclusions 
 
In conclusion, characterization of a catalytically active IPC intermediate inside the active 
site of an enzyme has provided a foundation from which to study enzyme-catalyzed carbene 
transfer reactions and explain the reactivity and selectivity of Rma TDE-catalyzed carbene 
transfer. Structural characterization of the Rma TDE enzyme showed that the three mutations 
introduced during directed evolution led to dramatic changes in a loop distal to the heme and 
generated a protein structure pre-organized for substrate binding and IPC formation. The 
experimental IPC structure and computational modelling showed that Rma TDE stabilizes a 
single conformation of the IPC that gives the enzyme complete stereoselectivity control 
during carbene transfer. The conformational restraints imposed by the enzyme also favor the 
formation of a singlet iron-carbene. This convergent approach to characterizing the emerging 
family of carbene transferases enables informed engineering that will enhance the generality 
and utility of these powerful catalysts. 
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A p p e n d i x  C  
SUPPORTING INFORMATION FOR CHAPTER 3 
Material from this chapter appears in “Lewis RD†, Garcia-
Borràs M†, Chalkley MJ, Buller AR, Houk KN, Kan SBJ, 
Arnold FH. (2018) Catalytic Iron-Carbene Intermediate 
Revealed in a Cytochrome c Carbene Transferase. 
PNAS, 115:7308-7313. doi: 10.1073/pnas.1807027115” 
Reprinted with permission from the Proceedings of the 
National Academy of Sciences. †Denotes equal author 
contribution. 
 
 
 
C.1 Materials and methods  
 
Unless otherwise noted, all chemicals and reagents for chemical reactions were obtained 
from commercial suppliers (Acros, Arch Bioscience, Fisher Scientific, Sigma-Aldrich, TCI 
America, VWR) and used without further purification. Multitron shakers (Infors, Annapolis 
Junction, MD) were used for cell growth. UV-Vis spectroscopy was performed using a 
Shimadzu UV-1800 spectrophotometer (Shimadzu, Carlsbad, CA). Sonication was 
performed using a Qsonica Q500 sonicator. Silica gel chromatography purifications were 
carried out using AMD Silica Gel 60, 230-400 mesh. 1H NMR spectra were recorded on a 
Bruker Prodigy 400 MHz instrument and are internally referenced to the residual solvent 
peak (chloroform). Data for 1H NMR are reported in the conventional form: chemical shift 
(δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, hept = heptet, m = 
multiplet, br = broad, app = appears as), coupling constant (Hz), integration. Gas 
chromatography (GC) analyses were carried out using a Shimadzu GC-17A gas 
chromatograph, a flame ionization detector (FID), and J&W HP-5 (30 m x 0.32 mm, 0.25 
µm film; 90 °C hold 1 min, 90 to 110 °C at 15 °C/min, 110 to 280 °C at 60 °C/min, 280 °C 
hold 1 min, 6.2 min total). Analytical chiral high pressure liquid chromatography (HPLC) 
was performed with a HP-Agilent 1100 series instrument using i-PrOH and hexanes as the 
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mobile phase, with visualization at 210 nm. A Chiralcel OD-H column was used for chiral 
separations (4.6 mm x 25 cm).  
Plasmid pET22 was used as a cloning vector, and cloning was performed using Gibson 
assembly1. The cytochrome c maturation plasmid pEC862 was used as part of a two-plasmid 
system to express prokaryotic cytochrome c proteins. Cells were grown using Lysogeny 
Broth medium or HyperBroth (AthenaES, Baltimore, MD) with 100 µg/mL ampicillin and 
20 µg/mL chloramphenicol (LBamp/chlor or HBamp/chlor). Primer sequences are available upon 
request. Electrocompetent Escherichia coli cells were prepared following the protocol of 
Sambrook et al.3. T5 exonuclease, Phusion polymerase, and Taq ligase were purchased from 
New England Biolabs (NEB, Ipswich, MA). Sodium phosphate (NaPi, 20 mM, pH 7.5) was 
used as a buffering system for purified proteins, unless otherwise specified. M9-N minimal 
medium (abbreviated as M9-N buffer; pH 7.4) was used without a carbon source; it contains 
47.7 mM Na2HPO4, 22.0 mM KH2PO4, 8.6 mM NaCl, 2.0 mM MgSO4, and 0.1 mM CaCl2.  
 
C.2 Plasmid construction 
 
All variants described in this paper were cloned and expressed using the pET22(b)+ 
vector (MilliporeSigma, St. Louis, MO). The gene encoding Rhodothermus marinus cyt c 
V75T M100D M103E (Rma TDE)4 was obtained as a single gBlock (Integrated DNA 
Technologies, Coralville, IA), codon-optimized for E. coli, and cloned using Gibson 
assembly1 into pET22(b)+ between restriction sites NdeI and XhoI in frame. The gene 
encoding Rma TDE contained an N-terminal pelB leader sequence and 6xHisTag 
(MKYLLPTAAAGLLLLAAQPAMAHHHHHH) and had the first seven amino acids of 
mature, wild-type Rma cyt c removed (TESGTAA). This plasmid was co-transformed with 
the cytochrome c maturation plasmid pEC862 into E. cloni® EXPRESS BL21(DE3) cells 
(Lucigen, Middleton, WI).  
 
DNA coding sequence of Rma cyt c V75T M100D M103E with an N-terminal pelB 
leader sequence and 6xHisTag: 
ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCG
GCGATGGCCCATCATCATCATCACCACCAAGACCCGGAAGCACTGGCAGCGGAAATTGG
TCCGGTCAAACAGGTGAGCCTGGGTGAACAGATTGATGCGGCCCTGGCGCAACAGGGAG
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AACAGCTCTTCAACACGTATTGTACTGCGTGCCACCGTCTGGATGAGCGTTTTATCGGA
CCGGCCCTGCGCGATGTTACCAAACGTCGTGGGCCGGTTTACATCATGAACACGATGCT
GAACCCGAATGGGATGATCCAGCGTCATCCGGTGATGAAACAGCTCGTGCAGGAATATG
GGACCATGGATACCGATGAGGCCCTGAGTGAAGAACAAGCGCGCGCAATTCTGGAGTAT
CTGCGCCAGGTTGCGGAAAACCAGTAATGA 
 
Amino acid sequence of Rma cyt c V75T M100D M103E with an N-terminal pelB 
leader sequence and 6xHisTag: 
MKYLLPTAAAGLLLLAAQPAMAHHHHHHQDPEALAAEIGPVKQVSLGEQIDAALAQQ
GEQLFNTYCTACHRLDERFIGPALRDVTKRRGPVYIMNTMLNPNGMIQRHPVMKQLVQE
YGTMDTDEALSEEQARAILEYLRQVAENQ 
 
C.3 Cytochrome c expression and purification 
 
Purified cytochrome c proteins were prepared as follows. In a 4 L flask, one liter 
HyperBroth (AthenaES) containing 100 µg/mL ampicillin and 20 µg/mL chloramphenicol 
(HBamp/chlor) was inoculated with an overnight culture (20 mL, Lysogeny Broth, with 100 
µg/mL ampicillin, 20 µg/mL chloramphenicol, LBamp/chlor) of recombinant E. cloni® 
EXPRESS BL21(DE3) cells containing a pET22(b)+ plasmid encoding the cytochrome c 
variant, and the pEC86 plasmid. The culture was shaken at 37°C and 200 rpm (no humidity 
control) until the OD600 was 0.7 (approximately 3 hours). The culture was placed on ice for 
30 minutes, and isopropyl β-D-1-thiogalactopyranoside (IPTG) and 5-aminolevulinic acid 
(ALA) were added to final concentrations of 20 µM and 200 µM, respectively. 
The incubator temperature was reduced to 25°C, and the culture was allowed to shake 
for 20 hours at 200 rpm. Cells were harvested by centrifugation (4 °C, 15 min, 4,000xg), 
and the cell pellet was stored at −20°C until further use (at least 24 hours). The cell pellet 
was resuspended in buffer containing 100 mM NaCl, 20 mM imidazole, and 20 mM Tris-
HCl buffer (pH 7.5 at 25 °C) and cells were lysed by sonication (4 minutes, 1 second on, 1 
second off, 30% duty cycle; Qsonica Q500 sonicator). Cell lysate was placed in a 75 °C 
heat bath for 10 minutes, and cell debris was removed by centrifugation for 20 min 
(30,000xg, 4 °C). Supernatant was sterile filtered through a 0.45 µm cellulose acetate filter 
and purified using a 1 mL Ni-NTA column (HisTrap HP, GE Healthcare, Piscataway, NJ) 
using an AKTA purifier FPLC system (GE Healthcare). The cytochrome c protein was 
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eluted from the column by running a gradient from 20 to 500 mM imidazole over 10 
column volumes. 
The purity of the collected cytochrome c fractions was analyzed using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Pure fractions were pooled and 
concentrated using a 3 kDa molecular weight cut-off centrifugal filter. Protein for 
crystallography was dialyzed overnight into 20 mM Tris-HCl buffer (pH 7.5 at 25 °C) 
using 3.5 kDa molecular weight cut-off dialysis tubing. Protein for non-crystallography 
use was dialyzed overnight into 20 mM sodium phosphate buffer (pH 7.5) using 3.5 kDa 
molecular weight cut-off dialysis tubing. The dialyzed protein was further concentrated 
using a 3 kDa molecular weight cut-off centrifugal filter, flash-frozen on dry ice, and stored 
at −20°C.  
The concentration of cytochrome c was determined in triplicate using the hemochrome 
assay described in section C.5. 
 
C.4 57Fe-labelled cytochrome c expression and purification 
 
In order to prepare protein samples for Mössbauer spectroscopy, 57Fe-labelled Rma cyt c 
was expressed and purified, using a protocol adapted from Liptak et al 5.  
 
For 1 L 57Fe media: 
950 mL  basic salts buffer 
10 mL trace metals mix 
10 mL vitamin cocktail 
300 µL  57Fe / H2SO4 solution 
10 mL 1 M MgCl2 
5 g L/D-glucose 
1 g NH4Cl 
16.8 mg 5-aminolevulinic acid (ALA) 
30 mg thiamine hydrochloride 
1 mL  20 mg/mL chloramphenicol in ethanol 
1 mL  100 mg/mL ampicillin in water 
 
 
For 950 mL basic salts buffer: 
950 mL water 
13.0 g KH2PO4 
13.1 g K2HPO4 ·(3H2O) 
17.1 g Na2HPO4 ·(7H2O) 
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3.6 g Na2SO4 
Adjusted pH to 7.4 with 5M NaOH, autoclaved, and stored at room temperature. 
 
For 100 mL Trace metals mix: 
90 mL water 
600 mg calcium chloride, dihydrate 
120 mg manganese chloride, tetrahydrate 
80 mg cobalt chloride, hexahydrate 
70 mg zinc sulfate, heptahydrate 
30 mg copper chloride, dihydrate 
2 mg boric acid 
500 mg EDTA 
Adjusted pH to 7.4 with 5M NaOH, and added water until final volume was 100 mL. Solution 
was deep purple. The solution was sterile filtered through a 0.2 µm PES membrane and 
stored at -20°C. 
 
For 100 mL vitamin cocktail: 
100 mL water 
10 mg biotin 
10 mg choline chloride 
10 mg folic acid 
10 mg nicotinamide 
10 mg calcium D-pantothenate  
10 mg pyridoxal phosphate 
1 mg riboflavin 
The solution was sterile filtered through a 0.2 µm PES membrane, and stored at -20°C. 
 
For 600 µL 57Fe / H2SO4 solution: 
25.0 mg 57Fe (95% enrichment, Isoflex USA, San Francisco) 
600 µL 2 M H2SO4 
H2SO4 was added to the iron powder under anaerobic conditions, and allowed to shake 
overnight, until the iron was dissolved. The solution was pale blue, and was stored at room 
temperature under anaerobic conditions.  
 
 
Purified 57Fe cytochrome c proteins were prepared as follows. In a 125 mL flask, 30 
mL of HBamp/chlor was inoculated with an overnight culture (1 mL, LBamp/chlor) of 
recombinant E. cloni® EXPRESS BL21(DE3) cells containing a pET22(b)+ plasmid 
encoding the cytochrome c variant, and the pEC86 plasmid. The culture was shaken at 
37°C and 200 rpm (no humidity control) until the OD600 was 0.7 (approximately 3 hours). 
In a 4 L flask, one liter of 57Fe medium was inoculated with 20 mL of the late-log phase 
HB amp/chlor culture. The culture was again shaken at 37°C and 200 rpm (no humidity 
control) until the OD600 was 0.3 (approximately 4 more hours). The culture was placed on 
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ice for 30 minutes, and isopropyl β-D-1-thiogalactopyranoside (IPTG) and 5-
aminolevulinic acid (ALA) were added to final concentrations of 20 µM and 200 µM, 
respectively. 
After addition of IPTG and ALA, the culture was returned to the shaker, allowed to 
shake for 24 hours at 37 °C, 200 rpm. Cells were harvested and lysed using the same 
procedure as described in C.2. 57Fe-labelled protein was then purified as described in C.3. 
 
C.5 Hemochrome assay  
 
A solution of sodium dithionite (10 mg/mL) was prepared in M9-N buffer. Separately, 
a solution of 1 M NaOH (0.4 mL) was mixed with pyridine (1 mL), followed by 
centrifugation (10,000xg, 30 seconds) to separate the excess aqueous layer gave a pyridine-
NaOH solution. To a cuvette containing 10 µL purified protein solution and 690 µL M9-N 
buffer, 50 µL of dithionite solution and 250 µL pyridine-NaOH solution were added. The 
cuvette was sealed with Parafilm, and the UV-Vis spectrum was recorded immediately. 
Cytochrome c concentration was determined using ε550-535 = 22.1 mM-1cm-1 4,6. 
 
C.6 Synthesis and characterization of authentic organosilicon product  
 
Ethyl 2-(dimethylphenylsilyl)propanoate was prepared in a similar manner to that 
published in Kan et al. 20164. In a 25 mL round bottom flask, 0.281 g of 
dimethylphenylsilane (2.0 mmol, 2.0 equiv.) were added, followed by, Rh2(OAc)4 (1.1 mg, 
0.25 mol%) and 5 mL of dichloromethane. The mixture was cooled to 0°C, after which 
0.128 g of ethyl-2-diazopropanoate (1.0 mmol, 1.0 equiv.) was added dropwise to the 
solution. The reaction was allowed to slowly warm up to room temperature over 4 hours 
and stirred at room temperature for another 1 hour. Evaporation of the organic solvent and 
purification by silica column chromatography using EtOAc and hexane as eluents afforded 
the organosilicon product ethyl 2-(dimethylphenylsilyl)propanoate with 54% yield. 1H 
NMR was used to confirm product identity and purity. 
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C.7 Biocatalytic reactions   
 
In an anaerobic chamber, 10 µL of 80 µM purified protein was added to 350 µL of 20 
mM sodium phosphate buffer (NaPi, pH 7.5) in a 2 mL crimp vial. Next, the protein was 
reduced by adding 20 µL Na2S2O4 (200 mM in NaPi, pH 7.5), and the reaction was initiated 
with the addition of reactants, 10 µL PhMe2SiH (400 mM in acetonitrile) and 10 µL Me-
EDA (400 mM in MeCN). The vial was crimp sealed, removed from the anaerobic 
chamber, and shaken at 400 rpm at room temperature for 2 hours. At the end of the reaction, 
the crimp vial was opened and the reaction was quenched with cyclohexane (1 mL). 
Internal standard was added (20 µL of 1,2,3-trimethoxybenzene in toluene) and the reaction 
mixture was transferred to a microcentrifuge tube, vortexed (1 minute), then centrifuged 
(14,000xg, 5 min) to completely separate the organic and aqueous layers. The organic layer 
(750 µL) was removed for GC and chiral HPLC analysis. All biocatalytic reactions were 
performed in triplicate. The total turnover numbers (TTNs) reported are calculated with 
respect to the protein catalyst and represent the total number of turnovers obtained using 
the catalyst under the stated reaction conditions. 
Concentration of organosilicon product was calculated based on the ratio of areas 
between the product peak and internal standard peak, as measured by GC-FID. Stock 
solutions of chemically synthesized ethyl 2-(dimethylphenylsilyl)propanoate were 
prepared at various concentrations (20 to 200 mM in MeCN). To a microcentrifuge tube 
were added 360 µL 20 mM sodium phosphate buffer, 20 µL Na2S2O4 (200 mM in NaPi, 
pH 7.5), 20 µL organosilicon product, 20 µL internal standard (20 mM 1,2,3-
trimethoxybenzene in toluene) and 1 mL cyclohexane. The mixture was vortexed (1 
minute) then centrifuged (14,000xg, 5 min) to completely separate the organic and aqueous 
layers. The organic layer (750 µL) was removed for GC analysis. Each concentration was 
prepared in duplicate, and both data points are shown for each concentration (Figure C-5). 
The standard curves plot product concentration in mM (x-axis) against the ratio of product 
area to internal standard area on the GC (y-axis).  
Enantiomeric excess for biocatalytically synthesized products was determined using 
chiral HPLC, with a Chiralcel OD-H column as the stationary phase and 1% isopropanol, 
99% hexanes as the mobile phase, at 40ºC for 30 minutes. 
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C.8 UV-Visible spectroscopy   
 
UV-Visible spectra were collected at room temperature between 600 and 380 nm on a 
UV-1800 Shimadzu spectrophotometer in quartz cuvettes sealed with Parafilm (aerobic 
conditions) or a screw cap with a pierceable septum (anaerobic conditions). Sodium 
phosphate (NaPi, 20 mM, pH 7.5) was used as a buffer system. Spectra of reduced Rma 
TDE was taken in buffer supplemented with 50 mM sodium dithionite to ensure complete 
reduction of the ferrous iron, and various co-solvents were added to demonstrate that the 
spectral characteristics are similar in 1% isopropanol, 5% acetonitrile, and 15% 
dimethylsulfoxide. Spectra of reduced, Me-EDA-treated Rma TDE was taken in buffer 
containing 50 mM sodium dithionite, 10 mM ethyl 2-diazo propanoate, and 1% 
isopropanol. Co-solvents were added to demonstrate that the addition of 5% acetonitrile or 
15% dimethylsulfoxide did not substantially impact the spectrum. For spectra taken under 
anaerobic conditions, the headspace of the cuvettes was de-gassed with argon for 5 minutes 
prior to the addition of sodium dithionite and Me-EDA.  
 
C.9 X-ray crystallography  
  
Fine screening for Rma TDE crystallization was performed around crystallography 
conditions previously reported to yield crystals of wild-type Rma cyt c7. Crystals were grown 
against a 1-mL reservoir with mother liquor comprised of 2.0 µL of 14.0 mg/mL Rma TDE 
(in 20 mM Tris HCl, pH 7.5) and 1.0 µL of well solution. Very small crystals were observed 
after two weeks in 1.8-1.9 M (NH4)2SO4, 2% isopropanol. Further optimization failed to 
yield larger crystals, but showed that the protein crystallized within the range of 1.4-1.9 M 
(NH4)2SO4, 1-3% isopropanol. Additive screening was performed using an additive 
screening kit (Hampton Research, Aliso Viejo, CA) and with mother liquor comprised of 2.0 
µL of 14.0 mg/mL Rma TDE, 1.0 µL of well solution (1.7 M (NH4)2SO4, 1.5% isopropanol), 
and 0.2 µL of additive solution. Additive screening showed that addition of NaSCN yielded 
larger and more numerous crystals. Further fine screening around this condition revealed that 
the best crystals were obtained using 1.43-1.48 M (NH4)2SO4, 300-400 mM NaSCN, and 
1.5% isopropanol (2.0 µL of 14.0 mg/mL Rma TDE, 1.0 µL well solution). Under these 
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conditions, crystals formed over 3-5 days, and reached maximum size after 7-10 days. 
Crystals were cryo-protected by addition of ethylene glycol to the well solution to a final 
concentration of 20%. Crystals were flash frozen and stored in liquid N2 until diffraction. 
For crystals soaked with the carbene precursor Me-EDA, the mother liquor was 
supplemented with 1 M Me-EDA in isopropanol to a final concentration of 40 mM Me-EDA. 
Crystals were soaked at room temperature for 30 minutes before moving the samples to 4ºC. 
At 4ºC, the crystals were soaked for approximately 1 minute in a solution of mother liquor 
supplemented with 40 mM Me-EDA and 50 mM sodium dithionite before flash-freezing in 
liquid nitrogen. Prolonged soaking in either of the Me-EDA supplemented solutions caused 
the crystals to dissolve.  
Diffraction data were collected remotely at the Stanford Synchrotron Radiation 
Laboratories on beamline 12-2, with a wavelength of 0.97946 Å, and at a temperature of 100 
K. Crystals routinely diffracted at or below 1.7 Å, and the data were integrated and scaled 
using XDS8 and AIMLESS9.
 
A resolution cutoff of I/ > 2.5 was applied along all axes of 
diffraction.
 
These data contributed to model quality as judged by Rfree in the final bin < 0.27. 
The structure was solved using molecular replacement with PHASER10, as implemented in 
CCP411. For Rma TDE, the search model comprised a single monomer of wild-type Rma cyt 
c (PDB ID: 3CP5)12 subjected to 10 cycles of geometric idealization in Refmac513 and 
removal of all ligands. For carbene-bound Rma TDE, the search model comprised a single 
monomer of Rma TDE (PDB ID: 6CUK) subjected to 10 cycles of geometric idealization in 
Refmac5 and removal of all ligands. Model building was performed in Coot14 beginning with 
data processed at 2.2 Å, followed by subsequent inclusion of increasingly higher resolution 
shells of data with relaxed geometric constraints. Refinement was performed using Refmac5.
 
The MolProbity server15 was used to identify rotamer flips and clashes. After the protein, 
ligand, and solvent atoms were built, TLS operators were added to refinement16, which 
resulted in substantial improvements in Rfree for the models. Crystallographic and refinement 
statistics are reported in Table S1. The carbene ligand was modelled in a single conformation 
at 100% occupancy, which resulted in the atoms comprising the Fe–C bond to have B-factors 
of 14.74 and 21.36, respectively. Occupancy was not refined by B-factor matching, as the 
electron density suggested only a single conformation, and B-factors on both atoms were 
both sufficiently low and similar to indicate high occupancy in the crystal. The carbene-
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bound Rma TDE structure is deposited with PDB ID: 6CUN, and the Rma TDE structure 
without the carbene ligand is deposited with PDB ID: 6CUK. Analysis of the protein 
structures with MolProbity showed that the carbene-bound Rma TDE structure had a 
MolProbity score of 1.0, and the Rma TDE structure had a MolProbity score of 0.9, putting 
both structures in the highest percentile rank for MolProbity scores. The carbene-bound Rma 
TDE structure contains 98.15% Ramachandran-favored rotamers, with no Ramachandran 
outliers, and the Rma TDE structure contains 99.12% Ramachandran-favored rotamers and 
no Ramachandran outliers. 
 
C.10 Mössbauer spectroscopy 
C.10.1 General description of Mössbauer spectroscopy 
 
Mössbauer spectra were recorded on a spectrometer from SEE Co. (Edina, MN) 
operating in the constant acceleration mode in a transmission geometry. The sample was kept 
in an SVT-400 cryostat form Janis (Wilmington, MA). The quoted isomer shifts are relative 
to the centroid of the spectrum of a metallic foil of α-Fe at room temperature (RT). Solution 
samples were transferred to a sample cup and chilled to 77 K inside of the glovebox, and 
unless noted otherwise, quickly removed from the glovebox and immersed in liquid N2 until 
mounted in the cryostat. Data analysis was performed using version 4 of the program 
WMOSS (www.wmoss.org) and quadrupole doublets were fit to Lorentzian lineshapes 
except where noted. See discussion below for detailed notes on the fitting procedure. 
 
C.10.2 Sample preparation for Mössbauer spectroscopy 
 
Sample preparation conditions for Mössbauer samples were designed to be similar to 
those conditions used to assay the biocatalytic activity of Rma TDE, as shown in 
Supplementary Figure 4F. In an anaerobic chamber, an aliquot of 57Fe-labelled purified Rma 
TDE (4.00 mM) was thawed. For the reduced Rma TDE sample, 341 µL of protein (4.00 
mM in 20 mM NaPi, pH 7.5) was added to a Mössbauer cup containing 3.7 mg sodium 
dithionite. Acetonitrile (18 µL) was added to the Mössbauer cup, and the sample was pipetted 
up and down to ensure the sample was homogenous (approximately 10 seconds). The sample 
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was then flash-frozen on liquid nitrogen. Final concentrations: 3.8 mM protein, 19 mM NaPi 
(pH 7.5), 50 mM sodium dithionite, 5% acetonitrile. 
For the reduced Me-EDA-treated Rma TDE sample, 341 µL of protein (4.0 mM in 20 
mM NaPi, pH 7.5) was added to a Mössbauer cup containing 3.7 mg sodium dithionite. 18 
µL of 1.0 M Me-EDA in acetonitrile was added to the Mössbauer cup, and the sample was 
pipetted up and down to ensure the sample was homogenous (approximately 10 seconds). 
The sample was then flash-frozen on liquid nitrogen. Final concentrations: 3.8 mM protein, 
19mM NaPi (pH 7.5), 50 mM sodium dithionite, 50 mM Me-EDA, 5% acetonitrile. 
 
C.11 Electron paramagnetic resonance (EPR) spectroscopy 
C.11.1 General description of EPR spectroscopy 
 
EPR spectra were recorded on a Bruker EMX X-band CW-EPR Spectrometer (Bruker, 
Billerica, MA) at 4 K. using Bruker Win-EPR software (ver. 3.0). Data were collected with 
in parallel mode with a power of 10 mW, and in perpendicular mode with a power of 2 mW.  
 
C.11.2 Sample preparation for EPR spectroscopy 
 
In an anaerobic chamber, an aliquot of purified Rma TDE was thawed and diluted to 1.00 
mM with 20 mM NaPi, pH 7.5 with 10% v/v DMSO. Solid sodium dithionite was added to 
the purified Rma TDE. For the reduced Rma TDE sample, 250 µL of the reduced protein 
(1.00 mM in 20 mM NaPi, pH 7.5) was added to an EPR tube containing 13 µL DMSO, 
vortexed briefly, and flash-frozen on liquid nitrogen. Final concentrations: 950 µM protein, 
30 mM sodium dithionite, 19 mM NaPi, 15% v/v DMSO. For the reduced, Me-EDA treated 
Rma TDE sample, 250 µL of reduced protein was added to an EPR tube containing 13 µL 
1M Me-EDA in DMSO, vortexed briefly, and flash-frozen on liquid nitrogen. Final 
concentrations: 950 µM protein, 50 mM Me-EDA, 30 mM sodium dithionite, 19 mM NaPi, 
15% v/v DMSO. Empty cavity measurements were performed without putting an EPR tube 
into the machine. 
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C.12 Supporting tables and figures 
 
Table C-1. Data collection and refinement statistics of Rma TDE 
  
 Carbene-bound Rma TDEa 
(6CUN) 
Rma TDEa 
(6CUK) 
Data collection   
Space group P3221 P3221 
Cell dimensions     
  a, b, c (Å) 60.3, 60.3, 77.2 60.0, 60.0, 77.3 
    a, b, g 
(°) 
90.0, 90.0, 120.0 90.0, 90.0, 120.0 
Resolution (Å) 38.62-1.29 
(1.32-1.29)b 
38.65-1.47 
(1.50-1.47)b 
Rmerge, Rmeas, Rpim 0.070, 0.072, 0.016  
(1.2, 1.2, 0.30) 
0.067, 0.073, 0.028 
(0.425, 0.469, 0.270) 
I/s(I) 21.4 (2.9) 15.2 (3.7) 
CC1/2 1.0 (0.95) 1.0 (0.95) 
Completeness (%) 100 (100) 99.8 (98.9) 
Multiplicity 19.4 (16.6) 6.6 (5.6) 
   
Refinement   
Resolution (Å) 1.29 1.47 
No. reflections 39554 27920 
Rwork / Rfree 0.182 / 0.202 0.183 / 0.209 
No. atoms 997 1076 
  Protein 847 949 
  Heme 
  Carbene 
43 
7 
43 
 
  Water 100 83 
B factors 15.67 23.62 
  Protein 12.95 23.09 
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  Heme 
  Carbene 
16.36 
26.17 
16.00 
 
  Water 37.66 33.57 
R.M.S. deviations   
  Bond lengths (Å) 0.002 0.017 
  Bond angles (°) 1.814 1.719 
a Data were collected on a single crystal 
b Values in parentheses are for highest-resolution shell. 
 
 
Table C-2. Bond lengths of interest 
 
Crystal Structure Fe–N(Imz) (Å) Fe–O (Å) Fe–C (Å) 
6CUK 2.0 2.1 N/A 
6CUN 2.1 N/A 1.9 
Fe(TPFPP)(CPh2)(MeIm) 2.17 N/A 1.83 
 
 
Figure C-1. Active-site front loop deviation. The active site front loop in Rma TDE is 
substantially deviated from its positioning in wild-type Rma cyt c.  
 
A. Alignment of Rma wild-type (PDB: 3CP5) and Rma TDE (PDB: 6CUK). The two 
structures superimposed on each other show that residues 98, 99, 100, and 101 have shifted 
the projection of their sidechains by approximately 180 degrees.  
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B. Measurement of alpha-carbon deviations between Rma wild-type (PDB: 3CP5) and 
Rma TDE (PDB: 6CUK). Distances were measured between the corresponding alpha 
carbons in wild-type Rma cyt c, and Rma TDE. The deviation measurements show that 
T98, M99, M100D, and T101 are substantially different in the two structures, with the 
largest deviation observed between M100 and D100 (4.8 Å).  
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Figure C-2. UV-Vis spectra. UV-Vis spectra of reduced Rma TDE taken with and with 
and without the presence of the carbene precursor Me-EDA show that the spectrum 
changes upon addition of the carbene precursor. 
 
 
 
A. Aerobic spectra of reduced Rma TDE, and reduced Rma TDE treated with Me-
EDA. The UV-Vis spectra of 7 µM reduced Rma TDE and 7 µM reduced Rma TDE, treated 
with Me-EDA were taken under the ambient atmosphere. The reduced spectrum shows a 
Soret band at 419 nm, a Q-band peak at 551 nm, and a Q-band minimum at 534 nm. The 
Me-EDA treated sample shows a Soret band at 416 nm, and two Q-band peaks at 529 and 
561 nm. Previously characterized small- molecule IPC complexes have Soret bands at 403-
408 nm and two Q-bands at 522-525 nm and 550-556 nm17.  
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B. Spectra of reduced Rma TDE under various conditions. The UV-Vis spectra of 7 µM 
reduced Rma TDE were taken in the presence of various solvents, and unless specified, under 
an argon atmosphere. The reduced spectra show no substantial differences with the presence 
of isopropanol, acetonitrile (MeCN), or dimethylsulfoxide (DMSO). The spectrum also 
appears to undergo no substantial changes between an aerobic atmosphere and an argon 
atmosphere. 
 
 
C. Spectra of reduced Rma TDE treated with Me-EDA under various conditions. The 
UV-Vis spectra of 7 µM reduced Rma TDE treated with Me-EDA were taken in the presence 
of various solvents, and unless specified, under an argon atmosphere. The spectra show no 
substantial differences with the presence of acetonitrile (MeCN) or dimethylsulfoxide 
(DMSO). The spectrum also appears to undergo no substantial changes between an aerobic 
atmosphere and an argon atmosphere. 
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Figure C-3. EPR spectroscopic analysis. 
 
 
A. EPR spectra in perpendicular mode. The spectra for all three samples look highly 
similar. No signals are discernible from these spectra, indicating that the protein complexes 
present have integer spin states. 
 
 
B. EPR spectra in parallel mode. The spectra for all three samples look highly similar. A 
signal is observed (at ~3300 Gauss) in all three spectra, including the empty cavity 
spectrum, which suggests this signal does not come from the protein. The observed signal 
is likely due to Cu(II) salts formed in the instrument as a result of oxidized conductors. 
Another small signal is observed (at ~800 Gauss) in the Rma TDE spectrum. This signal is 
typical of high spin Fe(II), but due to its low intensity, the signal likely comes from a small 
amount of Fe(II) contamination in the spectrum, rather than from Rma TDE. The lack of 
substantial protein-derived signal suggests that both protein complexes may be in low-spin 
states. 
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Figure C-4. Mössbauer spectroscopy studies. 
 
 
A. Zero-field Mössbauer spectrum at 80 K of 57Fe-protein (3.8 mM) in frozen NaPi (19 mM, 
pH 7.5) and MeCN (5% v/v) in the presence of sodium dithionite (50 mM). 
 
Fitting details for Figure C-4A. This Mössbauer was modelled as one species with the 
parameters seen below. In this case, the data was best fit using a Voigtian lineshape. The 
Voigtian lineshape is a Gaussian distribution of the typical Lorentzian lineshape observed in 
Mössbauer spectra. Although less typically observed for solution samples, small differences 
in the protein (e.g. folding), in the local active-site environment (e.g. solvent, H-bonding 
network), or small domains in the sample caused by rapid freezing could all result in such a 
lineshape. Alternative fits such as asymmetric Lorentzian lineshapes or adding in a second 
component lead to worse fits. Application of a small magnetic field (50 mT, Figure C-4B) 
rules out incipient magnetic behavior as the cause of this behavior. The isomer shift and 
quadrupole splitting of this species are in agreement with its assignment as a S = 0, heme 
species18.  
 
 
 
 
 
Component δ (mm s−1) ΔEQ (mm s−1) Linewidths, ΓL/ ΓR (mm s−1) 
Red line 0.45 ± 0.02 1.18 ± 0.02 −0.60/−0.60 
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B. Parallel applied 50-mT magnetic field Mössbauer spectrum at 80 K of 57Fe-protein (3.8 
mM) in NaPi (19 mM, pH 7.5) and MeCN (5% v/v) in the presence of sodium dithionite (50 
mM). 
 
Fitting details for Figure C-4B. As expected given the proposed diamagnetic nature of this 
species, the application of a small magnetic field does not result in any changes to the signal 
observed in the zero-field spectrum. 
 
 
 
 
 
 
 
 
Component δ (mm s−1) ΔEQ (mm s−1) Linewidths, ΓL/ ΓR (mm s−1) 
Red line 0.45 ± 0.02 1.18 ± 0.02 −0.63/−0.63 
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C. Zero-field Mössbauer spectrum at 80 K 57Fe-protein (3.8 mM) in frozen  
NaPi (19 mM, pH 7.5) and MeCN (5% v/v) in the presence of sodium dithionite (50 mM) 
and Me-EDA (50 mM). 
 
Fitting details for Figure C-4C. This Mössbauer was modelled as two species. The minor 
component is clearly defined by the absorbance feature at approximately −0.1 mm/sec. This 
fixes one half of that quadrupole doublet. The other absorbance is not clearly defined with 
respect to the major feature so the exact isomer shift and quadrupole splitting of this 
component is not well-defined. This is reflected in the slightly different parameters that are 
found for this feature in the spectrum taken with a 50 mT magnetic field applied. However, 
the fit featured here is reasonable for an Fe(II), S = 0 heme species which could be starting 
material, a reaction intermediate, or a carbene decomposition product. Forcing this feature to 
have the parameters of the S = 0 Fe(II) starting material (δFe = 0.45 and |ΔEQ| = 1.18) shown 
in Table C-4B did not substantially change the quality of the curve-fitting. To avoid over-
interpretation this fit has not been enforced. The major absorbance is in agreement with 
Mössbauer parameters previously reported for formally Fe(IV), S = 0 heme species18. 
 
 
Component δ (mm s−1) ΔEQ (mm 
s−1) 
Linewidths, ΓL/ ΓR (mm 
s−1) 
Relative area 
A (blue) 0.18 ± 
0.02 
1.83 ± 0.04 0.46/0.46 0.88 
B (green) 0.38 ± 
0.02 
1.06 ± 0.02 0.38/0.38 0.12 
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D. Parallel applied 50-mT magnetic field Mössbauer spectrum at 80 K of 57Fe-protein (3.8 
mM) in frozen NaPi (19 mM, pH 7.5) and MeCN (5% v/v) in the presence of sodium 
dithionite (50 mM) and Me-EDA (50 mM). 
 
Fitting details for Figure C-4D. This Mössbauer was modelled as three species. Again, the 
major component (modelled in blue) is consistent with a S = 0, formally Fe(IV) heme species. 
Again, there is a second species as seen in Figure S4.C (modelled in green) that shows 
parameters consistent with an S = 0, Fe(II) impurity. The third species here (modelled in 
orange) has isomer shift and quadrupole splitting characteristic of high-spin (S = 2) Fe(II) 
that is likely not bound to the heme. This species may be poorly resolved due to broadening 
in the absence of the applied magnetic splitting explaining why it is not seen in Figure C-4C. 
 
 
 
 
 
Component δ (mm s−1) ΔEQ (mm 
s−1) 
Linewidths, ΓL/ ΓR (mm 
s−1) 
Relative area 
A (blue) 0.18 ± 
0.02 
1.84 ± 0.04 0.41/0.41 0.82 
B (green) 0.42 ± 
0.02 
1.04 ± 0.02 0.38/0.38 0.13 
C (orange) 1.17 ± 
0.02 
3.40 ± 0.07 0.29/0.29 0.04 
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E. Comparison of Calculated and Experimental Mössbauer parameters 
Entry 
Number System Method 
Electronic 
statec 
∂Fe 
(mm/s) 
∆EQ 
(mm/s) Reference 
1 Rma TDE (CMeCOOEt) Experimental CSS 0.18 (-)
a 
1.83 (This work) 
2 Fe(Por)(CPh2)(MeIm) Calculated CSS 0.19 -1.76 
Khade et 
al.19 
3 Fe(TPFPP)(CPh2)b Experimental CSS 0.03 
(-)a 
2.34 Li et al.
17  
4 Fe(Por)(CPh2) Calculated CSS 0.10 -2.37 Khade et al.19  
Im = imidazole 
a Sign not determined experimentally 
b TPFPP = 5,10,15,20-Tetrakis(pentafluorophenyl)porphyrin 
 
The major species in Me-EDA treated Rma TDE was present at 88% abundance, a 
similarly high occupancy to that of the carbene observed in the crystal structure. This major 
species was best fit with ∂Fe = 0.18 mm·s-1 and |∆EQ| = 1.83 mm·s-1 (Figure C-4E, Entry 1). 
Although the isomer shift is higher than those typically observed for Fe(IV)–oxo species, the 
negative shift relative to the starting material is indicative of a short Fe−C bond. Additionally, 
the quadrupole splitting lies between the values typically observed for Fe(IV)–oxo species 
(1-1.5 mm·s-1) and the values typically observed for Fe(IV)–hydroxo species (2-2.1 mm·s-
1)20–22. Unlike the oxo species, both the hydroxo and carbene species are axially dissymmetric 
(dxz and dyz are no longer equivalent) and therefore are expected to display larger quadrupole 
splittings. Thus, based on its high occupancy and distinctive Mössbauer parameters, we 
conclude that the major species observed in the Me-EDA-treated sample is carbene-bound 
Rma TDE. 
Previously, Khade and Zhang created a model of the IPC Fe(Por)(CPh2) in a closed shell 
singlet state and simulated its Mössbauer parameters (Figure C-4E, Entry 3). Their 
simulations yielded numbers similar to those obtained experimentally for the complex 
Fe(TPFPP)(CPh2) (Figure C-4E, Entry 4). Khade and Zhang also predicted parameters for 
the N-methylimidazole-ligated version of this complex, Fe(Por)(CPh2)(MeIm) (Figure C-
4E, Entry 2). Although further experimental characterization such as high-field Mössbauer 
or SQUID magnetometry would have to be conducted to unambiguously assign the spin 
state, the data thus far suggest that the enzyme IPC, like small molecule IPC complexes, 
exists in a singlet state. 
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F. Comparison of sample preparation conditions between Mössbauer samples and 
biocatalytic reaction samples 
 
Component Final concentration in Me-
EDA Mössbauer sample 
Final concentration in 
biocatalytic reaction 
sample 
Rma TDE 3800 µM 2.0 µM 
NaPi, pH 7.5 19 mM 19 mM 
Sodium dithionite 50 mM 10 mM 
Me-EDA 50 mM 10 mM 
Dimethylphenylsilane 0 mM 10 mM 
Acetonitrile 5% (v/v) 5% (v/v) 
 
To demonstrate the catalytic relevance of the captured carbene species, Mössbauer 
samples were prepared under conditions similar to those used to assay the activity and 
enantioselectivity of Rma TDE. The same buffer system and co-solvent were used for both 
the biocatalytic samples and the Mössbauer samples. Increased concentrations of purified 
Rma TDE protein were necessary in the Mössbauer samples to achieve sufficient signal. 
Similarly, the concentration of sodium dithionite was increased in the Mössbauer samples to 
ensure complete reduction of the protein, and the concentration of the carbene-precursor Me-
EDA was also increased to ensure that the protein was subjected to multi-turnover conditions, 
with excess carbene precursor. 
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Table C-3. Out-of-plane heme distortion parameters for various IPC structures. 
Normal-Coordinate Structural Decomposition (NCS) quantitative analysis of the out-of-
plane heme deformations using vibrational normal coordinates and complete-basis, as 
proposed by Jentzen and Shelnutt23, and implemented in the online script by Liptak and co-
workers24. The out-of-plane normal deformations considered are: mean deviation out-of-
plane (Doop), saddling (B2u), ruffling (B1u), doming (A2u), waving (Eg(x), Eg(y)), and 
propellering (A1u). Values are given in Å. The values used for discussion in the manuscript 
are highlighted in bold.  
 
Species Doop 
Saddling 
B2u 
Ruffling 
B1u 
Domin
g 
A2u 
Wavin
g (x) 
Eg(x) 
Waving 
(y) 
Eg(y) 
Propellering 
A1u 
Rma TDEa 0.709 0.162 0.620  0.115 0.037 0.277 0.016 
Carbene-bound Rma 
TDEb 
0.60
3 0.243 0.491 0.164 0.099 0.162 0.026 
Fe(TPFPP)(CPh2)(MeIm
z)b 
 
1.02
8 0.345 0.744 0.078 0.046 0.615 0.019 
a Measured from 6CUK PDB structure.  
b Measured from 6CUN PDB structure.  
b Measured from 1208784.cif crystal structure reported in Ref 17. 
 
Out-of-plane distortion analysis on Rma TDE with and without the carbene ligand 
showed that for both structures, the primary out-of-plane distortion is ruffling, although the 
structure without the carbene ligand (6CUK, 0.620 Å) displays more ruffling than the 
structure with the carbene ligand (6CUN, 0.491 Å). Among the truncated model DFT-
optimized structures, the triplet state is the least consistent with the out-of-plane deviations 
observed in carbene-bound Rma TDE, as the saddling deviation of the triplet is much lower 
than is crystallographically observed (0.010 Å vs 0.243 Å), and the ruffling deviation is 
much higher than is crystallographically observed (0.784 Å vs 0.491 Å). When considering 
the optimized structures by QM/MM, which take into account conformational restraints 
imposed by the protein on porphyrin ruffling, the out-of-plane distortion parameters for all 
three electronic structures are similar to that observed in the crystal structure due to the 
rigidity imposed by the protein to the heme.  
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Figure C-5. GC Standard curve for ethyl 2-(dimethylphenylsilyl)propanoate product.  
 
 
Total turnover for reactions with 2 µM Rma TDE was determined to be 828 +/- 15 TTN.  
Pdt / std = ratio of product to internal standard (see section C.7) 
 
Figure C-6. 1H NMR for Ethyl 2-(dimethylphenylsilyl)propanoate product. 1H NMR 
(400 MHz, CDCl3) δ 7.55-7.46 (m, 2H), 7.43-7.32 (m, 3H), 4.02 (q, J = 7.1 Hz, 2H), 2.25 
(q, J = 7.1 Hz, 1H), 1.17-1.11 (m, 6H), 0.37 (d, J = 0.6 Hz, 6H).  
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Figure C-7. Separation of ethyl 2-(dimethylphenylsilyl)propanoate. 
 
 
A. Separation of racemic ethyl 2-(dimethylphenylsilyl)propanoate. A representative 
chiral HPLC trace of chemically-synthesized ethyl 2-(dimethylphenylsilyl)propanoate 
shows that the product is racemic, as expected. 
 
 
 
B. Separation of enzymatically-produced ethyl 2-(dimethylphenylsilyl)propanoate. A 
representative chiral HPLC trace of ethyl 2-(dimethylphenylsilyl)propanoate produced 
from a reaction catalyzed by Rma TDE shows that the enzyme produces product with 99% 
ee. The product was assigned as having the R absolute configuration based on comparison 
of retention times to the literature.4,25 
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C h a p t e r  4  
ORIGINS OF CHEMOSELECTIVITY IN CYTOCHROME C-CATALYZED 
CARBENE INSERTIONS INTO SILICON–HYDROGEN BONDS 
Material from this chapter is adapted from a manuscript in 
preparation which will be submitted with the following author 
list: Garcia-Borràs M†, Lewis RD†, Tang A, Jimenez-Osés G, 
Kan SBJ, Arnold FH, Houk KN.       
† Denotes equal author contribution. 
 
 
4.1 Abstract 
 
Heme proteins have recently been engineered to catalyze the formation of carbon–silicon 
bonds via carbene insertion into Si–H bonds. Although this reactivity was unprecedented in 
the biological world, engineered cytochrome c proteins are now the most efficient and 
selective catalysts available for this transformation. Using computational and experimental 
tools, we create a detailed model of how the reaction occurs in the active site of the protein. 
Our model reveals that enzyme activity and chemoselectivity are modulated by the 
conformational ensemble of the cytochrome c protein front loop. Using mechanistic 
understanding to guide directed evolution, we further showed that the cytochrome c carbene 
transferase can switch chemoselectivity from silylation to amination. This work 
demonstrates that information on protein structure, dynamics, and enzyme mechanism can 
provide explanations of how non-natural chemical transformations become possible in the 
biological world, can guide evolution in the laboratory and can propel the discovery of new 
enzyme functions.  
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4.2 Introduction 
 
The discovery of novel carbene transfer enzymes has largely been driven by 
repurposing existing heme proteins, and evolving these proteins for improved activity for 
a specific, novel reaction1–12. Fundamentally, the process of repurposing and evolving 
enzymes for novel reactivity is an alteration of enzyme chemoselectivity, which makes 
engineering carbene transfer enzyme chemoselectivity key to the development of new 
carbene transfer enzymes. Engineering enzymes for chemoselectivity is also important for 
developing useful biocatalysts that can selectively functionalize compounds without the 
need for protection and deprotection steps8,13,14. Despite the importance of engineering 
altered chemoselectivity in carbene transfer enzymes, how these enzymes achieve 
chemoselectivity remains poorly understood8. Metal carbene intermediates are innately 
reactive towards a broad array of functional groups, and yet carbene transfer enzymes are 
able to achieve high degrees of chemoselectivity1,7,8.  
Previously, we discovered that a protein engineered to forge carbon–silicon bonds (Rma 
TDE, see Chapter 2) is a remarkably chemoselective carbene transfer enzyme1. Rma TDE 
is capable of differentiating between the functionalization of Si–H and N–H bonds with 
97% selectivity for silylation, even though selection pressure for chemoselectivity was not 
applied during the directed evolution of this enzyme1. This preference for Si–H 
functionalization is the opposite of what a small molecule catalyst would typically 
prefer1,15, and the opposite of what is observed in myoglobin-based (Mb) carbene transfer 
competition experiments8. Interestingly, wild-type Rma cyt c functionalizes N–H and Si–
H bonds with approximately equal preference, suggesting that the mutations in Rma TDE 
(V75T M100D M103E) somehow encode chemoselectivity for silicon functionalization1.  
In order to understand how the protein achieves chemoselectivity in this new-to-nature 
reaction, we must first elucidate precisely how the reaction occurs in the protein. Heme 
protein-catalyzed carbene insertion reactions are proposed to occur through the formation 
of a reactive iron porphyrin carbene (IPC) intermediate, followed by transfer of the carbene 
equivalent to a second substrate, such as an olefin, Si–H bond, or an amine N–H bond16–19 
(Scheme 4-1). Previous studies of iron porphyrin-catalyzed carbene transfer reactions have 
suggested that three distinct IPC electronic states could be involved in these reactions: the 
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closed-shell singlet (CSS), open-shell singlet (OSS), and triplet (T) states17,18,20–22. The 
protein structure has been shown to influence the relative stabilities of various electronic 
states and therefore has to be considered when determining the overall reaction 
mechanism19. Herein, using experimental and computational methods, we investigate the 
mechanism of iron porphyrin-catalyzed carbene Si–H insertion and determine how the 
reaction mechanism is affected by the protein scaffold and mutations introduced by 
directed evolution. Using our understanding of how the reaction occurs in the enzyme, we 
elucidate how the enzyme controls the selectivity of carbene transfer to competing Si–H 
and N–H bonds, and further use our findings to guide enzyme engineering to switch 
silylation-amination chemoselectivity.  
 
Scheme 4-1. a) Stereoselective carbon–silicon bond formation catalyzed by Rma 
cytochrome c V75T M100D M103E variant (Rma TDE). Rma TDE was specifically 
evolved to catalyze carbene insertions into Si–H bonds using silane 1 and ethyl 2-
diazopropanoate (Me-EDA, 2) as substrates. b) Schematic description of the proposed 
mechanism for Rma cytochrome c-catalyzed carbon–silicon bond formation via 1) iron-
carbene formation; followed by 2) carbene Si–H insertion. 
 
4.3 Results and Discussion 
4.3.1 Quantum mechanical characterization of the reaction mechanism 
 
To understand how iron porphyrin catalyzes carbene insertion into Si–H bonds, we first 
applied Density Functional Theory (DFT) calculations to a simple truncated model 
(imidazole-ligated iron porphyrin). Along the reaction pathway, three possible electronic 
states for the iron center were considered: closed-shell singlet (CSS), open-shell singlet 
(OSS), and triplet (T) (see Appendix D, D.2). For iron-carbene formation from the ethyl 2-
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diazopropanoate substrate (Me-EDA, 2), DFT calculations suggest that the closed-shell 
singlet electronic state TS1-CSS is lowest in energy (ΔG‡ = 27.5 kcal·mol–1) (Figure 4-1). 
Hybrid quantum mechanics/molecular mechanics (QM/MM) calculations (simulating the 
iron-carbene-forming transition state in Rma TDE) again show that the closed-shell 
transition state TDE-TS1-CSS has the lowest energy barrier of the three electronic states. 
We next investigated the mechanism of the C–Si bond formation step, and used the 
truncated model to characterize the electronic and geometric features of the transition state 
(TS2) using dimethyl(phenyl)silane 1 as substrate. The closed-shell singlet transition state 
for Si–H insertion (TS2-CSS) was found to be lowest in energy, with ΔG‡ = 13.0 kcal·mol–
1. This is 12.5 kcal·mol–1 lower in Gibbs energy than the optimized triplet transition state 
(Figure 4-1, TS2-T). Optimization of the open-shell singlet transition state TS2-OSS was 
not successful using this truncated model (see Appendix D, D.2). The intrinsic reaction 
coordinate (IRC) for TS2-CSS shows that Si–H insertion is concerted but highly 
asynchronous, consisting of partial hydride-transfer from the silane to the carbene carbon, 
followed by C–Si bond formation (Figure 4-2). In contrast, TS2-T favors a radical 
stepwise pathway. A partial positive charge is accumulated on the silicon atom in TS2-
CSS, consistent with previous Hammett analysis of the Rma TDE-catalyzed reaction: when 
the relative reaction rates of various para-substituted aryldimethylsilanes were plotted 
against the Hammett σ values for the corresponding para-substituents, the calculated ρ 
value for Rma TDE was –0.70 (indicating a partial positive charge build-up on the Si atom 
in the rate-determining transition state)1. This ρ value is larger than those reported for Rh 
and Cu-based catalysts, for which ρ is –0.31 and –0.54, respectively23,24.  
QM/MM calculations were also used to model the C–Si bond formation step in the 
context of Rma TDE. The concerted closed-shell singlet TDE-TS2-CSS has a ΔE‡ = 20.0 
kcal·mol–1, which is similar in energy to the open-shell singlet TDE-TS2-OSS (ΔΔE‡ = 
0.4 kcal·mol–1), and lower in energy than the triplet TDE-TS2-T (ΔΔE‡ = 10.1 kcal·mol–
1) transition states. 
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Figure 4-1. Computed reaction pathway for carbene Si–H insertion reaction between 
PhMe2SiH 1 and Me-EDA 2 catalyzed by a model imidazole-ligated iron porphyrin 
(truncated QM-model). Results with three iron electronic states are given. Electronic and 
Gibbs free energies are given in kcal·mol–1. 
 
 
 
Figure 4-2. Intrinsic reaction coordinate (IRC) calculation for the lowest energy Si–H 
carbene insertion transition state (TS2-CSS) calculated using truncated models. Key 
distances and angles are shown in Å and degrees. 
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4.3.2 Rate-determining step of the enzymatic reaction 
 
QM calculations on the model system and QM/MM calculations on Rma TDE both 
predict that the energy barrier for C–Si bond formation is lower than that for carbene 
formation, suggesting formation of the carbene is intrinsically rate-determining in the 
overall reaction. However, this contrasts with our earlier Hammett analysis, where we 
observed that substitutions to the silane can increase the initial rate of the reaction, which 
suggests that the Si–H insertion step is rate-determining. To further interrogate the reaction 
mechanism and rate-determining step (RDS) experimentally, the initial-rate primary 
kinetic isotope effect (KIE) of the Rma TDE-catalyzed reaction was determined using 
dimethyl(phenyl)silane (PhMe2Si-H) and dimethyl(phenyl)silane-d (PhMe2Si-D). The KIE 
value obtained for Rma TDE was 2.1 ± 0.2 (see Appendix D, Figure D.1), demonstrating 
Si–H bond cleavage is rate-determining in an experimental system, while carbene 
formation is not. The experimental initial-rate KIE for Rma TDE is comparable to that 
computed for TDE-TS2-CSS (1.74). The predicted KIE values for TDE-TS2-OSS and 
TDE-TS2-T are 2.80 and 2.95, respectively (Table S1). In addition to the initial-rate KIE 
value, the end-point KIE value was also measured for Rma TDE, and determined to be 1.34 
± 0.08. This is similar to the end-point KIE values reported for Rh-, Ir-, and Cu-catalyzed 
reactions (1.29 and 1.5 for Rh, 1.6 for Ir, 1.08 for Cu), where the C–Si bond formation step 
is believed to be both rate-limiting and concerted23–25. Overall, our experimental results 
support a concerted carbene Si–H insertion mechanism, and suggest the C–Si bond 
formation step is rate-limiting in Rma TDE. A concerted reaction mechanism is in 
agreement with our QM/MM calculations, which suggest that the concerted and nonradical 
TDE-TS2-CSS is the lowest energy transition state. Additionally, a concerted mechanism 
also supports our previous hypothesis on how the enzyme controls stereoselectivity: the 
stereochemical outcome of C–Si bond formation is solely determined by how the silane 
substrate approaches the IPC intermediate in the enzyme active site19.  
Experimental evidence demonstrates that carbene Si–H insertion is rate-determining, 
although our quantum mechanical results show that the intrinsic energy barrier for C–Si 
bond formation is lower than that of carbene formation. This apparent discrepancy may 
arise because our quantum mechanical calculations use a substrate-protein complex in 
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which the silane substrate is already optimally positioned to approach the carbene-bound 
protein (the Michaelis-Menten complex). If the rate of dissociation of the Michaelis-
Menten complex is much greater than the rate of C–Si bond formation, the C–Si bond 
formation step will be rate-limiting26. Fast dissociation of the Michaelis-Menten complex 
suggests that its formation is thermodynamically unfavorable, and that the enzymatic rate-
determining step (∆G‡RDS) depends on both the quantum mechanical energy barrier (∆G‡Si–
H) and the binding energy (∆GºBinding) associated with the energy required for the enzyme 
to bind silane substrate in a catalytically competent pose (Scheme 4-2 and Scheme D-1). 
In the next section, we will address how silane binding occurs and how it may affect the 
rate of enzymatic silylation. 
 
 
Scheme 4-2. Schematic representation of the reaction profile of Rma cyt c IPC insertion 
into Si–H bond, the rate-determining step (RDS) of enzymatic C–Si bond formation. The 
RDS energy barrier consists of two components: i) the silane substrate binding affinity 
(∆GºBinding), which is >0 when binding is endergonic; and ii) the Si–H insertion energy 
barrier (∆G‡Si–H). When silane binding becomes more favorable (less endergonic), ∆G‡RDS 
decreases, leading to an overall faster reaction. Silane binding is more favorable for Rma 
TDE IPC than for wild-type Rma IPC because of the more flexible protein front loop in the 
evolved variant (see Section 3 for details). 
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4.3.3 Silane binding to Rma cyt c 
 
Previously, we found that one effect of the mutations in Rma TDE is to modulate the 
conformation of the protein front loop (residues 98–103) in such a way that facilitates 
access to the active site of carbene-bound Rma TDE by the silane substrate (Figure 4-3a)19. 
We hypothesized that the changes in the protein front loop conformation might also 
modulate the energetics of silane binding, and thus the rate-determining step of the reaction 
(Scheme 2). Using umbrella sampling MD (US-MD) simulations (see Appendix D, D.4), 
we compared the energetic cost of silane binding in carbene-bound wild-type Rma cyt c 
(WT IPC) and carbene-bound Rma TDE (TDE IPC) (Figure 4-3b). In both cases, the 
protein front loop must change conformation to accommodate the incoming silane 
substrate, and in both cases the silane substrate is only loosely bound by the protein: it is 
highly solvent exposed and not completely surrounded by the protein residues (Figure 4-
3c, left structure). As a consequence, the silane binding process is found to be 
thermodynamically unfavorable, with positive binding energies in both cases (∆GºBinding > 
0) (Figure 4-3b and Scheme 4-2). Because Rma cyt c does not naturally bind any 
substrates, it is perhaps unsurprising that both wild-type and Rma TDE have a poor ability 
to bind silane 1 after the IPC is formed in the cyt c active site. However, the silane binding 
energy in Rma TDE ca. 2 kcal·mol–1 lower (more favorable) than in the wild-type system. 
(Figure 4-3b). This improvement in the ability of Rma TDE to bind the silane may arise 
from increased front loop flexibility in IPC-bound Rma TDE IPC relative to IPC-bound 
Rma wild-type, or could also arise from the increased solvent exposure of D100 and E103, 
(Figure 4-3d), which might cause the protein front loop to adopt a conformation that better 
favors silane binding.  
Based on these results, the C–Si bond formation step is dependent on the concentration 
of a thermodynamically unfavorable Michaelis-Menten complex, which likely is what 
causes the C–Si bond formation step to be rate-determining in the experimental system. 
Because of the improved silane binding in Rma TDE with respect to Rma wild-type, the 
concentration of the Michaelis-Menten complex would be higher in the Rma TDE system, 
resulting in higher turnover frequency.  
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From kinetics experiments, we have determined that Rma TDE has a 7-fold increase in 
initial rate relative to the wild-type protein (Figure D-1) In the transition state theory (TST) 
framework, a 7-fold increase in rate represents an energy difference of ca. 1.2 kcal·mol–1 
between the RDS barriers for wild-type Rma cyt c and Rma TDE. This experimentally 
estimated energy difference (∆∆G‡RDS) of 1.2 kcal·mol–1 agrees with the computationally 
estimated energy difference in silane binding (∆∆GºBinding) between wild-type Rma cyt c 
and Rma TDE (ca. 2 kcal·mol–1 more favorable in Rma TDE).  
 
 
Figure 4-3. a) Representative snapshots obtained from MD simulations of IPC bound in 
wild-type Rma cyt c (gray), and the Rma TDE variant (purple). Front loop M100/D100 and 
M103/E103 residues are represented in space filling format. Hydrophobic methionines 
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(M100 and M103) close the substrate channel in wild-type Rma cyt c, but mutations 
M100D and M103E introduce hydrophilic residues that are exposed to the solvent in Rma 
TDE along the MD simulations, allowing an easier access of the silane substrate to interact 
with the IPC. V75T creates new key H-bond with Y71 that induce a more hydrophobic 
environment for the IPC intermediate. b) Potential of mean force (PMF) measured along 
the reaction coordinate defined as the distance between the IPC central C atom and the 
center of mass of the silane substrate 1 for wild-type Rma cyt c and Rma TDE IPC variants. 
c) Representative snapshots of the PMF reaction coordinate obtained from the Rma TDE 
PMF simulations. d) Overlay of 50 snapshots (every 10 ns) obtained from 500 ns MD 
simulations for wild-type Rma cyt c and Rma TDE variants in its apo and IPC-bound states. 
Residues mutated in the front loop (original M100 and M103 in WT, and D100 and E103 
in TDE variant) are shown in orange. Insets highlight the flexibility acquired by the front 
loop due to new introduced mutations (going from “WT apo” to “TDE apo”) and the 
formation of the IPC (going from “WT apo” and “TDE apo” to “WT IPC” and “TDE IPC”, 
respectively).  
 
4.3.4 Rationalization of chemoselectivity 
 
With our model of the Si–H functionalization mechanism in satisfactory agreement 
with our experimental results, we compared the mechanisms of imidazole-ligated iron 
porphyrin-catalyzed carbene transfer to N–H and Si–H bonds (Figures 4-3a–b). N–H 
functionalization can occur through a concerted N–H insertion mechanism involving 
hydrogen atom transfer (HAT) (Figure 4-3c), or through nucleophilic attack by the 
nitrogen lone pair followed by subsequent ylide rearrangement5,20 (Figure 4-3b). Using 
DFT calculations to model the reaction between imidazole-ligated IPC and 4-
(dimethylsilyl)aniline 6, the preferred amination pathway was determined to be N-
nucleophilic attack followed by ylide rearrangement, which agrees with previous 
mechanistic work on this reaction20. We found that silylation and amination have 
geometrically distinct transition states, as the required substrate approach to the carbene 
carbon are different in these reactions, and that in the absence of the protein scaffold, 
amination has a lower energy barrier than Si–H carbene insertion (ΔΔG‡ = 3.5 kcal·mol–1) 
(Figures 4-3a–c). 
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Figure 4-4. DFT optimized transition states using 4-(dimethylsilyl)aniline 6 as substrate: 
a) Si–H carbene insertion; b) N-nucleophilic attack to the electrophilic IPC carbon atom; 
and c) direct N–H carbene insertion. Gibbs free energies are estimated from lowest in 
energy OSS IPC 5, and are given in kcal·mol-1. Key distances and angles are given in Å 
and degrees, respectively. Different orientations of the substrate towards the carbene are 
required. Analysis of the substrate binding pose and near attack conformations through 
constrained MD simulations (N(silane) – C(carbene) distance constrained along 500 ns 
MD trajectories). Representative snapshot of constrained MD simulations (constrained N 
– C distance) in the d) wild-type and e) TDE IPC Rma enzyme active sites. (f) C(carbene)-
N(silane)-C(silane) attack angles explored along the constrained MD simulations. The 
ideal C(carbene)-N(silane)-C(silane) attack angle value for an effective N-nucleophilic 
attack is 121.5º, determined from DFT optimized TS.  
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We hypothesized that the enzyme might achieve chemoselectivity by distinguishing 
between the geometrically distinct transition states. Using carbene-bound wild-type Rma 
cyt c and Rma TDE as starting structures, we docked 4-(dimethylsilyl)aniline 6 into both 
enzyme active sites, with conformation and orientation of 6 resembling how this substrate 
attacks the carbene in the DFT-optimized N-nucleophilic attack transitions state (Figure 4-
4b). The docked structures then served as starting points for MD simulations, in which the 
N(substrate 6) – C(carbene) distance was kept constrained during the entire simulation. 
These constrained MD simulations showed that in wild-type Rma cyt c, 6 prefers a bound 
near attack conformation that resembles the N-nucleophilic attack TS, in which the 
measured ∠C(carbene)-N(substrate 6)-C(substrate 6) angle is 121.5° (Figures 4-4d and 4-
4f). In contrast, in Rma TDE, 6 prefers a binding pose that resembles the near attack 
conformation for the energetically disfavored DFT optimized N–H hydrogen abstraction 
TS (ΔG‡= 41.7 kcal·mol-1, Figure 4-4c) with an enlarged ∠C(carbene)-N(substrate 6)-
C(substrate 6) angle (Figures 4-4e–f), rather than the corresponding N-nucleophilic attack 
TS. Taken together, DFT calculations and MD simulations suggest that the front loop 
conformation ensemble in Rma TDE prevents amination by disfavoring the N-nucleophilic 
attack transition state while at the same time, facilitating the silylation reaction. 
 
4.3.5 Engineering inverted chemoselectivity in Rma TDE 
 
As a mechanistic understanding of Rma TDE helped us explain chemoselectivity, we 
next sought to demonstrate that such understanding can be leveraged to engineer 
chemoselectivity, allowing these enzymes to be easily tailored for new catalytic 
applications. For this demonstration, we sought to create an enzyme that favors the 
amination product of 4-(dimethylsilyl)aniline (7) over the competing silylation product (8), 
the opposite to what Rma TDE prefers. We hypothesized that by mutating residues that 
help control the conformational dynamics of the front loop, we could identify a protein that 
prefers the amination transition state. Toward this end, three amino acid residues in Rma 
TDE were chosen for site-saturation mutagenesis: E103, M99, and N80. While front loop 
residue E103 has been experimentally shown to affect the chemoselectivity of the enzyme1, 
residue M99, which also resides on the front loop, has not, but it does affect front loop 
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conformation as observed in our MD simulations. N80 is an amino acid residue found on 
the D helix of Rma cyt c. Through MD simulations, N80 was found to persistently interact 
with the front loop through hydrogen bonding interactions with the main chains of M99, 
M100D, T101, and D102, as well as the D102 side chain. We therefore predict N80 could 
modulate the conformation and dynamics of the front loop, and thus the reaction 
chemoselectivity. 
Using Rma TDE as our parent enzyme, we generated site-saturation libraries at each of 
the three sites, and screened for chemoselectivity, as measured by products ratios of 
carbene transfer to an amine substrate (4-isopropylaniline) and a silane substrate 
(dimethyl(phenyl)silane, 1) in a single competition reaction. Variants displaying improved 
selectivity for the amination reaction were then evaluated for their chemoselectivity on 
4(dimethylsilyl)-aniline (6). The most amination-selective variants from each library were 
determined to be E103I, M99P and N80F, which produced the amination product as 27–
34% of the total product, as compared to 3% for the parent Rma TDE (Figure 4-5a). When 
we combined these three mutations in a single protein (Rma TD N80F M99P E103I, 
abbreviated as Rma TDFPI), the resulting catalyst produces the amination product as 90% 
of the total product, suggesting that the front loop now occupies a new and distinct 
conformation that selectively favors amination over silylation.  
A computational model for carbene-bound Rma TDFPI was then generated and used to 
perform MD simulations to understand the effects of the new mutations. Our simulations 
revealed a significant change in front loop conformation in Rma TDFPI compared to Rma 
TDE (Figure 4-5b). Notably, the M99P and E103I mutations work synergistically to 
disfavor the silylation transition state by changing the conformational preference of the 
front loop (M99P) and blocking the preferred binding pose required for the silane to 
approach the IPC (E103I) (Figure 4-5c). The new active site found in Rma TDFPI has a 
substrate access tunnel between the D helix and the protein front loop that guides substrate 
6 to approach the carbene-bound heme from the top, a trajectory that favors a near attack, 
amination conformation via an N-nucleophilic attack transition state (Figure 4-5c). This 
trajectory is also favored by the N80F mutation: because of steric repulsion between the 
phenylalanine side chain and the protein front loop, the front loop is now distanced from 
the D helix where N80F resides. Finally, by docking substrate 6 into carbene-bound Rma 
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TDFPI with an amination-like conformation and constraining the N(substrate 6) – 
C(carbene) distance (2.5 Å), constrained MD simulations were used to analyze the 
catalytically competent binding poses of substrate 6 in Rma TDFPI. These simulations 
showed that the binding pose of substrate 6 is modulated by hydrophobic interactions 
between E103I and the aromatic ring of 6, which stabilizes the substrate in a near attack 
conformation that leads to the N-nucleophilic attack TS (Figure 4-5c).  
 
 
Figure 4-5. a) Site saturation mutagenesis of Rma TDE for chemoselective amination 
over Si–H carbene insertion using 4(dimethylsilyl)-aniline 6 and diazo compound 2. 
Reactions were performed with heat-treated cell lysates with 1 µM Rma cyt c protein, 10 
mM 6, 10 mM 2, and 10 mM sodium dithionite in M9–N buffer. Chemoselectivity was 
measured as the percent of amination product over total product formed, and was 
determined by gas chromatography. Total turnover number (TTN) is defined as the 
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combined concentration of 7 and 8, over protein concentration. See SI for full description 
of the experimental procedures. b) Overlay of different snapshots obtained from 500 ns 
MD trajectories of Rma TDE (purple) and Rma TDFPI (gray) IPC-bound complexes. The 
most important structural changes correspond to the preferred “top-open” conformation 
adopted by the front loop (residues 98-103) in Rma TDFPI as compared to the parent Rma 
TDE variant. c) Overlay of snapshots obtained from 500 ns MD trajectory for Rma TDFPI 
IPC-bound complex. The mutations N80F, M99P, and E103I are highlighted in orange. 
Inset: Snapshot from constrained-MD simulation of Rma TDFPI IPC-bound complex with 
substrate 6, showing how substrate 6 prefers to adopt a binding pose that favors amination 
via N-nucleophilic attack.  
 
4.4 Conclusions 
 
The catalytic versatility and selectivity observed in engineered carbene transfer 
enzymes has led to growing interest in developing these systems for chemical catalysis. 
Understanding the catalytic mechanism of these engineered enzymes and how the protein 
scaffold influence the reaction outcomes offers fundamental insights into how non-natural 
enzymes function and how we might design new ones. Here, we have characterized, 
through computations and experiments, how Rma cyt c variants catalyze the formation of 
carbon–silicon bonds. We determined that the enzyme catalyzes carbene insertion into Si–
H bonds through a concerted, nonradical mechanism, in which closed-shell singlet 
transition states are lowest in energy for both carbene formation and Si–H insertion. 
Organosilane binding to the enzyme requires unfavorable displacement of the protein front 
loop, rendering C–Si bond formation the rate-determining step of the overall reaction. We 
reasoned that directed evolution transformed Rma TDE into a faster enzyme by making 
silane binding more favorable in Rma TDE than in the wild-type protein, which reduces 
the rate-determining energy barrier of carbene Si–H insertion. Importantly, the mutations 
in Rma TDE also confer chemoselectivity to the enzyme by stabilizing a substrate binding 
pose that favors one reaction (silylation) over another (amination), through modulation of 
the protein front loop conformation and dynamics. Finally, taking advantage of the 
mechanistic details uncovered in this study, we predictably switch the enzyme 
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chemoselectivity from silylation to amination, demonstrating how insights into protein 
conformational dynamics and reaction mechanism can guide the evolution of new 
enzymatic reactions, offering a framework for future mechanism-guided engineering of 
useful and novel carbene transfer enzymes. 
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A p p e n d i x  D  
SUPPLEMENTARY INFORMATION FOR CHAPTER 4 
 
D.1  Materials and methods  
 
Unless otherwise noted, all chemicals and reagents for chemical reactions were obtained 
from commercial suppliers (Acros, Arch Bioscience, Fisher Scientific, Sigma-Aldrich, TCI 
America, VWR) and used without further purification. Multitron shakers (Infors, Annapolis 
Junction, MD) were used for cell growth. UV-Vis spectroscopy was performed using a 
Shimadzu UV-1800 spectrophotometer (Shimadzu, Carlsbad, CA). Sonication was 
performed using a Qsonica Q500 sonicator. Silica gel chromatography purifications were 
carried out using AMD Silica Gel 60, 230-400 mesh. 1H NMR spectra were recorded on a 
Bruker Prodigy 400 MHz instrument and are internally referenced to the residual solvent 
peak (chloroform). Data for 1H NMR are reported in the conventional form: chemical shift 
(δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, hept = heptet, m = 
multiplet, br = broad, app = appears as), coupling constant (Hz), integration. Gas 
chromatography (GC) analyses were carried out using an Agilent 7820A gas chromatograph, 
a flame ionization detector (FID), and J&W HP-5 (30 m x 0.32 mm, 0.25 µm film; 90 °C 
hold 1 min, 90 to 110 °C at 15 °C/min, 110 to 280 °C at 60 °C/min, 280 °C hold 1 min, 6.2 
min total).  
Plasmid pET22 was used as a cloning vector, and cloning was performed using Gibson 
assembly.1 The cytochrome c maturation plasmid pEC862 was used as part of a two-plasmid 
system to express prokaryotic cytochrome c proteins. Cells were grown using Lysogeny 
Broth medium or HyperBroth (AthenaES, Baltimore, MD) with 100 µg/mL ampicillin and 
20 µg/mL chloramphenicol (LBamp/chlor or HBamp/chlor). Primer sequences are available upon 
request. Electrocompetent Escherichia coli cells were prepared following the protocol of 
Sambrook et al..3 T5 exonuclease, Phusion polymerase, and Taq ligase were purchased from 
New England Biolabs (NEB, Ipswich, MA). M9-N minimal medium (abbreviated as M9-N 
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buffer; pH 7.4) was used as a buffering system unless otherwise specified. M9-N minimal 
medium (abbreviated as M9-N buffer; pH 7.4) was used without a carbon source; it contains 
47.7 mM Na2HPO4, 22.0 mM KH2PO4, 8.6 mM NaCl, 2.0 mM MgSO4, and 0.1 mM CaCl2.  
 
D.2  Plasmid construction 
 
All variants described in this paper were cloned and expressed using the pET22(b)+ 
vector (MilliporeSigma, St. Louis, MO). The gene encoding Rhodothermus marinus cyt c 
V75T M100D M103E (Rma TDE) was obtained as a single gBlock (Integrated DNA 
Technologies, Coralville, IA),4 codon-optimized for E. coli, and cloned using Gibson 
assembly1 into pET22(b)+ between restriction sites NdeI and XhoI in frame. The gene 
encoding Rma TDE contained an N-terminal pelB leader sequence and 6xHisTag 
(MKYLLPTAAAGLLLLAAQPAMAHHHHHH) and had the first seven amino acids of 
mature, wild-type Rma cyt c removed (TESGTAA). This plasmid was co-transformed with 
the cytochrome c maturation plasmid pEC862 into E. cloni® EXPRESS BL21(DE3) cells 
(Lucigen, Middleton, WI).  
 
DNA coding sequence of Rma cyt c V75T M100D M103E with an N-terminal pelB leader 
sequence and 6xHisTag: 
 
ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGC
GATGGCCCATCATCATCATCACCACCAAGACCCGGAAGCACTGGCAGCGGAAATTGGTC
CGGTCAAACAGGTGAGCCTGGGTGAACAGATTGATGCGGCCCTGGCGCAACAGGGAGAA
CAGCTCTTCAACACGTATTGTACTGCGTGCCACCGTCTGGATGAGCGTTTTATCGGACC
GGCCCTGCGCGATGTTACCAAACGTCGTGGGCCGGTTTACATCATGAACACGATGCTGA
ACCCGAATGGGATGATCCAGCGTCATCCGGTGATGAAACAGCTCGTGCAGGAATATGGG
ACCATGGATACCGATGAGGCCCTGAGTGAAGAACAAGCGCGCGCAATTCTGGAGTATCT
GCGCCAGGTTGCGGAAAACCAGTAATGA 
 
Amino acid sequence of Rma cyt c V75T M100D M103E with an N-terminal pelB leader 
sequence and 6xHisTag: 
 
MKYLLPTAAAGLLLLAAQPAMAHHHHHHQDPEALAAEIGPVKQVSLGEQIDAALAQQGE
QLFNTYCTACHRLDERFIGPALRDVTKRRGPVYIMNTMLNPNGMIQRHPVMKQLVQEYG
TMDTDEALSEEQARAILEYLRQVAENQ* 
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DNA coding sequence of Rma cyt c V75T N80F M99P M100D M103I with an N-terminal 
pelB leader sequence and 6xHisTag: 
 
ATGAAATACCTGCTGCCGACCGCTGCTGCTGGTCTGCTGCTCCTCGCTGCCCAGCCGGC
GATGGCCCATCATCATCATCACCACCAAGACCCGGAAGCACTGGCAGCGGAAATTGGTC
CGGTCAAACAGGTGAGCCTGGGTGAACAGATTGATGCGGCCCTGGCGCAACAGGGAGAA
CAGCTCTTCAACACGTATTGTACTGCGTGCCACCGTCTGGATGAGCGTTTTATCGGACC
GGCCCTGCGCGATGTTACCAAACGTCGTGGGCCGGTTTACATCATGAACACGATGCTGA
ACCCGTTTGGGATGATCCAGCGTCATCCGGTGATGAAACAGCTCGTGCAGGAATATGGG
ACCATGGATCCGGATATTGCCCTGAGTGAAGAACAAGCGCGCGCAATTCTGGAGTATCT
GCGCCAGGTTGCGGAAAACCAGTAATGA 
 
Amino acid sequence of Rma cyt c V75T N80F M99P M100D M103I with an N-terminal 
pelB leader sequence and 6xHisTag: 
 
MKYLLPTAAAGLLLLAAQPAMAHHHHHHQDPEALAAEIGPVKQVSLGEQIDAALAQQGE
QLFNTYCTACHRLDERFIGPALRDVTKRRGPVYIMNTMLNPFGMIQRHPVMKQLVQEYG
TMDPDIALSEEQARAILEYLRQVAENQ* 
 
 
D.3   Cytochrome c expression and purification  
 
Purified cytochrome c proteins were prepared as follows. In a 4 L flask, one liter 
HyperBroth (AthenaES) containing 100 µg/mL ampicillin and 20 µg/mL chloramphenicol 
(HBamp/chlor) was inoculated with an overnight culture (20 mL, Lysogeny Broth, with 100 
µg/mL ampicillin, 20 µg/mL chloramphenicol, LBamp/chlor) of recombinant E. cloni® 
EXPRESS BL21(DE3) cells containing a pET22(b)+ plasmid encoding the cytochrome c 
variant, and the pEC86 plasmid. The culture was shaken at 37 °C and 200 rpm (no humidity 
control) until the OD600 was 0.7 (approximately 3 hours). The culture was placed on ice for 
30 minutes, and isopropyl β-D-1-thiogalactopyranoside (IPTG) and 5-aminolevulinic acid 
(ALA) were added to final concentrations of 20 µM and 200 µM, respectively. 
 
The incubator temperature was reduced to 25 °C, and the culture was allowed to shake 
for 20 hours at 200 rpm. Cells were harvested by centrifugation (4 °C, 15 min, 4,000xg), 
and the cell pellet was stored at −20 °C until further use (at least 24 hours). The cell pellet 
was resuspended in buffer containing 100 mM NaCl, 20 mM imidazole, and 20 mM 
sodium phosphate buffer (pH 7.5) and cells were lysed by sonication (4 minutes, 1 second 
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on, 1 second off, 30% duty cycle; Qsonica Q500 sonicator). Cell lysate was placed in a 75 
°C heat bath for 10 minutes, and afterwards cell debris was removed by centrifugation for 
20 min (30,000xg, 4 °C). Supernatant was sterile-filtered through a 0.45 µm cellulose 
acetate filter and purified using a 1 mL Ni-NTA column (HisTrap HP, GE Healthcare, 
Piscataway, NJ) using an AKTA purifier FPLC system (GE Healthcare). The cytochrome 
c protein was eluted from the column by running a gradient from 20 to 500 mM imidazole 
over 10 column volumes. 
The purity of the collected cytochrome c fractions was analyzed using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Pure fractions were pooled and 
concentrated using a 3 kDa molecular weight cut-off centrifugal filter. Protein was dialyzed 
overnight into 20 mM sodium phosphate buffer (pH 7.5) using 3.5 kDa molecular weight 
cut-off dialysis tubing. The dialyzed protein was further concentrated using a 3 kDa 
molecular weight cut-off centrifugal filter, flash-frozen on dry ice, and stored at −80 °C. 
The concentration of cytochrome c was determined in triplicate using the hemochrome 
assay described in section D.7. 
 
D.4   Hemochrome assay  
 
A solution of sodium dithionite (100 mM) was prepared in M9-N buffer. Separately, a 
solution of 1 M NaOH (0.4 mL) was mixed with pyridine (1 mL), followed by 
centrifugation (10,000xg, 30 seconds) to separate the excess aqueous layer gave a pyridine-
NaOH solution. To a cuvette containing 10 µL purified protein solution and 640 µL M9-N 
buffer, 100 µL of dithionite solution and 250 µL pyridine-NaOH solution were added. The 
cuvette was sealed with Parafilm, and the UV-Vis spectrum was recorded immediately at 
room temperature between 600 and 380 nm on a UV-1800 Shimadzu spectrophotometer. 
Cytochrome c concentration was determined using ε550-535 = 22.1 mM–1cm–1.4,5  
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D.5   Library construction 
 
Cytochrome c site-saturation mutagenesis libraries were generated using a modified 
version of the 22-codon site-saturation method.6 For each site-saturation library, 
oligonucleotides were ordered such that the coding strand contained the degenerate codon 
NDT, VHG or TGG. The reverse complements of these primers were also ordered. The 
three forward primers were mixed together in a 12:9:1 ratio, (NDT:VHG:TGG) and the 
three reverse primers were mixed similarly. Two PCRs were performed, pairing the 
mixture of forward primers with a pET22(b)+ internal reverse primer, and the mixture of 
reverse primers with a pET22b internal forward primer. The two PCR products were gel 
purified, ligated together using Gibson assembly,1 and transformed into E. cloni® 
EXPRESS BL21(DE3) cells. Primer sequences are available upon request. 
 
 
D.6   Enzyme library screening   
 
Single colonies were picked with toothpicks off of LBamp/chlor agar plates, and grown in 
deep-well (2 mL) 96-well plates containing LBamp/chlor (400 µL) at 37 °C, 250 rpm shaking, 
and 80% relative humidity overnight. After 16 hours, 30 µL aliquots of these overnight 
cultures were transferred to deep-well 96-well plates containing HBamp/chlor (1 mL) using a 
12-channel EDP3-Plus 5-50 µL pipette (Rainin). Glycerol stocks of the libraries were 
prepared by mixing cells in LBamp/chlor (100 µL) with 50% v/v glycerol (100 µL). Glycerol 
stocks were stored at −78 °C in 96-well microplates. Growth plates were allowed to shake 
for 3 hours at 37 °C, 250 rpm shaking, and 80% relative humidity. The plates were then 
placed on ice for 30 min. Cultures were induced by adding 10 µL of a solution, prepared 
in sterile deionized water, containing 2 mM IPTG and 20 mM ALA. The incubator 
temperature was reduced to 24 °C, and the induced cultures were allowed to shake for 20 
hours (250 rpm, no humidity control). Cells were pelleted (4,000xg, 5 min, 4 °C) and 
resuspended in 450 µL M9-N buffer. For cell lysis, plates were placed in a 75 °C water 
bath for 10 min, followed by centrifugation (4,000xg, 5 min, 4 °C) to remove cell debris. 
The resulting heat-treated lysates (320 µL) were then transferred to deep-well plates for 
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biocatalytic reactions. In an anaerobic chamber, to deep-well plates of heat-treated lysates 
were added 40 µL Na2S2O4 (100 mM in dH2O), and 40 µL reactant solution (100 mM 
phenyl(dimethyl)silane, 100 mM 4-isopropylaniline, 150 mM Me-EDA in MeCN). The 
plates were sealed with aluminum sealing tape, removed from the anaerobic chamber, and 
shaken at 400 rpm for 1.5 h. Reactions were quenched with acetonitrile (400 µL), and 
allowed to sit at room temperature for 30 minutes to allow proteins to precipitate from 
solution. The plates were centrifuged (5,000xg, 10 min) and the organic layer (400 µL) was 
transferred to shallow-well 96-well plates for reverse phase HPLC analysis. Protein 
variants that displayed improved selectivity for the 4-isopropylaniline substrate were then 
regrown in shake flasks, and evaluated for their activity and selectivity with 4-
dimethylsilylaniline in small-scale biocatalytic reactions, which were analyzed by GC for 
accurate determination of turnovers and chemoselectivity. 
 
D.7  Protein lysate preparation  
Protein lysates for biocatalytic reactions were prepared as follow: E. coli cells expressing 
Rma cyt c variant were pelleted (4,000xg, 5 min, 4 °C), resuspended in M9-N buffer and 
adjusted to the appropriate optical density at 600 nm (OD600). The whole-cell solution was 
sonicated, (1 minute, 1 second on, 1 second off, 30% duty cycle) heat-treated (75 °C for 10 
min) and then centrifuged (14,000xg, 10 min, 4 °C) to remove cell debris. The supernatant 
was sterile filtered through a 0.45 µm cellulose acetate filter, concentration of cytochrome c 
protein in the lysate was determined using the hemochrome assay described in section D.7. 
Using this protocol, the protein concentrations we typically observed for OD600 = 30 lysates 
were in the 3-15 µM range. 
 
D.8 Biocatalytic reactions   
 
In an anaerobic chamber, heat-treated cell lysate containing an Rma cyt c variant was 
diluted to concentration of 1.2 µM with M9-N buffer, and 340 µL of this solution was 
transferred to a 2 mL crimp vial. Next, the protein was reduced by adding 40 µL Na2S2O4 
(100 mM in M9-N buffer), and the reaction was initiated with the addition of reactants, 10 
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µL the appropriate silane solution (400 mM in MeCN) and 10 µL Me-EDA (400 mM in 
MeCN). The vial was crimp sealed, removed from the anaerobic chamber, and shaken at 
400 rpm at room temperature for 2 hours. At the end of the reaction, the crimp vial was 
opened and the reaction was quenched with cyclohexane (1 mL). Internal standard was 
added (20 µL of 20 mM 1,2,3-trimethoxybenzene in toluene or 20 µL of 20 mM 2-
phenylethanol in toluene) and the reaction mixture was transferred to a microcentrifuge 
tube, vortexed (1 minute), then centrifuged (14,000xg, 5 min) to completely separate the 
organic and aqueous layers. The organic layer (800 µL) was removed for GC and chiral 
HPLC analysis. All biocatalytic reactions were performed in triplicate. The total turnover 
numbers (TTNs) reported are calculated with respect to the protein catalyst and represent 
the total number of turnovers obtained using the catalyst under the stated reaction 
conditions. 
 
Concentration of organosilicon product was calculated based on the ratio of areas 
between the product peak and internal standard peak, as measured by GC-FID. 
 
Stock solutions of chemically synthesized authentic standard organosilicon products 
were prepared at various concentrations (20 to 200 mM in MeCN). To a microcentrifuge 
tube were added 340 µL M9-N buffer, 40 µL Na2S2O4 (100 mM in M9-N buffer), 20 µL 
organosilicon product, 20 µL internal standard (20 mM 1,2,3-trimethoxybenzene in toluene 
or 20 µL of 20 mM 2-phenylethanol in toluene) and 1 mL cyclohexane. The mixture was 
vortexed (1 minute) then centrifuged (14,000xg, 5 min) to completely separate the organic 
and aqueous layers. The organic layer (800 µL) was removed for GC analysis. Each 
concentration was prepared in duplicate, and both data points are shown for each 
concentration (Figure D-3). The standard curves plot product concentration in mM (x-
axis) against the ratio of product area to internal standard area on the GC (y-axis).  
 
D.8.1 Kinetic time course reactions   
In an anaerobic chamber, purified protein was added to 3400 µL of M9-N buffer in a 6 
mL headspace vial with a magnetic stir bar. Next, the protein was reduced by adding 400 
µL Na2S2O4 (100 mM in M9-N) and the reaction was initiated with the addition of 
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reactants, 100 µL PhMe2SiH (400 mM in MeCN) and 100 µL Me-EDA (400 mM in 
MeCN). At two minute intervals (2, 4, 6, 8, and 10 min) 400 µL of the reaction solution 
was removed the 6 mL vial, and was transferred to a microcentrifuge tube containing 1000 
µL cyclohexane and an internal standard (20 µL of 20 mM 1,2,3 trimethoxybenzene in 
toluene). The microcentrifuge tube was vortexed for 30 seconds, and then allowed to sit 
until all samples from all time points had been produced. At the end of the kinetic time 
course reaction, the microcentrifuge tubes were centrifuged (14,000xg, 1 min) to 
completely separate the organic and aqueous layers. The organic layer (800 µL) was 
removed for GC analysis. All biocatalytic reactions were performed in triplicate or 
quadruplicate. The initial rates reported are calculated with respect to the protein catalyst 
and represent the number of turnovers per minute per enzyme, obtained using the enzyme 
under the stated reaction conditions. 
 
 
D.9 Synthesis and characterization of organosilicon compounds 
 
  
Phenyl(dimethyl)-silane-d (Compound D-1) 
 
Phenyl(dimethyl)-silane-d was prepared by adapting a procedure for the hydrogenation 
of chlorosilanes by NaBH4.7 In a 100 mL-round bottom flask, 2.5 g sodium borodeuteride 
(NaBD4, 60 mmol, 2.0 equiv., Cambridge Isotope Labs) were added. The flask was purged 
with argon, and 30 mL anhydrous acetonitrile was added. Under anaerobic conditions, 5.0 
g phenyl(dimethyl)silyl chloride (30 mmol, 1 equiv.) was added dropwise over 30 minutes 
at room temperature, with continuous stirring. The round bottom flask became very hot 
over the addition of phenyl(dimethyl)silyl chloride, and so slower addition than performed 
here, and/or addition at 0 °C is recommended for a safer procedure. After completing the 
addition of the phenyl(dimethyl)silyl chloride, the reaction was allowed to stir at room 
temperature for an additional 30 min. The reaction was then cooled to 0 °C, after which the 
flask was opened to aerobic atmosphere and quenched with dropwise addition of saturated 
aqueous ammonium chloride (NH4Cl, approximately 10 mL). Purification by silica column 
chromatography using 100% pentane as an eluent afforded phenyl(dimethyl)-silane-d with 
61% yield. 
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Compound D-1. Phenyl(dimethyl)silane-d 
1H NMR (400 MHz, CDCl3) δ 7.48-7.62 (m, 2H), 7.30-7.44 (m, 3H), 0.35 (app q, J = 0.6 
Hz, 6H). 
 
All other compounds were synthesized as described in ref. (4). 
 
Si
D
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D.10  Supporting figures and tables 
 
Figure D-1. Kinetic time course data for reaction between ethyl 2-diazopropanoate and 
phenyl(dimethyl)-silane (PhMe2Si–H or PhMe2Si–D, as specified), catalyzed by Rma 
cytochrome c variants. 
 
 
 
 
A. Kinetic time course data for reaction using Rma TDE and PhMe2Si–H. Five independent 
runs are shown, and the corresponding turnover frequencies are summarized in the table 
below. 
 
Rma TDE (PhMe2Si–H) 
Run 1 25.0 /min 
Run 2 21.2 /min 
Run 3 27.9 /min 
Run 4 25.0 /min 
Run 5 22.9 /min 
Average 24.4 /min 
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B. Kinetic time course data for reaction using Rma TDE and PhMe2Si–D. Four independent 
runs are shown, and the corresponding turnover frequencies are summarized in the table 
below. 
 
Rma TDE (PhMe2Si–D) 
Run 1 10.2 /min 
Run 2 13.4 /min 
Run 3 8.4 /min 
Run 4 13.0 /min 
Average 11.3 /min 
 
  
  
127 
 
 
C. Kinetic time course data for reaction using wild-type Rma cyt c and PhMe2Si–H. Four 
independent runs are shown, and the corresponding turnover frequencies are summarized in 
the table below.  
 
Wild-type Rma cyt c (PhMe2Si–H) 
Run 1 4.0 /min 
Run 2 3.8 /min 
Run 3 2.6 /min 
Run 4 2.9 /min 
Average  3.3 /min 
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D. Kinetic time course data for reaction using wild-type Rma cyt c and PhMe2Si–H. Five 
independent runs are shown, and the corresponding turnover frequencies are summarized in 
the table below. 
 
Wild-type Rma cyt c (PhMe2Si–D) 
Run 1 2.3 /min 
Run 2 1.9 /min 
Run 3 2.7 /min 
Run 4 1.8 /min 
Run 5 2.7 /min 
Average 2.3 /min 
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Figure D-2. 1H NMR for phenyl(dimethyl)silane and phenyl(dimethyl)silane-d.  
1H NMR (400 MHz, CDCl3) 
 
Top spectrum: δ 7.48-7.62 (m, 2H), 7.30-7.44 (m, 3H), 0.35 (app q, J = 0.6 Hz, 6H). 
Bottom spectrum: δ 7.48-7.62 (m, 2H), 7.30-7.44 (m, 3H), 4.36-4.50 (m, 1H), 0.28-0.42 
(m, 6H). 
The absence of peak C (4.36-4.50 ppm) in the top spectrum indicates that the Si–H bond 
has been replaced by a Si–D bond. 
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Figure D-3. GC Standard curve for ethyl 2-(dimethylphenylsilyl)propanoate product.  
The analysis of product formation in enzymatic reactions was performed based on GC 
standard curves. The standard curve use to quantify the kinetic time course reactions is shown 
below; all other standard curves were prepared and used as described in reference (4). 
Stock solutions of chemically synthesized organosilicon products at various concentrations 
(20 to 200 mM in MeCN) were prepared. To a microcentrifuge tube were added 340 µL M9-
N buffer, 40 µL NaS2O4 (100 mM in dH2O), 20 µL organosilicon product, 20 µL internal 
standard (20 mM of 1,2,3 trimethoxybenzene in toluene) and 1 mL cyclohexane. The mixture 
was vortexed (10 seconds, 3 times) then centrifuged (14,000xg, 5 min) to completely separate 
the organic and aqueous layers. The organic layer (750 µL) was removed for GC analysis. 
All data points represent the average of duplicate runs. The standard curves plot product 
concentration in mM (x-axis) against the ratio of product area to internal standard area on the 
GC (y-axis).  
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Scheme D-1. Schematic representation of the Si–H insertion enzymatic rate-determining 
step (RDS) profile and how silane binding might affect to the enzyme-catalyzed RDS barrier. 
The enzyme-catalyzed RDS barrier consists of two components: i) the silane substrate 
binding affinity (∆GºBinding); and ii) the Si–H insertion energy barrier (∆G‡Si–H), assuming a 
previously formed silane-enzyme bound complex. In the case of an endergonic silane 
binding, the rate-determining step observed depends on both the endergonic silane-enzyme 
complex formation (∆GºBinding > 0) and the carbene Si–H insertion energy barrier (∆G‡Si–H). 
On the other hand, an exergonic silane binding (∆GºBinding < 0) would result into an RDS step 
that only depends on the carbene Si–H insertion energy barrier (∆G‡Si–H).  
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C h a p t e r  5  
MECHANISM BASED INACTIVATION IN HEME-DEPENDENT 
CARBENE TRANSFERASES 
Material from this chapter appears in “Renata H†, Lewis RD†, 
Sweredoski MJ, Moradian A, Hess S, Wang ZJ, Arnold 
FH. (2016) Identification of mechanism-based inactivation 
in P450-catalyzed cyclopropanation facilitates 
engineering of improved enzymes. JACS, 138:12527-
12533. doi:10.1021/jacs.6b06823”. Reproduced with 
permission from the American Chemical Society. †Denotes 
equal author contribution. 
 
 
5.1 Abstract 
 
Following the recent discovery that heme proteins can catalyze carbene transfer reactions 
with high efficiency and selectivity, interest in engineering these proteins for use in chemical 
synthesishas burgeoned. Many of these “carbene transferases” are derived from cytochrome 
P450 enzymes, but natural P450 enzymes are subject to mechanism-based inhibition by 
carbene precursors. Here, we present evidence for two inactivation pathways that are 
operative in engineered carbene transferases. Using a combination ofUV−vis, mass 
spectrometry, and proteomic analyses, we showthat the heme cofactor and several 
nucleophilic side chainsundergo covalent modification by the carbene precursor ethyl 
diazoacetate (EDA). Substitution of two of the affected residues with less-nucleophilic amino 
acids led to a more than twofold improvement in cyclopropanation performance (total 
turnover number, TTN). Substitution of the damaged heme cofactor after the reaction results 
in modest improvements in TTN, indicating that both pathways are involved in enzyme 
inactivation. Elucidating the inactivation pathways of heme protein-based carbene transfer 
catalysts should aid in the optimization of this new biocatalytic function by providing 
information to guide engineering efforts.  
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5.2 Introduction 
 
Over the past few years, we1–6 and others7–11 have reported that engineered P450 enzymes 
and other heme proteins4,5,7,11–13 can catalyze non-natural carbene transfer reactions, e.g., 
olefin cyclopropanation (Figure 5-1A), with high efficiency and selectivity. The proposed 
catalytic cycle initiates by reduction of the Fe3+ heme enzyme to its Fe2+ counterpart, which 
then reacts with a diazo molecule to form an iron carbene intermediate14. Transfer of the 
carbene to a second substrate forms product and regenerates the active Fe2+ enzyme. 
Although a myriad of carbene transfer biocatalysts have been engineered from cytochrome 
P450s1,2,6,15, carbenes are implicated in the mechanism of suicide inactivation observed with 
natural P450s in the presence of halothane16–18 and CCl419–21. Similarly, rat liver P450s are 
known to be inactivated by the decomposition of 3- [[2-(2,4,6-trimethylphenyl)thio]ethyl]-
4-methylsydnone, which is believed to occur via formation an iron carbene intermediate that 
reacts with the heme cofactor to form N-vinylprotoporphyrin IX22. 
Because understanding inactivation pathways can facilitate development of more stable 
and efficient enzymes23–25, we investigated whether P450-derived carbene transferases are 
similarly inactivated by undesired reactions of the iron carbene intermediate. Our goal is to 
understand the mechanism of inactivation and delay or circumvent it. 
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Figure 5-1. On-cycle and off-cycle catalytic pathways for carbene transfer A. Proposed 
catalytic cycle for heme protein-catalyzed carbene transfer to an olefin starts from the 
reduced ferrous state, which undergoes reaction with a diazo compound to form the putative 
iron carbene. The carbene reacts with an olefin, forming the cyclopropane product and 
regenerating the ferrous heme protein. B. Proposed mechanism-based inactivation via (a) 
porphyrin and (b) side chain modification involving the same iron carbene intermediate that 
mediates productive olefin cyclopropanation.  
 
5.3  Results 
5.3.1 EDA-induced inactivation of P450 BM3-HStar 
 
We previously discovered that substitution of the proximal cysteine ligand with histidine 
in cytochrome P450-BM3 led to a highly active cyclopropanation catalyst3. This finding 
enabled the engineering of a histidine-ligated P450 (BM3-HStar: P450-BM3 V78M L181V 
T268A C400H L437W) that catalyzes the cyclopropanation of phenylacrylamide 1 in a 
highly stereoselective fashion (Scheme 1) en route to the synthesis of levomilnacipran, a 
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United States Food and Drug Administration (FDA)-approved antidepressant3. As BM3-
HStar produced a useful pharmaceutical precursor, we hoped to improve the utility of the 
enzyme by abrogating any possible enzyme inactivation. 
 
 
Scheme 5-1. Cyclopropanation reaction catalyzed by BM3-HStar. 
 
We chose to investigate inactivation of the isolated BM3-HStar enzyme in order to avoid 
possible complications from cellular components. From control experiments, we noted that 
purified enzyme that was preincubated with ethyl diazoacetate (EDA) in the absence of 
Na2S2O4 retained virtually all of its catalytic activity, whereas preincubation with EDA and 
reductant led to rapid inactivation (Appendix E, Figure E-1). The fact that inactivation 
requires reductant suggests that carbene formation is the first step in the inactivation 
pathway, as the heme-catalyzed carbene transfer reactions typically require an Fe2+ heme1–
3,26.   
 
5.3.2 Heme cofactor modification 
 
Previous reports of mechanism-based P450 inactivation indicate that carbene precursors 
can lead to covalent modification of the heme prosthetic group or protein side chain(s)16–
22,27–33 (Figure 5-2B). In particular, Ortiz de Montellano and co-workers observed porphyrin 
modification in the reaction of P450 and model Fe-porphyrin complexes with 3-[[2-(2,4,6-
trimethylphenyl)thio]ethyl]-4- methylsydnone22 or diazoacetophenone32 and proposed an 
intramolecular carbene insertion reaction to account for their observations. To investigate 
whether an analogous pathway is operative in our system, we analyzed the porphyrins from 
the reaction of EDA and 1 using purified BM3-HStar and quenched after 15 s and 1 min. 
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After extraction from the reaction mixture, the crude organics were analyzed by liquid 
chromatography−mass spectrometry (LC-MS) using detection at 330 nm to minimize 
background signal. In agreement with the observed dependence of enzyme inactivation on 
presence of the reductant, extracts from reaction mixture that did not contain Na2S2O4 yielded 
a single species with a mass spectrum and retention time that correspond to unmodified Fe-
protoporphyrin IX (Fe-PPIX) cofactor, as determined by LC-MS analysis of authentic 
standard (Figure 5-2). However, the crude extracts obtained after 15 s of reaction of 1 and 
EDA using reduced BM3-HStar showed diminished signal for Fe-PPIX and the presence of 
additional species. Strikingly, after 1 min, only modified Fe-PPIX remained in the reaction 
mixture. Similar analyses performed with other heme protein-based carbene transfer 
catalysts, myoglobin (Mb) mutant H64V V68A7 and a Ser-ligated P450-BM32, also revealed 
loss of Fe-PPIX.  
Thin-layer chromatography (TLC) analysis of the reaction mixture indicated the presence 
of a new red-fluorescent band, which was subsequently purified by preparative TLC and 
analyzed by UV−vis spectroscopy and mass spectrometry. Absorption spectra obtained for 
the isolated porphyrin species showed that it is distinct from PPIX, both as the free porphyrin 
(Figure E-2) and as the Zn complex (Figure 5-3). The absorption spectrum of the modified 
porphyrin after complexation with Zn2+ yielded a Soret peak at 430 nm with a slight shoulder, 
which is a characteristic feature of N-alkylprotoporphyrin derivatives22. Furthermore, the 
mass spectrum of the isolated porphyrin exhibited two major peaks with m/z of 735.3374 
and 821.3753, corresponding to loss of Fe3+ and addition of two and three ethyl acetylidene 
fragments (C4H6O2 , m/z = 86.1 Da) to the heme cofactor, respectively. Together with 
previous literature on P450 cofactor modification, our evidence suggests that the heme 
cofactor is subject to N-alkylation during the carbene transfer reaction22,32,34.  
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Figure 5-2. LC-MS monitoring of heme content of the reaction mixture (MWD set at 330 
nm) at different reaction times: Amount of unmodified heme decreases during the course of 
the reaction, and new species appear.  
 
 
Figure 5-3. High-resolution mass spectrometry (HRMS) analysis of modified porphyrin 
isolated after the cyclopropanation reaction, showing major peaks with m/z of 735.3378 and 
821.3753, which correspond to multiple additions of C4H6O2 fragment. Inset: Electronic 
absorption spectrum of porphyrin isolated after the cyclopropanation reaction as the Zn-
complexed form indicates modification; spectrum of Zn-PPIX standard is provided for 
comparison. 
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5.3.3 Modification of protein side chains and structural changes  
 
Given the precedent of protein side chain alkylation during oxidation of acetylenic 
compounds29–31, we investigated whether a similar phenomenon occurs during the enzyme-
catalyzed cyclopropanation reaction. To this end, cyclopropanation was performed with 
purified BM3-HStar, quenched after 15 s, and the crude reaction mixture was submitted to 
mass spectrometry (MS) analysis. Extreme heterogeneity of the enzyme could already be 
observed (Figure E-3). Deconvolution of the mass spectrum afforded multiple species with 
molecular weights that correspond to integer number additions of the carbene fragment (86 
Da). Under the denaturing conditions used for MS analysis, the heme cofactor is extruded 
from the protein. Thus, any observed mass difference in the spectra can be attributed solely 
to modification of the polypeptide chain.  
Circular dichroism (CD) spectroscopy of EDA-treated enzyme also showed changes 
relative to unreacted enzyme in the far-UV region (Figure 5-4). We noted reduced molar  
ellipticity at 222 nm, which suggests decreased α-helical content and increased random coil 
content of the protein. Taking into account both the MS and CD spectral observations, we 
propose a model wherein EDA modifies the cofactor and multiple protein side chains, 
leading to disruption of secondary structures and partial unfolding. Comparison of these data 
and LC-MS observation of cofactor modification suggest that the side chain and porphyrin 
alkylations happen on similar time scales, although we cannot determine the exact order of 
events.  
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Figure 5-4. Circular dichroism (CD) spectra of ferrous BM3-HStar before (black) and after 
reaction with EDA (blue). Decrease in molar ellipticity at 222 nm suggests a change in the 
secondary structure after the reaction, specifically a decrease in α-helical content and an 
increase in random coil.  
 
5.3.4 Identification of modified residues 
 
To identify the residues that are modified during the initial stages of the reaction, protein 
from the crude cyclopropanation reaction mixture after 5 s was analyzed by trypsin digestion 
followed by tandem LC-MS/MS analysis. From this analysis (Figure 5-5), we observed 
modifications (underlined residues indicate the site of modification) on peptide fragments 
EACDESRFDK (residues 60−69), NLSQALKFMR (residues 70−79), 
DFAGDGLFTSWTHEK (residues 80−94), and AHNILLPSFSQQAMK (residues 99−113). 
Modifications were addition of a C4H6O2 fragment (86.1 Da), corresponding to the ethyl 
acetylidene moiety, onto residues C62, S72, K76, R79, H92, and H100. We also observed 
modification of residue K69 on fragment FDKNLSQALK (residues 67−76) in samples taken 
at later time points. Control experiments with CO-treated enzyme (inactive for 
cyclopropanation) revealed much-diminished signals for modified peptides during the 
proteomic analysis, again suggesting that the iron carbene generated from the ferrous heme 
is responsible for the modifications. That the affected residues are all nucleophilic in nature 
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is consistent with the proposed electrophilic character of the carbene species14,35–37. 
Modifications presumably occur by way of O−, N−, and S− alkylation by the carbene 
fragment.  
 
 
 
Figure 5-5. Representative LC-MS/MS analysis of peptide fragments from crude 
cyclopropanation mixture. Modified peptides from inactivated BM3- HStar were analyzed 
using mass spectrometry after incubation with Na2S2O4 EDA and 1 for 5 s. The modified 
residue is highlighted in orange.  
 
In the absence of a crystal structure for His-ligated P450-BM3, the crystal structure of 
wild-type (WT) BM3 (PDB ID: 2IJ2) was used to map the locations of these residues relative 
to the heme cofactor (Figure 5-6). To our surprise, other than K69, which makes a polar 
contact with the propionate moiety of the heme cofactor, all the alkylated residues are more 
than 10 Å away from the iron center. One possible explanation is that the Hstar active site is 
devoid of nucleophilic residues, and that all likely alkylation targets are distant. It is worth 
noting, however, that residues S72, K76, and R79 are situated in the B′-helix and H92 is in 
the B′/C loop. The B′-helix has been proposed as an important recognition site that controls 
substrate specificity in P450s38. It has also been shown crystallographically that a single 
mutation (F81L) in this region can affect its collapse toward the active site39. Moreover, our 
recent report on the X-ray crystal structure of His-ligated CYP119 shows notable 
rearrangements in the protein to compensate for non-native ligation, including unresolved 
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portions in the B′- and F-helices and increased disorder in the C-helix40. If similar 
rearrangements occur upon mutation of the axial residue from Cys to His in P450-BM3, it is 
possible that the region where S72, K76, R79, and H92 reside undergoes large-scale 
movements that bring them closer to the active site. Furthermore, the P450s possess 
remarkable structural plasticity41,42, and iron carbene formation could also induce structural 
and dynamic changes37 that bring this region in closer contact.  
The remaining three alkylated residues also deserve mention, as we surmise that they 
would play vital roles in maintaining the folded structure of P450-BM3. As previously noted, 
K69 is involved in a polar contact with the heme prosthetic group (Figure E-4). H100 is 
implicated in a hydrogen bonding interaction with the FMN domain of the fused reductase 
partner and is conserved as a basic amino acid residue in P450s43. Mutation of C62 in P450-
BM3 has been reported to lower thermostability44. Thus, modifications of these residues 
could result in disruption of key interactions and loss of structural integrity.  
 
 
Figure 5-6. Location of alkylated residues relative to the heme cofactor as mapped onto WT 
BM3 crystal structure (PDB ID: 2IJ2). Measured distances to the Fe center (in parentheses) 
are determined based on the wild-type P450-BM3 crystal structure.  
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5.3.5 Site-directed mutagenesis of modified residues improves catalyst 
performance 
 
The observations outlined above indicate that these modifications have deleterious 
effects on the secondary structure of the enzyme and the efficiency of the cyclopropanation 
reaction. We hypothesized that even though BM3-HStar will eventually be inactivated 
through modification of the heme prosthetic group, mutations of the alkylated residues to 
attenuate their nucleophilicity might better preserve structure and function during the 
reaction and, ultimately, improve carbene transfer efficiency to the substrate (measurable in 
terms of total turnover number to product). We therefore created seven single variants of 
BM3-HStar in which the alkylated residues were replaced with their non-nucleophilic 
isosteres. This design entails mutation of His to Asn (mutations H92N and H100N), Arg to 
Gln (mutation R79Q), Cys and Ser to Ala (mutations C62A and S72A), and Lys to Arg 
(mutations K69R and K76R). The seven variants were first tested for cyclopropanation 
activity in cell lysate. Three of the variants, C62A, K69R, and K76R, were poorly expressed 
and not studied further. Two of the variants, H92N and H100N, gave improved total turnover 
numbers (1.2- and 1.4-fold improvement, respectively) for the formation of 2, while the 
remaining two failed to yield any improvements. Following this observation, we 
characterized the performance of the purified H92N and H100N variants and were pleased 
to observe similar enhancements in cyclopropanation activity. While purified BM3-HStar 
showed only modest conversion and poor selectivity, variants H92N and H100N in purified 
form gave much improved reaction yields and selectivities for cyclopropanation of 1 (Figure 
5-7A). Moreover, these two mutations could be combined in a double variant H92N H100N 
that, as purified enzyme, afforded up to 560 TTN (0.1% enzyme loading, 1.8- fold 
improvement over BM3-HStar) and 98:2 d.r. and 87% ee; selectivity numbers that are very 
close to those previously observed in reactions with whole cells expressing BM3-HStar 
(Scheme 5-1).  
Next, we evaluated the performance of the new variants in whole-cell reactions, as the 
enzymes have hitherto provided superior performance when used as whole-cell catalysts. 
Gratifyingly, the improvement was even more significant (Figure 5-7B). In particular, 
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variant H92N H100N gave more than 20,000 TTN in the production of 2 (2.7-fold 
improvement over BM3-HStar), while maintaining the excellent diastereo- and 
enantioselectivity of the parent catalyst. Variants H92N, H100N, and H92N H100N express 
at similar levels to parent enzyme BM3-HStar (0.20−0.25 µM at OD600 = 10, see the 
Appendix E, section E.5 for determination of protein concentration in whole-cell 
suspension). Thus, the observed increase in TTN translates to similar improvements in 
product per dry cell weight.  
Finally, the improvement in activity imparted by mutations H92N and H100N could be 
generalized to other carbene transfer reactions, including styrene cyclopropanation and 
carbene insertion into the N−H bond of aniline (Figure E-5). Under whole-cell reaction 
conditions, HStar H92N H100N yielded 55% and 30% increases in styrene cyclopropanation 
and aniline N−H insertion activities over the parent BM3-HStar.  
 
5.3.6  Characterization of BM3-HStar H92N H100N 
 
Comparing the kinetics of formation of 2 with BM3-HStar and HStar H92N H100N 
under whole-cell reaction conditions at 10 mM substrate concentrations and ca. 0.2 µM 
enzyme concentration shows that the engineered variant supports faster product formation, 
but both rates decrease after 30 min (Figure E-6). We performed similar inactivation 
analyses on BM3-HStar H92N H100N to find out whether the inactivation mechanism had 
changed. We noted changes in the CD spectral features upon treatment of ferrous BM3-HStar 
H92N H100N with EDA, similar to BM3-HStar (Figure E-7). In addition, bottom-up 
proteomic analyses indicated that residues K69, S72, K76, S89, K97, S304, and K306 of 
BM3-HStar H92N H100N were alkylated during the initial stages of this reaction, but no 
modification occurred at N92 or N100. Of these, only K69, S72, and K76 were observed to 
undergo modification in the parent enzyme BM3-HStar. Lastly, LC-MS analysis of purified 
BM3-HStar H92N H100N after cyclopropanation showed that the porphyrin cofactor 
underwent identical alkylative modifications as in BM3-HStar.  
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Figure 5-7. Site-directed mutagenesis of BM3-HStar to improve yield and selectivity of 
cyclopropanation of acrylamide 1 with EDA. A. Reactions were performed with 10 μM 
enzyme, 10 mM 1, 20 mM EDA, and 10 mM Na2S2O4 in 100 mM KPi buffer (pH = 8.0). 
Yields and diastereoselectivity were determined by GC calibrated for 2. Enantioselectivity 
was determined by chiral SFC (see Appendix E, E.7 and E.8). B. Total turnover numbers 
(TTNs) for cyclopropanation of 1 with whole cells expressing BM3-HStar variants. 
Reactions were performed with whole cells expressing the enzyme (resuspended in M9-N 
media to OD600 = 10), 10 mM 1, and 20 mM EDA. Enzyme concentration in whole-cell 
suspension was determined by ferrous expression assay (Appendix E); product concentration 
at the end of the reaction was determined by GC calibrated for 2.  
 
5.3.7 Replacement of the modified heme cofactor 
 
Our engineering efforts targeting alkylated side chains in BM3-HStar could not prevent 
inactivation entirely, but yielded some improvement to the turnover and selectivity of the 
enzymes. As our strategy did not investigate the effects side chain alkylation in the absence 
heme cofactor modification, it is difficult to conclude if both factors lead to inactivation, or 
if one proceeds the other. Therefore, we next sought to develop a method that could help 
address the problem of heme modification. We hypothesized that, if after a reaction, we could 
remove the modified heme cofactor and replace it with unmodified heme, it could regenerate 
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the enzyme and allow it to be reused (Scheme 5-2). In order to develop a system to 
replace the heme cofactor, we chose to focus on a protein other than BM3-HStar, as we 
hypothesized that the poor folding associated with histidine-ligated P450 enzymes might lead 
to problems when attempting to remove and replace the heme cofactor40. Instead, we chose 
to focus on Bacillus subtilis truncated globin Y25L T45A Q49A (Bsu TrHb LAA), a carbene 
transfer heme enzyme engineered to catalyze a cyclopropanation reaction, producing an 
intermediate of the anti-stroke agent ticagrelor4.  
 
Scheme 5-2. Proposed method for replacing modified heme to circumvent enzyme 
inactivation. 
 
Initially, we sought to be able to recover our enzymes from the reaction solution, so that 
they could be used multiple times and their activity loss over time could be monitored.  We 
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expressed and purified Bsu TrHb LAA, and covalently immobilized the protein on a solid 
support (See Appendix E, section E.20). Using the reaction between styrene and EDA as a 
model reaction (Scheme 5-2), we ran successive reactions with the beads, recovering the 
beads after each reaction.  Over the multiple uses, we observed a substantial decrease in 
activity. 
We then sought to develop a method to denature the protein on the beads, remove the 
heme cofactor, and then refold the protein with unmodified heme cofactor (Scheme 5-2). 
After screening a panel of denaturants and buffer conditions, we found that heme could be 
extracted off the beads in a neutral buffer solution containing 50% v/v acetone (Appendix E, 
section E.21). 
Then we looked for conditions that enabled denatured enzyme to properly refold and 
reincorporate heme, as measured by the proteins ability to catalyze the model reaction with 
high selectivity and high activity. We emphasized high enantioselectivity to ensure that the 
protein and heme cofactor were together and folded properly, since the native Bsu TrHb LAA 
displays very high selectivity for the cyclopropanation of styrene, and poorly folded protein 
displays low selectivity. Ultimately, we discovered that the protein could be refolded in M9-
N buffer, supplemented with heme, imidazole, and guanadinium chloride (Appendix E, 
section E.21). 
Control experiments demonstrated that the protein-beads are essentially inactive after 
heme removal, and that the reconstituted protein-beads have activity and selectivity 
comparable to the native protein-beads (Appendix E, Figure E-9). These control 
experiments indicated that our heme removal and heme reconstitution steps are highly 
efficient, and allow us to fully replace any modified heme cofactor. When the protein-beads 
were subjected to a cycle of heme removal and heme reconstitution before each reaction 
(treated protein-beads), we observed that the treated protein-beads displayed activity and 
selectivity comparable to untreated protein-beads for the first two reactions.  For the third 
and fourth reactions, we observed that the treated protein-beads had 2-fold and 3-fold higher 
activity than the untreated protein-beads (respectively), although the treated protein-beads 
still displayed a marked decrease in activity, suggestive of enzyme inactivation. 
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Figure 5-8. Use and re-use of the biocatalyst Bsu TrHb LAA immobilized on agarose beads. 
Replacement of the heme cofactor before each use yields some improvement over simple re-
use of the beads, but the enzyme is still subject to inactivation under both conditions.  TTN 
calculated relative to total amount of protein immobilized to beads. All reactions generated 
product with 98%-99% ee and >99:1 d.r. 
 
5.4  Discussion 
 
Various reports of irreversible inhibition of P450s by carbene precursors led us to 
investigate whether such pathways compete with productive catalysis in engineered “carbene 
transferases” derived from heme-containing proteins. This new enzyme activity involves a 
reactive intermediate that can damage the cofactor and protein if the carbene is not efficiently 
transferred to the substrate. Mutations to the protein sequence could assist productive 
catalysis, either by promoting productive transfer through improved binding and orientation 
of the substrate or by disfavoring non-productive transfer to the protein itself.  Evolution 
finds both types of solutions by molding the protein active site and dynamics to promote 
productive catalysis, even when highly reactive species are generated during the catalytic 
cycle. Native P450 reactions that go through Compound I provide an excellent example of 
how an enzyme can generate a highly reactive species and direct it (most of the time) to a 
substrate. In contrast to P450-catalyzed monooxygenations, however, the newly-developed 
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carbene transfer activities of heme proteins have not yet been highly tuned by evolution. 
We are starting to investigate opportunities for enhancing this non-natural activity by 
directed evolution1 and rational engineering based on understanding some of the failure 
modes. 
We found that the heme cofactor and several nucleophilic residues are modified by 
transfer of the reactive carbene to the enzyme rather than the olefin substrate during 
cyclopropanation of phenylacrylamide with EDA. Up to three additions of ethyl acetylidene 
fragment on the porphyrin were observed, and spectroscopic analysis of the modified 
porphyrin species suggests the formation of N-alkylporphyrin products. Presumably, this 
modification also interferes with metal binding, leading to the expulsion of Fe3+ as seen in 
the mass spectrum. These results suggest erosion of the active heme species, eventually 
leading to complete loss of the cofactor and catalytic function. Similar cofactor loss during 
reactions with other heme protein-based catalysts (myoglobin and a Ser-ligated P450) 
suggests that this off-cycle reaction is an inherent feature of porphyrin-based protein catalysts 
of carbene transfer reactions.  
We also obtained evidence that carbene formation can result in the modification of 
protein side chains and disruption of BM3-HStar secondary structure. The observation of 
multiply modified species in the proteomic analyses implies that BM3-HStar is still capable 
of reacting with EDA even after initial modification. However, the iron carbene species 
might possess increasingly diminished reactivity and/or selectivity for productive 
cyclopropane formation due to the cumulative effects of protein structural modifications, 
accounting for the observed erosion in activity selectivity of BM3-HStar during pre-
incubation with EDA.  
We reasoned that reducing the nucleophilicity of some of the modified residues could 
reduce protein damage and possibly lead to better secondary structure preservation during 
the reaction and less inactivation. We identified two beneficial mutations in BM3-HStar, 
H92N and H100N, that improve carbene transfer activity and selectivity. That BM3-HStar 
double mutant H92N H100N performed better in other types of carbene transfer reactions—
styrene cyclopropanation and N–H insertion—indicates that the improvements are general 
rather than specific to substrate 1. A possible explanation for the effects of the mutations is 
  
150 
that the reaction ensemble contains more active form of the enzyme. BM3-HStar H92N 
H100N, however, still undergoes irreversible inactivation: even though the mutations avert 
potentially deleterious modification at residues 92 and 100, the reactive iron carbene species 
nonetheless inflicts alkylative damage on the porphyrin and other nucleophilic residues, 
including several that did not appear to be alkylated in BM3-HStar.   
Our results indicate that EDA-induced inactivation is operative in reactions with purified 
enzyme and whole-cell catalyst. Yet, the relative rates of inactivation are strikingly different, 
with purified enzyme suffering much more rapid inactivation as well as inferior initial 
activity and selectivity. The origins of this difference still unclear, but several possible 
explanations can be put forth. One is that cellular components contribute to higher enzyme 
stability through the protective effects of, for example, molecular chaperones45,46, 
macromolecular crowding47–49, or even cytoplasmic molecules acting as sacrificial carbene 
acceptors.  Another possibility is that of diffusion across the cell membrane acting causes a 
“slow addition” of the carbene precursor to the enzyme, which is known to decrease side 
reactions in synthetic systems.   
Finally, we were able to develop a system to replace the heme after each reaction, which 
allowed us to separate the cofactor modification pathway from the peptide modification 
pathway.  Even in the system that allows for complete replacement of the heme cofactor, we 
still observe catalyst inactivation, although to a lesser degree than without cofactor 
replacement. It remains to be seen whether further engineering efforts, possibly through a 
combination of directed evolution, targeted mutagenesis, and cofactor replacement 
strategies, can generate a carbene transferase that is highly resistant to inactivation—
performing hundreds of thousands of turnovers, and only inactivating in a manner that is 
easily reversible. 
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5.5 Conclusions 
 
Exploiting the ability of proteins to evolve and adapt to new challenges, our laboratory 
has developed variants of heme proteins as platforms for non-natural reactions with 
xenobiotic diazo compounds. However, introduction of xenobiotic reagents to natural 
enzymes can lead to undesired repercussions such as inactivation23–25. We have provided 
clear evidence for mechanism-based inactivation of a His-ligated P450-BM3 variant by ethyl 
diazoacetate that results in the modification of the heme prosthetic group and several protein 
side chains, which degrades enzyme performance and causes irreversible activity loss. Site-
directed mutagenesis of some of the affected residues to amino acids that are less easily 
modified created superior variants with improved cyclopropanation activity as both purified 
enzymes and whole-cell catalysts. An alternate strategy, replacement of the modified 
cofactor, also yielded improvements in catalyst performance, but was also unable to 
completely avoid catalyst inactivation. 
Classical directed evolution could also be applied to address the problem of catalyst 
inactivation—simply screening enough variants until an enzyme with the desired turnover 
and selectivity is discovered. However, screening can be slow for some reactions, especially 
when high enantioselectivity is desired, and so other engineering methods can be introduced 
to complement directed evolution.  
Tracing the catalyst’s fate during the reaction enables the identification of inactivation 
“hotspots”, and allows for the discovery of beneficial mutations at more distant residues. 
Similarly, understanding that damage to the cofactor is a reversible source of inactivation 
may allow for the development of industrial processes that help improve catalyst utility. 
Echoing a recent report on mitigation of substrate inhibition in a DERA enzyme25, our results 
demonstrate the merits of mechanistic analyses in improving the overall activity of enzymes 
for biotechnological applications, especially ones that are employed in non-native 
environments. As interest grows in developing new and useful carbene transferases, we 
expect that a holistic mechanistic understanding of these enzymes will serve as an invaluable 
guide for their engineering. 
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A p p e n d i x  E  
SUPPORTING INFORMATION FOR CHAPTER 5 
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in P450-catalyzed cyclopropanation facilitates 
engineering of improved enzymes. JACS, 138:12527-
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permission from the American Chemical Society. †Denotes 
equal author contribution. 
 
 
 
E.1  Materials and methods  
 
Unless otherwise noted, all chemicals and reagents for chemical reactions were obtained 
from commercial suppliers (Sigma-Aldrich, Acros) and used without further purification. 
Sonication was performed using a Qsonica Q500 sonicator. For UV-vis analyses, spectra 
were collected between 650 and 390 nm on a UV1800 Shimadzu spectrophotometer. 
Circular dichroism (CD) analyses were performed using Aviv Biomedical Model 410 CD 
spectrophotometer. Gas chromatography (GC) analyses were carried out using a Shimadzu 
GC-17A gas chromatograph with FID detector and J&W HP-5 column (30 m x 0.32 mm, 
0.25 µm film) and 2-phenylethanol as an internal standard. Analytical SFC was performed 
with a Mettler SFC supercritical CO2 analytical chromatography system with isopropanol 
and liquid CO2 as the mobile phase. Enantiomers were separated using a Chiralpak AS 
column (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd. High resolution 
mass spectrometry (HRMS) was performed with Agilent 6200 Series TOF with an Agilent 
G1978A multimode source in electrospray ionization (ESI), atmospheric pressure chemical 
ionization (APCI), or mixed (MM) ionization mode. Enzymes (DpnI, Phusion polymerase) 
were purchased from New England Biolabs (NEB, Ipswich, MA).  
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E.2 Generation of enzyme variants  
 
Plasmid pET22b(+) was used as a cloning and expression vector for all enzymes used in 
this study. Site-directed mutagenesis was accomplished by modified QuikChangeTM protocol 
using primers bearing the desired mutations (IDT, San Diego, CA). The PCR products were 
gel purified, digested with DpnI, repaired using Gibson assembly1, and used directly to 
transform E. coli strain BL21(DE3). Variants were stored as glycerol stocks at –80 ºC. 
 
E.3 Hemochrome binding assay   
 
A solution of pyridine was made by combining 1.75 mL pyridine with 0.75 mL 1 M 
NaOH.  The solution mixed at room temperature was centrifuged for 30 s at 5000 rcf to 
remove excess aqueous base.  To a cuvette containing 0.75 mL of protein solution in 
phosphate buffer (0.1 M, pH 8.0), 0.25 mL of the pyridine solution was added followed by a 
few grains (less than 2.0 mg) of sodium dithionite.  The cuvette was sealed with parafilm and 
a UV-vis spectrum was recorded immediately.  P450 concentration was determined from the 
absorbance of the hemochrome complex using extinction coefficient ε418 = 196 mM-1 cm-1.  
Absorbance was assigned as the difference between the peak max at 418 nm and the baseline 
at 420 nm as determined by extrapolating from two points on either side of the hemochrome 
peak.   
 
E.4  Determination of εmax for ferrous histidine-ligated P450 enzymes 
 
BM3-HStar holoprotein with known concentration (determined by hemochrome binding 
assay) was used for extinction coefficient determination.  An appropriate amount of the 
protein was transferred to a semi-micro cuvette fitted with a screw septum cap (Starna Cells, 
product number 9-SOG-10-GL14-S). The cuvette was made anaerobic by flushing with 
argon. In 6 mL crimp-sealed vials, a phosphate buffer solution (0.1 M, pH = 8.0) and a 12.5 
mM solution of sodium dithionite in phosphate buffer (0.1 M, pH = 8.0) were degassed by 
bubbling with argon. To the semi-micro cuvette, 700 µL of the degassed phosphate buffer 
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and 250 µL of the degassed Na2S2O4 solution were added, and then the UV-vis spectrum 
was recorded. Absorbance was assigned as the difference between the peak max at 424 nm 
and the baseline as determined by extrapolating from two points on either side of the ferrous 
peak (390 nm and 460 nm). The measurement was repeated for five different enzyme 
concentrations and a calibration curve was constructed to determine the ferrous εmax.  
 
From the above calibration curve, we determine εmax = 119 mM-1cm-1 
 
E.5  Ferrous concentration assay  
 
Ferrous concentration assay was used to determine the concentration of His-ligated 
P450-BM3 variant in crude lysate.  To an anaerobic cuvette containing 800 µL of P450 lysate 
of unknown concentration was added 200 µL of degassed Na2S2O4 solution (2 mg/mL), and 
the UV-vis spectrum was recorded.  Absorbance was assigned as the difference between the 
peak max at 424 nm and the baseline as determined by extrapolating from two points on 
either side of the ferrous peak (390 nm and 460 nm). P450 concentration was determined 
from the absorbance of the ferrous species using an extinction coefficient of ε = 119 mM-1 
cm-1 for histidine-ligated P450-BM3.   
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E.6  P450 expression and purification 
 
One liter Hyperbrothamp (AthenaES©) was inoculated with an overnight culture (25 mL, 
LBamp) of recombinant E. coli BL21(DE3) cells harboring a pET22b(+) plasmid encoding 
the P450 variant. The cultures were shaken at 200 rpm at 37 °C for roughly 3 h or until an 
optical of density of 0.7–1.0 was reached.  Cultures were cooled on ice (20 min) and then 
induced by adding IPTG and aminolevulinic acid to a final concentration of 0.5 mM and 1.0 
mM, respectively.  The cultures were allowed to continue for another 20 hours at 20 ºC and 
shaking at 200 rpm. Cell were harvested by centrifugation (4 °C, 15 min, 3,000xg), and the 
cell pellet was stored at –20 °C or below for at least 2 h.  
Purification was performed with an AKTA purifier FPLC system (GE Healthcare). For 
the purification of 6XHis tagged P450s, the thawed cell pellet was resuspended in Ni-NTA 
buffer A (25 mM Tris.HCl, 200 mM NaCl, 25 mM imidazole, pH 8.0, 4 mL/g of cell wet 
weight) and lysed by sonication (2x1 min, 30% duty cycle). The lysate was centrifuged at 
27,000xg for 20 min at 4 °C to remove cell debris. The collected supernatant was subjected 
to a Ni-NTA chromatography step using a Ni Sepharose column (HisTrap-HP, GE 
healthcare, Piscataway, NJ). The P450 was eluted from the Ni Sepharose column using 25 
mM Tris.HCl, 200 mM NaCl, 300 mM imidazole, pH 8.0. Ni-purified protein was buffer 
exchanged into 0.1 M phosphate buffer (pH = 8.0) using a 10 kDa MW cut-off centrifugal 
filter.  Protein concentrations were determined by hemochrome binding assay described 
above.  For storage, proteins were portioned into 300 µL aliquots and stored at –80 °C.  
 
E.7  Small-scale whole-cell bioconversions  
 
E. coli BL21(DE3) cells with plasmid coding for a P450 mutant were grown from 
glycerol stock overnight (37 °C, 250 rpm) in 5 ml LBamp. A portion of the pre-culture (1.25 
mL) was used to inoculate 50 mL of Hyperbroth medium (1 L Hyperbroth prepared from 
powder from AthenaES©, 0.1 mg mL-1 ampicillin) in a 250 mL Erlenmeyer flask and this 
culture was incubated at 37 °C, 200 rpm for approximately 3 h. At OD600 = 0.7–1.0, the 
cultures were cooled on ice (20 min) before inducing with IPTG (0.5 mM final concentration) 
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and δ-aminolevulinic acid (1.0 mM final concentration). Shaking was continued at 20 ºC, 
200 rpm. Cultures were harvested after 20 h and resuspended in nitrogen-free M9-N medium 
(1 L: 31 g Na2HPO4, 15 g KH2PO4, 2.5 g NaCl, 0.24 g MgSO4, 0.01 g CaCl2) until the 
indicated OD600 was reached (OD600 = 30 unless otherwise noted). Aliquots of the cell 
suspension were used for determination of the P450 expression level (2–3 mL) after lysis.   
Anaerobic reaction conditions: E. coli cells of the appropriate OD600 were transferred to a 
crimped 6 mL vial and degassed with argon for 5-10 min.  In parallel, a solution of glucose 
in M9-N (250 mM) was degassed with argon for the same period of time. All solutions were 
uncapped and transferred to an anaerobic chamber. Glucose solution (50 µL, 250 mM) was 
added to 2 mL crimp vials, followed by cell suspension (425 µL), the olefin substrate (12.5 
µL of a 400 mM solution in EtOH), and EDA (12.5 µL of a 800 mM solution in EtOH). The 
vials were sealed, removed from the anaerobic chamber and shaken on a tabletop shake plate 
at room temperature for 1 h at 350 rpm.  The reactions were quenched by addition of 20 µL 
of 3 M HCl, followed by 20 µL of the internal standard (20 mM 2-phenylethanol solution in 
cyclohexane) and 1 mL cyclohexane. The mixture was transferred to a 1.7 mL Eppendorf 
tube, vortexed and then centrifuged (10,000x rcf, 30 s).  The organic layer was removed and 
analyzed by GC to determine yield and chiral SFC to determine enantioselectivity. 
 
E.8  Small-scale cyclopropanation reactions with purified enzymes  
 
Small-scale (400 µL) reactions were carried out in 2 mL glass crimp vials (Agilent 
Technologies, San Diego, CA). P450 solution (60 µL, 67 µM) was added to an unsealed 
crimp vial. In parallel, a 12.5 mM solution of sodium dithionite in phosphate buffer (0.1 M, 
pH = 8.0) was degassed by bubbling with argon in a 6 mL crimp-sealed vial. All solutions 
were uncapped and transferred to an anaerobic chamber. The buffer/dithionite solution (320 
µL) was added to each reaction vial containing P450 solution, followed by the olefin 
substrate (10 µL, 400 mM in EtOH) and EDA (10 µL, 800 mM in EtOH). The reaction vials 
were capped, removed from the anaerobic chamber, and then placed in a tray on a plate 
shaker and left to shake at 350 rpm for 2 h at room temperature.  The final concentrations of 
the reagents were typically: 10 olefin, 20 mM EDA, 10 mM Na2S2O4, and 10 µM purified 
  
162 
enzyme.  The reaction was quenched by the addition of 3 M HCl (20 µL), followed by 
20 µL of the internal standard (20 mM 2-phenylethanol solution in cyclohexane) and 1 mL 
cyclohexane.  The mixture was transferred to a 1.7 mL Eppendorf tube and vortexed and 
centrifuged (10,000x rcf, 30 s). The organic layer was then analyzed by GC to determine 
yield and chiral SFC to determine enantioselectivity. GC analysis of product 2 was performed 
using J&W HP-5 column (30 m x 0.32 mm, 0.25 µM film) with the method 90 °C hold 2 
min, 90-110 at 6 °C/min, 110-190 at 40 °C/min, 190-280 at 20 °C/min, 280 °C hold 1 min, 
12.8 min total): internal standard (3.55 min), trans-2 (9.55 min), and cis-2 (9.69 min). Yields 
of cyclopropanation products were determined using calibration curves previously described 
in reference 1. Analytical SFC of product 2 was performed on a Chiralpak AS column, 
eluting with 2% iPrOH at 2.5 mL/min: λ = 210 nm, tR (min): major = 8.50, minor = 9.48. 
  
E.9  Analysis of diazo-induced inactivation 
 
Small-scale reaction mixtures with whole cells expressing the appropriate enzyme 
variants or purified enzymes were prepared according to the general procedures outlined 
above. To the reaction vial was added 10 µL of EDA solution (800 mM in EtOH). After the 
specified pre-incubation time, 10 µL of olefin solution (400 mM in EtOH) was added. For 
determination of olefin-induced inactivation, the order of addition was reversed. The 
reactions were shaken on a tabletop shake plate at room temperature for 1 h at 350 rpm.  The 
reactions were quenched by addition of 20 µL of 3 M HCl, followed by 20 µL of the internal 
standard (20 mM 2-phenylethanol solution in cyclohexane) and 1 mL cyclohexane. The 
mixture was transferred to a 1.7 mL Eppendorf tube, vortexed and then centrifuged (10,000x 
rcf, 30 s).  The organic layer was removed and analyzed by GC to determine yield and by 
chiral SFC to determine enantioselectivity. 
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E.10 Liquid chromatography-mass spectrometry (LCMS) analysis of cofactor 
modification 
 
To a 6 mL crimp-sealed vial was added BM3-HStar (final concentration = 10 µM) and 
the vial was made anaerobic by degassing the headspace with argon for 10 min. In a separate 
6 mL crimp-sealed vial, a 12.5 mM solution of Na2S2O4 in phosphate buffer (0.1 M, pH = 
8.0) was degassed by bubbling with argon for 10 min. The buffer/dithionite solution (1.8 
mL) was then added to the reaction vial via syringe, followed by 50 µL of 200 mM EDA 
solution. For investigation of reductant effects, degassed phosphate buffer solution (1.8 mL) 
was added in place of buffer/dithionite solution. The reaction was quenched at the 
appropriate time points by adding 100 µL of 3 M HCl, followed by 2.5 mL of 9:1 
dichloromethane:MeOH. The mixture was transferred to a 15 mL Falcon tube, vortexed and 
centrifuged (5000 rpm, 5 min). The organics were collected, and the extraction procedure 
was repeated one more time. The organics were combined, concentrated in vacuo, 
redissolved in MeCN, and submitted for LCMS analysis. For reaction progress monitoring, 
the analyses were performed at 15 s and 1 min time points.  
 
E.11  Isolation of modified porphyrin cofactor 
 
Cofactor was extracted from the reaction mixture of isolated BM3-HStar and EDA using 
the procedure outlined above. Following extraction, the crude organics were concentrated in 
vacuo and then purified by preparative TLC (10:90:0.1 MeOH:DCM:AcOH), isolating the 
red fluorescent band (Rf = 0.3). The isolated porphyrin was dissolved in MeOH and then 
submitted to HRMS analysis. UV-vis analysis was performed using a solution of isolated 
porphyrin in DCM. For UV-vis analysis of Zn2+-complexed porphyrin, isolated porphyrin 
was dissolved in 0.5% ZnCl2 solution in 5:95 MeOH/DCM and submitted for analysis. 
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E.12  Analysis of enzyme modification by top-down proteomics 
 
Small-scale reactions were performed following the general procedure for catalysis using 
purified enzyme. The protein samples were analyzed on an LC-MSD SL 1100 series 
(Agilent) liquid chromatography mass spectrometry system. The samples were subjected to 
reverse phase chromatography on a 2.1 x 150 mm Zorbax 300SB-C3 column (Agilent) using 
a gradient consistent of 0.2% formic acid (solvent A) and 0.2% formic acid in acetonitrile 
(89.8%) and methanol (10%) (solvent B). Eluted intact proteins were ionized using 
electrospray ionization and measured in the single quadrupole mass spectrometer and 
quantified. 
 
E.13  Alkylation analysis by bottom-up proteomics 
 
Small-scale reactions were performed following the general procedure for catalysis using 
purified enzyme. Appropriate amounts of the reaction aliquot were lyophilized to afford 10–
20 µg of proteins. Dried pellets were dissolved in 40 µL of 8 M urea/100 mM Tris-HCl (pH 
8.5) mixture. Proteins were reduced by addition of 0.25 µL of 500 mM TCEP (tris(2-
carboxyethyl)-phosphine hydrochloride) and alkylated by addition of 0.9 µL of 500 mM 
iodoacetamide. For sample digestion, 1 µL of 0.1 gL-1 of lysyl endopeptidase (from A. 
lyticus) in 100 mM Tris-HCl (pH 8.5) was added, and the samples were incubated at room 
temperature for 4 h in the dark. The samples were diluted with 120 µL of 100 mM Tris-HCl 
(pH 8.5) and 1.6 µL of 100 mM CaCl2, followed by addition of 1 µL of 0.5 gL-1 of trypsin. 
After overnight incubation at room temperature, the digests were diluted to 5% formic acid 
concentration, desalted and lyophilized, and then resuspended in 0.2% formic acid solution 
for analysis. In-solution digested samples were subjected to LC-MS/MS analysis on a 
nanoflow LC system, EASY-nLC II, (Thermo Fisher Scientific) coupled to a LTQ Orbitrap 
mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped with a 
Nanospray Flex ion source (Thermo Fisher Scientific). 
For the EASY-nLC II system, solvent A consisted of 97.8% H2O, 2% MeCN, and 0.2% 
formic acid and solvent B consisted of 19.8% H2O, 80% MeCN, and 0.2% formic acid. 
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Samples were directly loaded onto a 16-cm analytical HPLC column (75 mm ID) packed 
in-house with ReproSil-Pur C18AQ 3 um resin (120A° pore size, Dr. Maisch, Ammerbuch, 
Germany). The column was heated to 45° C. The peptides were separated with a 90 min 
gradient at a flow rate of 350 nL/min. The gradient was as follows: 2–30% Solvent B (90 
min), 30–100% B (1 min), and 100% B (9 min). Eluted peptides were then ionized using a 
standard coated silica tip (New Objective, Woburn, MA) as an electrospray emitter and 
introduced into the mass spectrometer.  The LTQ Orbitrap was operated in a data-dependent 
mode, automatically alternating between a full-scan (m/z 300-1700) in the Orbitrap and 
subsequent MS/MS scans of the 15 most abundant peaks in the linear ion trap (Top15 
method). Data acquisition was controlled by Xcalibur 2.0.7 and Tune 2.4 software (Thermo 
Fisher Scientific). 
Raw files were searched using MaxQuant (v 1.5.1.2) using default parameters except 
where noted. UniProt E. coli entries along with expressed protein sequence and a 
contaminant database were considered in the search. A decoy database was generated and 
searched in parallel to estimate the false discovery rate. Trypsin was specified as the digestion 
enzyme with up to two missed cleavages allowed. Precursor mass tolerance was 4.5 ppm 
after recalibration and fragment ion mass tolerance was 0.5 Da. Variable modifications 
included carbamidomethylation of cysteine (+57.0215 Da), oxidation of methionine 
(+15.9949 Da), protein N-terminal acetylation (+42.0106 Da), and the custom modification 
(+86.0368 Da) on lysine, cysteine, histidine, serine, and arginine. PSM, Protein, and Site 
FDRs were all less than 1% as estimated by the target-decoy approach. 
 
E.14 Circular dichroism analysis 
 
Small-scale reactions were performed following the general procedure for catalysis using 
the heme domain of the appropriate enzyme variants after isolation and purification by 
HisTrap-HP column (final concentrations: 10 µM protein, 2 mM substrates, 2 mM Na2S2O4). 
CD samples were obtained by mixing 20 µL aliquot of the reaction with 1.0 mL of 10 mM 
phosphate buffer (pH 8), and 2.0 mL of H2O. CD spectra were recorded in the far UV region, 
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190–260 mm, using a quartz cell with 1 cm optical path length. Measurements were taken 
every 1 nm at a scan rate of 1 nm/sec.  
 
E.15 Whole-cell reaction of styrene with EDA catalyzed by BM3-HStar variants 
 
Following the procedure for small-scale whole-cell reactions under anaerobic conditions, 
E. coli expressing BM3-HStar, and BM3-HStar H92N H100N were grown and resuspended 
to OD600 = 10.  To determine the P450 concentration of each sample, 2 mL of each cell stock 
was removed and analyzed by ferrous concentration assays following the general procedure 
outlined above. Small-scale reactions were performed following the general procedure with 
10 mM final concentrations each of styrene and EDA.  Reactions were shaken for 2 h at room 
temperature.  GC analysis of product 2 was performed using J&W HP-5 column (30 m x 
0.32 mm, 0.25 µM film) with the method 90 °C hold 2 min, 90-190 at 6 °C/min, 190-230 °C 
at 40 °C/min, 230 °C hold 2 min (internal standard: 3.19 min, Z product 8.97 min, E product 
9.99 min). Yields of cyclopropanation products were determined using calibration curves 
previously described in Wang et al. (2014)2. 
 
E.16 Whole-cell reaction of aniline with EDA catalyzed by BM3-HStar variants 
 
Following the procedure for small-scale whole-cell reactions under anaerobic conditions, 
E. coli expressing BM3-HStar, and BM3-HStar H92N H100N were grown and resuspended 
to OD600 = 10.  To determine the P450 concentration of each sample, 2 mL of each cell stock 
was removed and analyzed by ferrous concentration assays following the general procedure 
outlined above. Small-scale reactions were performed following the general procedure with 
20 mM and 10 mM final concentrations of aniline and EDA, respectively.  Reactions were 
shaken for 2 h at room temperature.  GC analysis of product 2 was performed using J&W 
HP-5 column (30 m x 0.32 mm, 0.25 µM film) with the method 90 °C hold 2 min, 90-190 at 
6 °C/min, 190-230 °C at 40 °C/min, 230 °C hold 2 min (internal standard: 3.19 min, product 
9.84 min). Yields of N–H insertion product were determined using calibration curves 
described below. 
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E.17  Immobilization of Bsu TrHb LAA 
 
1 mL of purified Bsu TrHb LAA3 (expressed and purified as described in Appendix A, 
section A.5, purified as described in Appendix E, section E.6) concentration of 5 mg/mL, 
310 mM) was added to 78.5 mg of N-hydroxysuccinimide-linked agarose resin beads 
(ThermoFisher) in a 1.7 mL Eppendorf tube. The tube was rotated end-over-end for 90 
minutes at room temperature. The solution was then transferred to a spin column, 
centrifuged at 1000xg for 1 min, and the flow-through was collected. The beads were then 
washed with 1 mL of 20 mM sodium phosphate buffer pH 8, centrifuged at 1000xg for 1 
min, and the flow-through was again collected. The two flow-through solutions were 
combined and concentrated to 300 uL. Finally, 1 mL of 1 M Tris-HCl pH 8 was added to 
the beads, and then the column was rotated end-over-end for 1 hr at room temperature. 
Then column was then centrifuged at 1 g for 1 min, and the flow-through was discarded. 
The beads were transferred to a new 1.7 mL Eppendorf tube, resuspended to a volume of 
1.1 mL with sterile M9-N buffer, and stored at 4°C. 
To determine the coupling efficiency of the beads, a bicinchoninic acid assay (using 
bovine serine albumin as a standard) was used to measure the concentration of protein in 
the flow-through as well as the starting protein concentration. The coupling efficiency was 
calculated by subtracting the amount of flow-through protein from that of the starting 
protein to find the amount of protein immobilized, then dividing that number by the amount 
of starting protein. The coupling efficiency was 83.7%, with a protein bead concentration 
of 178 uM. 
 
E.18  Protein-bead reactions 
 
In triplicate, 25.6 uL of beads (178 uM protein) was added to a 2 mL crimp vial with 
399.4 uL of M9-N to a total volume of 425 uL. Under anaerobic conditions, 50 uL of 100 
mM sodium dithionite in M9-N, and then 25 uL of 1 M styrene in ethanol, was added to 
each vial. After shaking each vial briefly, 6.25 uL of 8 M ethyl diazoacetate was added. 
The final reaction conditions were 9.11 uM protein, 50 mM styrene, 100 mM ethyl 
diazoacetate, 10 mM dithionite, and 5% ethanol in M9-N. The vials were left to shake at 
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room temperature at 60 rpm for 90 min, after which 20 uL of 40 mM ethyl phenylacetate 
and 1 mL of cyclohexane were added. The solution was transferred to a 1.7 mL Eppendorf 
tube and centrifuged at 1000 g for 1 min. The organic layer was extracted and analyzed via 
GC. 
For bead recovery, residual cyclohexane was first removed from the tubes. The reaction 
vials were also washed with ~500 uL of M9-N to collect any remaining beads and their 
solutions were transferred to the tubes. The tubes were centrifuged at 1 g for 1 min, and 
then the supernatant was removed. The beads were resuspended with 418.8 uL of M9-N, 
then 139.6 uL of the solution were transferred to each of three new crimp vials. This was 
repeated three times, so each vial had a volume of 418.8 uL and the beads were evenly 
distributed. Reactions were then conducted in the conditions described in the previous 
paragraph. This was repeated until the beads had lost most of their activity, which ended 
up being four uses. 
 
E.19  Protein-bead heme removal and replacement 
 
A denaturation buffer was prepared with 500 uL acetone, 500 uL of a 20 mM MOPS 
buffer, pH 7.5, with 400 mM imidazole, and 1 uL of 2 M dithiothreitol. 1 mL of this 
solution was added to ~100 uL of beads into a 1.7 mL Eppendorf tube. The tube was then 
shaken at room temperature for 40 min, after which it was centrifuged at 1000xg for 1 min, 
the supernatant removed, and the denaturation buffer replaced. This denaturation was 
performed three times, after which the solution was centrifuged at 1000 g for 1 min and 
the supernatant was removed. 
A renaturation buffer was prepared with 25 uL of 1 M imidazole in M9-N, 500 uL of 
4 M guanidinium chloride, 1 uL of 2 M dithiothreitol, 424 uL of M9-N, and 50 uL of 1 
mM hemin in dimethylsulfoxide. This buffer was added to ~100 uL of beads and the tube 
was shaken at room temperature for 1 hr. The solution was then centrifuged at 1000 g for 
1 min, and the supernatant was removed. Protein-beads were rinsed once with 500 uL of 
M9-N before use. 
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E.20  Supporting tables and figures 
 
Table E-1. Amino acid sequences of mutants, relative to wild type P450-BM3 (WT). All 
mutations listed below are in the heme domain. There are no mutations present in the 
reductase domain. 
Enzyme Amino acid substitution with respect to WT 
BM3-HStar V78M, L181V, T268A, C400H, L437W 
BM3-HStar H92N V78M, H92N, L181V, T268A, C400H, L437W 
BM3-HStar H100N V78M, H100N, L181V, T268A, C400H, L437W 
BM3-HStar H92N H100N V78M, H92N, H100N, L181V, T268A, C400H, L437W 
 
Table E-2. Total turnover numbers, diastereoselectivities, and enantioselectivities of whole-
cell bioconversions of 1 and EDA. Experiments were performed at room temperature using 
whole cells expressing the BM3-HStar variant, resuspended to OD600 = 10, with 10 mM 1, 
and 20 mM EDA. Results are the average of experiments performed with three independent 
batches of E. coli cultures, each used to perform three independent chemical reactions (total 
of 9 reactions for each enzyme variant). ee = enantiomeric excess. 
 
Variant TTN %trans %ee 
BM3-Hstar 7400 91 61 
Hstar H92N 10900 91 82 
Hstar H100N 12300 95 69 
Hstar H92N H100N 20100 96 83 
 
Table E-3. Total turnover numbers, diastereoselectivities, and enantioselectivities of 
reaction of 1 and EDA with purified enzymes. Results are the average of three independent 
chemical reactions, performed with 10 µM enzyme concentration, 10 mM of 1, 20 mM of 
EDA, and 10 mM of Na2S2O4 at room temperature 
 
Variant TTN %trans %ee 
BM3-Hstar 310 92 10 
Hstar H92N 360 93 61 
Hstar H100N 420 91 57 
Hstar H92N H100N 560 98 89 
 
 
  
170 
 
 
 
 
 
Figure E-1. Pre-incubation experiments with EDA (top left, reaction with whole cells 
expressing the enzyme; top right, reaction with purified enzyme) showed rapid loss in 
activity and enantioselectivity, suggesting EDA-induced inactivation. For whole-cell 
experiments, reactions were performed with whole E. coli cell suspension (OD600 = 60), 10 
mM of 1, and 20 mM of EDA. For experiments with purified enzyme, reactions were 
performed with purified BM3-HStar (10 µM), 10 mM of 1, and 20 mM of EDA. Pre-
incubation experiments with EDA in the absence of Na2S2O4 (bottom graph) showed that the 
enzyme maintained its activity in the absence of reductant; reaction conditions: purified 
BM3-HStar (10 µM), 10 mM of 1, and 20 mM of EDA, with Na2S2O4 solution added 
concurrently with 1.  
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Figure E-2. Comparison of absorption spectra of isolated porphyrin species from BM3-
HStar after cyclopropanation reaction with that of authentic protoporphyrin IX (PPIX) 
standard. 
 
 
 
 
Figure E-3. Whole protein mass spectrometry analysis of BM3-HStar heme domain at the 
end of reaction with 1 and EDA. Mass spectrum exhibits extreme heterogeneity, which can 
be deconvoluted to reveal the presence of multiply-modified protein species.  
 
 
A BFerric BM3-HStar Ferrous BM3-HStar + EDA
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Table E-4. Representative deconvolution of purified, intact protein. Error on the LC-
MSD SL 1100 series is approximately 100 ppm, or ± 5.4 Da in a 54000 Da protein. 
 
Expected mass (Da) Observed mass (Da) EDA equivalents 
53866.49 53871.29 0 
 
Table E-5. Representative deconvolution of EDA-treated, intact protein. Error on the LC-
MSD SL 1100 series is approximately 100 ppm, or ± 5.4 Da in a 54000 Da protein. 
 
Expected mass (Da) Observed mass (Da) EDA equivalents 
53866.49 53870.49 0 
53952.59 53952.75 1 
54038.69 54039.62 2 
54124.79 54125.00 3 
54210.89 54212.2 4 
54296.99 54300.46 5 
54383.09 not detected 6 
54469.19 54477.2 7 
 
 
 
 
 
Figure E-4. Polar contact between K69 and the propionate side-chain of the heme in P450-
BM3. 
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Figure E-5. Comparison of TTNs for styrene cyclopropanation and carbene insertion into 
the N–H bond of aniline between HStar and HStar H92N H100N. Reaction conditions for 
cyclopropanation: whole E. coli cells expressing the enzyme variant (suspension in M9-N, 
OD600 = 10), 10 mM of styrene, 10 mM of EDA, room temperature, 2 h. Reaction conditions 
for N–H insertion: whole E. coli cells expressing the enzyme variant (suspension in M9-N, 
OD600 = 10), 20 mM of aniline, 10 mM of EDA, room temperature, 2 h. 
 
Figure E-6. Time-course of cyclopropanation of 1 with EDA using whole E. coli cells 
expressing BM3-HStar variants. Reaction conditions: whole E. coli cells expressing enzyme 
variants (OD600 = 10, 0.2 µM enzyme), 10 mM of 1, 20 mM of EDA, room temperature. 
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Figure E-7. Circular dichroism (CD) spectra of ferrous BM3-HStar H92N H100N before 
(black) and after reaction with EDA (red). 
 
 
Figure E-8. GC calibration curve for the reaction product between aniline and EDA. 
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Figure E-9. Control reactions with immobilized Bsu TrHb LAA show that almost all activity 
is lost in the denaturation process, and that all activity is regained in regeneration. 
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